

INGREDIENTS Eligible for Reviewed

EWG REVIEWED™ FOR INGREDIENTS

The substances listed below are eligible for submission to the EWG Reviewed for Ingredients program. Inclusion on this list indicates initial eligibility only. Each submitted substance must still meet all applicable ingredient level restrictions to be considered fully reviewed by EWG.

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| 1-BENZOPYRYLIUM, 3,5,7-TRIHYDROXY-2-(3,4,5- TRIHYDROXYPHENYL)-, CHLORIDE | 528-53-0 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E163) |
| 1-BENZOPYRYLIUM, 3,5,7-TRIHYDROXY-2-(4- HYDROXYPHENYL)-, CHLORIDE | 134-04-3 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E163) |
| 1-HEXANOL, 2-ETHYL-, TETRAESTER WITH SILICIC ACID | 115-82-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| 1-HEXANOL, 2-ETHYL-, TETRAESTER WITH SILICIC ACID | 115-82-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| 1-METHYL-4-METHYLVINYL-CYCLOHEXENE | 7705-14-8 | The European Commission restricts this ingredient's peroxide content to less than 20 mmoles/L. Required Warning: The European Commission requires that the presence of this substance be indicated in the list of ingredients when its concentration exceeds 0.001% in leaveon products and 0.01% in rinseoff products. |
| 1-PHENANTHRENEBUTANOIC ACID, 1,4,4A,4B,5,6,7,8,8A,9,10,10 A-DODECAHYDRO-6-((3-O-(2- | 211108-46-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| 1-PHENANTHRENEBUTANOIC ACID, 1,4,4A,4B,5,6,7,8,8A,9,10,10 A-DODECAHYDRO-6-((3-O-(2- | 211108-46-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| 1,2,4-TRIHYDROXYBENZENE | 533-73-3 | This substance must contain <0.1% hydroquinone based on the European Commission SCCS Opinion 1598/18. |
| 2-AMINOBUTANOL | 96-20-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| 2-HYDROXYETHYLAMINO-5-NITROANISOLE | 66095-81-6 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| 2-HYDROXYETHYLAMINO-5-NITROANISOLE | 66095-81-6 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| 2-METHYL-5-HYDROXYETHYLAMINOPHENOL | 55302-96-0 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| 2-METHYL-5-HYDROXYETHYLAMINOPHENOL | 55302-96-0 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| 2-PYRIDINECARBOXYLIC ACID, 5-((3-CHLOROPROPYL)THIO)-, 3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8, | 85446-89-5 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(2-PROPENYLTHIO)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-90-8 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(3,4-DIBROMOBUTYL)-, 3,4- DIHYDRO-2,5-2,5,7,8-TETRAMETHYL-2-(4,8, | 85446-72-6 | This ingredient should not contain detectable levels of hydroquinone. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| 2-PYRIDINECARBOXYLIC ACID, 5-(3,4-DICHLOROBUTYL)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-73-7 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(4-BROMOBUTYL)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-74-8 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(4-CHLOROBUTOXY)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-82-8 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(4-CHLOROPHENOXY)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-83-9 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(4-HYDROXYBUTYL)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-77-1 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(BUTYLTHIO)-, 3,4-DIHYDRO- 2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-84-0 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-(PHENYLMETHYL)-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 85446-76-0 | This ingredient should not contain detectable levels of hydroquinone. |
| 2-PYRIDINECARBOXYLIC ACID, 5-BUTYL-, 3,4-DIHYDRO-2,5,7,8- TETRAMETHYL-2-(4,8,12- | 85446-70-4 | This ingredient should not contain detectable levels of hydroquinone. |
| 2,8,9-TRIOXA-5-AZA-1-SILABICYCLO(3.3.3)UNDECANE, 1- ETHOXY- | 3463-21-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| 2,8,9-TRIOXA-5-AZA-1-SILABICYCLO(3.3.3)UNDECANE, 1- ETHOXY- | 3463-21-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| 3-CARENE | 13466-78-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| 3-METHYLAMINO-4-NITROPHENOXYETHANOL | 59820-63-2 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| 3-METHYLAMINO-4-NITROPHENOXYETHANOL | 59820-63-2 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| 3-NITRO-P-HYDROXYETHYLAMINOPHENOL | 65235-31-6 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| 3-NITRO-P-HYDROXYETHYLAMINOPHENOL | 65235-31-6 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| 4-HYDROXYPROPYLAMINO-3-NITROPHENOL | 92952-81-3 | The European Commission restricts this ingredient to a maximum concentration of 2.6% in non-oxidative hair dye products. For hair dye substance in oxidative hair dye products, the maximum concentration after mixing under oxidative conditions must not exceed 2.6% as free base. Cannot be used with nitro sating agents and maximum nitrosamine content: 50 µg /kg. Keep in nitrite-free containers |
| 4-HYDROXYPROPYLAMINO-3-NITROPHENOL | 92952-81-3 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| 4-HYDROXYPROPYLAMINO-3-NITROPHENOL | 92952-81-3 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| 4-NITROPHENYL AMINOETHYLUREA | 27080-42-8 | The European Commission restricts this ingredient to a maximum concentration of 0.25% applied to hair after mixing under oxidative conditions in oxidative hair dye products, and 0.5% in nonoxidative hair dye products. Additionally, this substance cannot be used with nitrosating agents, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. Required Warning: The European Commission requires the following warning text on the product label/package: 'Hair colourants can cause severe allergic reactions'; 'Read and follow instructions' |
| 4-OCTADECENOIC ACID, 5,9,13,17-TETRAMETHYL-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 72614-65-4 | This ingredient should not contain detectable levels of hydroquinone. |
| 4,8-DECADIENOIC ACID, 5,9-DIMETHYL-, 3,4-DIHYDRO-2,5,7,8- TETRAMETHYL-2-(4,8,12- | 72614-62-1 | This ingredient should not contain detectable levels of hydroquinone. |
| 4,8,12-TETRADECATRIENOIC ACID, 5,9,13-TRIMETHYL-, 3,4- DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12- | 72614-64-3 | This ingredient should not contain detectable levels of hydroquinone. |
| 4,8,12,16,20,24,28,32,36-OCTATRIACONTANONAENOIC ACID, 5,9,13,17,21,25,29,33,37-NONAMETHYL-,3, | 72614-67-6 | This ingredient should not contain detectable levels of hydroquinone. |
| 4,8,12,16,20,24,28,32,36,40-DOTETRACONTADECAENOIC ACID, 5,9,13,17,21,25,29,33,37,41- | 72614-66-5 | This ingredient should not contain detectable levels of hydroquinone. |
| 6-METHOXY-2-METHYLAMINO-3-AMINOPYRIDINE HCL | 90817-34-8 | The European Commission restricts this ingredient to a maximum concentration of 0.68% as free base (1.0% as dihydrochloride) applied to hair or eyelashes after mixing under oxidative conditions in oxidative hair dyes and products intended for coloring eyelashes, and 0.68% as free base (1.0% as dihydrochloride) in nonoxidative hair dye products. Additionally, this substance cannot be used with nitrosating agents, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. This ingredient is only permitted for professional use in products intended for coloring eyelashes. Required Warning: The European Commission requires the following on the product label/package of oxidative hair dyes: The mixing ratio; 'Hair colorants can cause severe allergic reactions.', 'Read and follow instructions.', 'This product is not intended for use on persons under the age of 16.', 'Temporary 'black henna' tattoos may increase your risk of allergy.'; 'Do not colour your hair if: — you have a rash on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction to a temporary 'black henna' tattoo in the past.' The European commission requires the following on the product label/package of products intended for coloring eyelashes: The mixing ratio; 'For professional use only'.', 'This product can cause severe allergic reactions.', 'This product label/package of products intended for coloring eyelashes: The mixing ratio; 'For professional use only'.', 'This product can cause severe allergic reactions.'; 'Read and follow instructions.'; 'The or professional use only'.', 'This product is not intended for use on persons under the age of 16.'; 'Temporary 'black henna' tattoos may increase your risk of allergy.'; 'Eyelashes shall not be coloured if the consumer: — has a rash on the face or sensitive, irritated and damaged scalp, — has experienced a reaction to a temporary 'black henna' tattoo in the past'; 'Rinse eyes immediately if product comes into cont |
| TETRAMETHYL-2-(4,8,12-TRIMETHYLTRIDECYL)- | 72614-63-2 | hydroquinone. |
| 8'-APO-BETA-CAROTENAL | 1107-26-2 | criteria as set out in Commission Directive 95/45/EC (E 160e) |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| ABIES (FIR) NEEDLE OIL | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES ALBA LEAF OIL | 8021-27-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES ALBA LEAF OIL | 8021-27-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES BALSAMEA (BALSAM) | 8007-47-4 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES BALSAMEA (BALSAM) EXTRACT | 85085-34-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES BALSAMEA (BALSAM) EXTRACT | 85085-34-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES BALSAMEA (BALSAM) EXTRACT | 85085-34-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES BALSAMEA (BALSAM) NEEDLE OIL | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA BARK/LEAF EXTRACT | 92128-34-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA EXTRACT | 90028-76-5 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA NEEDLE EXTRACT | 92128-34-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA NEEDLE EXTRACT | 92128-34-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA NEEDLE EXTRACT | 92128-34-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA NEEDLE OIL | 92128-34-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA OIL | 8021-27-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA OIL | 8021-27-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA OIL | 8021-27-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES PECTINATA OIL | 8021-27-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES SIBIRICA (SIBERIAN FIR) OIL | 8021-29-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES SIBIRICA (SIBERIAN FIR) OIL | 8021-29-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES SIBIRICA (SIBERIAN FIR) OIL | 8021-29-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES SIBIRICA NEEDLE EXTRACT | 91697-89-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES SIBIRICA NEEDLE EXTRACT | 91697-89-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABIES SIBIRICA NEEDLE OIL | 91697-89-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ABSORPTION OILS, BICYCLO AROM. AND HETEROCYCLIC HYDROCARBON FRACTION | 101316-45-4 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.005% w/w benzo[a]pyrene |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| ACACIA CATECHU GUM | 8001-76-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA CONCINNA FRUIT EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA DEALBATA LEAF EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA DECURRENS EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA FARNESIANA EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA FARNESIANA FLOWER WAX | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA FARNESIANA FLOWER/STEM EXTRACT | 89958-31-6 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA FARNESIANA GUM | 2593228 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA SENEGAL EXTRACT | 97659-43-3 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA SENEGAL GUM | 2593228 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 9%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACACIA SENEGAL GUM EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/Pesticide residue, arsenic, heavy metals, and lead. |
| ACETIC ACID, (ETHYLENEDINITRILO)TETRA-, DISODIUM SALT, COPPER COMPLEX, TRIHYDRATE | 73637-19-1 | Per the U.S. FDA., disodium EDTA-copper shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Total copper, not less than 13.5 percent. Total (ethylene-dinitrilo) tetracetic acid, not less than 62.5 percent. Free copper, not more than 100 parts per million. Free disodium salt of (ethylene-dinitrilo) tetraacetic acid, not more than 1.0 percent. Moisture, not more than 15 percent. Water insoluble matter, not more than 0.2 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. |
| ACRYLAMIDE/ETHALKONIUM CHLORIDE ACRYLATE COPOLYMER | 74153-51-8 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| ACRYLAMIDE/ETHYLTRIMONIUM CHLORIDE ACRYLATE/ETHALKONIUM CHLORIDE ACRYLATE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE/ACRYLIC ACID COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| ACRYLAMIDES COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| ACRYLAMIDES/DMAPA ACRYLATES/METHOXY PEG METHACRYLATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLAMIDES/DMAPA ACRYLATES/METHOXY PEG METHACRYLATE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| ACRYLATES/ AMINOACRYLATES/ C10-30 AKLYL PEG-20 ITACONATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-----|--|
| ACRYLATES/ AMINOACRYLATES/ C10-30 ALKYL PEG-20 ITACONATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/ CETETH-20 ITACONATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/ STEARETH-20 ITACONATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/CETETH-20 METHACRYLATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/LAURETH-25 METHACRYLATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/METHOXY PEG-15 METHACRYLATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/METHOXY PEG-23 METHACRYLATE/PERFLUOROOCTYL ETHYL ACRYLATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ACRYLATES/PEG-10 MALEATE/STYRENE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ADEPS SUILLUS | 0 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| AGARUM CRIBOSUM EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ALARIA ESCULENTA EXTRACT | 0 | This substance should not contain detectable levels of cadmium, lead, mercury, copper, zinc, arsenic, nickel, silver, or iodine. |
| ALARIA ESCULENTA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| Alcohol ethoxylates (C10-12, 5-7EO) branched | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| Alcohol ethoxylates (C10-12, 8EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C10-12) | 0 | The U.S. Food & Drug Administration has identified 1,4- dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4-dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C10-14) | 66455-15-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C10-16, 9EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C10-16) | 68002-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C10-C16) SODIUM SALT | 68585-34-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C10-C16) SODIUM SALT | 68585-34-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C11-14-iso-, C13-rich) | 78330-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C11-15) secondary | 68131-40-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-13) | 66455-14-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-14) 9EO | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-14) linear, saturated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-14) propoxylated | 68439-51-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| Alcohol ethoxylates (C12-14) secondary | 84133-50-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, 12-20EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, 20-30EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, 3-12EO, branched) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, 30+EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, 7EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, 9-12EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, avg 12-13, 6-9EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15, avg 15, 6-9EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-15) | 106232-83-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-16, 7EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C12-16) | 68551-12-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-18, 0-3EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------------|------------|---|
| Alcohol ethoxylates (C12-18, 10-20EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12-18, 5-10EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C12-18) | 68213-23-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------------|------------|---|
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C12) | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C14-15) | 68951-67-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C16-18, 2-8EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C16-18, 20-30EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C16-18, 25EO) | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C16-18, 25EO) | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C16-18, 30+EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C16-18, 9-18EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C4-C8, 5EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES (C6-12) | 68439-45-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C7-21) | 68991-48-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C8-10) | 74565-57-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| Alcohol ethoxylates (C9-11, 3-6EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C9-11, 4-8EO) | 68439-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C9-11, 4-8EO) | 68439-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C9-11, 4-8EO) | 68439-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C9-11, 5-11EO, branched) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates (C9-11, 6-10EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol Ethoxylates Blend (C12-18 & C12-16) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol Ethoxylates, Propoxylated (C10-16, 6-7EO, 0-3PO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates, propoxylated (C12-14) | 68439-51-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol Ethoxylates, Propoxylated (C12-15, 2-6EO, 2-6PO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES, PROPOXYLATED (C12-15) | 68551-13-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOL ETHOXYLATES, PROPOXYLATED (C12-15) | 68551-13-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates, propoxylated (C12-15) branched and linear | 120313-48-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| Alcohol ethoxylates, propoxylated (C6-10) | 68987-81-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates, propoxylated (C6-12) | 68937-66-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohol ethoxylates, propoxylated fumerated (C6-10) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohols, C12-15-branched and linear, ethoxylated | 106232-83-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOLS, C12-18, ETHOXYLATED PROPOXYLATED | 69227-21-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohols, C13-15 branched and linear, butoxylated ethoxylated | 111905-53-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOLS, C16-18, ETHOXYLATED PROPOXYLATED | 68002-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alcohols, C16-22, ethoxylated | 69227-20-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALCOHOLS, C8-10, ETHOXYLATED PROPOXYLATED | 68603-25-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALGAE OLIGOSACCHARIDES | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ALGAEOYL PHYTOSPHINGOSINE | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ALGIN | 9005-38-3 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ALKANES, C1-4, C3-RICH | 90622-55-2 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.1% w/w Butadiene |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|-------------|--|
| Alkyl Ether Sulfates (C12-15, 1-3EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alkyl Ether Sulfates (C16-18, 3-4EO) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Alkyl polyglucoside (C8-10) | 68515-73-1 | |
| Alkylphenol ethoxylates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALLYL 2-METHYLBUTOXYACETATE | 67634-01-09 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL 3,5,5-TRIMETHYLHEXANOATE | 71500-37-3 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL BUTYRATE | 2051-78-7 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL CINNAMATE | 1866-31-5 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL CYCLOHEXYLACETATE | 4728-82-9 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL CYCLOHEXYLOXYACETATE | 68901-15-5 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL CYCLOHEXYLPROPIONATE | 2705-87-5 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL HEPTANOATE | 142-19-8 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL ISOVALERATE | 2835-39-4 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL NONANOATE | 7493-72-3 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL OCTANOATE | 4230-97-1 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL PHENETHYL ETHER | 14289-65-7 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL PHENOXYACETATE | 7493-74-5 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL PHENOXYACETATE | 7493-74-5 | The International Fragrance Association restricts the level of free allylalcohol in the ester to a maximum concentration of less than 0.1%. |
| ALLYL PHENYLACETATE | 1797-74-6 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL PROPIONATE | 2408-20-0 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALLYL TRIMETHYLHEXANOATE | 68132-80-9 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ALMOND OIL PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALMOND OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALMONDAMIDE DEA | 124046-18-0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|-------------|--|
| ALMONDAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB) |
| ALMONDAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| ALOE ABORESCENS | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ANDONGENSIS EXTRACT | 84837-08-01 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ANDONGENSIS EXTRACT | 84837-08-01 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ANDONGENSIS LEAF EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ANDONGENSIS LEAF JUICE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ANDONGENSIS LEAF JUICE | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ARBORESCENS FLOWER EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ARBORESCENS LEAF EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ARBORESCENS LEAF JUICE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE ARBORESCENS LEAF JUICE | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE ARBORESCENS LEAF PROTOPLASTS | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| ALOE ARBORESCENS LEAF PROTOPLASTS | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) | 8001-97-6 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) | 8001-97-6 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) BUTTER | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) BUTTER | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) CELLULOSE | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) CELLULOSE | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) EXTRACT | 85507-69-3 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) EXTRACT | 85507-69-3 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) FLOWER EXTRACT | 85507-69-3 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE BARBADENSIS (ALOE VERA) FLOWER EXTRACT | 85507-69-3 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) LEAF EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) LEAF EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE (decolorized) | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE (decolorized) | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE (decolorized) | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE POWDER | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| ALOE BARBADENSIS (ALOE VERA) LEAF JUICE POWDER | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) OIL | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) OIL | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) OIL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) OIL EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS (ALOE VERA) ROOT EXTRACT | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS (ALOE VERA) ROOT EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS LEAF POLYSACCHARIDES | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS LEAF POLYSACCHARIDES | 0 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE BARBADENSIS LEAF POLYSACCHARIDES | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS LEAF POWDER | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| ALOE BARBADENSIS LEAF POWDER | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE BARBADENSIS LEAF WATER | 0 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE BARBADENSIS LEAF WATER | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE EXTRACT, LIPID FRACTION | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE FEROX (CAPE ALOE) EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE FEROX (CAPE ALOE) EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE FEROX (CAPE ALOE) LEAF EXTRACT | 84649-82-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE FEROX (CAPE ALOE) LEAF EXTRACT | 84649-82-1 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE FEROX LEAF JUICE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE FEROX LEAF JUICE | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE FEROX LEAF JUICE EXTRACT | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| ALOE FEROX LEAF JUICE EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE FEROX LEAF JUICE POWDER | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| ALOE FEROX LEAF JUICE POWDER | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| Aloe Maculata Leaf Extract | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| Aloe Maculata Leaf Extract | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE PERRYI EXTRACT | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE YOHJU MATSU EKISU | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE YOHJYU MATSU | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| ALOE, POWDERED | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| alpha-PINENES | 80-56-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L |
| alpha-TERPINENE | 99-86-5 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ALPHA-TOCOPHEROL PHOSPHATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| ALUMINA MAGNESIUM METASILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINA MAGNESIUM METASILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM CALCIUM IRON MAGNESIUM POTASSISUM OXIDE SILICATE | 181659-14-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM CALCIUM IRON MAGNESIUM POTASSISUM OXIDE SILICATE | 181659-14-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM CALCIUM SODIUM SILICATE | 1344-01-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM CALCIUM SODIUM SILICATE | 1344-01-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| ALUMINUM CHLOROHYDREX PEG | 173762-81-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALUMINUM DICHLOROHYDREX PEG | 173720-80-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALUMINUM IRON SILICATES | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM IRON SILICATES | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM SESQUICHLOROHYDREX PEG | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ALUMINUM SILICATE | 1318-74-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM SILICATE | 1318-74-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ALUMINUM ZIRCONIUM TETRACHLOROHYDREX PEG | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMETHYST | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMETHYST | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMETHYST EXTRACT | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMETHYST EXTRACT | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMETHYST POWDER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| AMETHYST POWDER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMIDES, C12-14, N,N-BIS(HYDROXYETHYL)- | 97926-10-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMIDES, C12-14, N,N-BIS(HYDROXYETHYL)- | 97926-10-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| Amidopropyl Betaines | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| AMINES, C12-14-TERT-ALKYL, ETHOXYLATED | 73138-27-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Amines, C12-14-tert-alkyl, ethoxylated propoxylated | 68603-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMINES, TALLOW ALKYL, ETHOXYLATED | 61791-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMINOETHYLPROPANEDIOL-ACRYLATES/ACRYLAMI DE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| AMINOMETHYL PROPANOL | 124-68-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMINOPROPYL TOCOPHERYL PHOSPHATE | 348099-49-0 | This ingredient should not contain detectable levels of hydroquinone. |
| AMMONIUM ACRYLOYLDIMETHYLTAURATE/LAURETH-7 METHACRYLATE COPOLYMER | 683748-07-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM DIMETHICONE PEG-7 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM FLUOROSILICATE | 16919-19-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|------------|--|
| AMMONIUM FLUOROSILICATE | 16919-19-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMMONIUM GLYCYRRHIZATE | 53956-04-0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5%. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, toxic metals and heavy metals. |
| AMMONIUM LAURETH SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH-12 SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH-5 SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH-6 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH-7 SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH-8 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM LAURETH-9 SULFATE | 32612-48-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| AMMONIUM NONOXYNOL-30 SULFATE | 31691-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM NONOXYNOL-4-SULFATE | 31691-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM SILVER ZINC ALUMINUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMMONIUM SILVER ZINC ALUMINUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| AMMONIUM, DIETHYLMETHYL(2-(4-(2-NONOXYBENZAMIDO) BENZOYLOXY)ETHYL)-, BROMIDE | 26187-16-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMMONIUM, DIETHYLMETHYL(2-(4-(2-NONOXYBENZAMIDO) BENZOYLOXY)ETHYL)-, IODIDE | 26095-60-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AMNIOTIC FLUID | 0 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| AMP ISOSTEAROYL HYDROLYZED SOY PROTEIN | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP ISOSTEAROYL HYDROLYZED WHEAT PROTEIN | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ACRYLATES COPOLYMER | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ACRYLATES/ALLYL METHACRYLATE COPOLYMER | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ACRYLATES/C1-18 ALKYL ACRYLATE/C1-8 ALKYL ACRYLAMIDE/HYDROXYETHYLACRYLATE COPOLYMER | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|---|-----------|--|
| AMP-ACRYLATES/DIACETONEACRYLAMIDE COPOLYMER | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ACRYLATES/DIMETHYLAMINOETHYLMETHACR YLATE COPOLYMER | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ACRYLATES/ETHYLHEXYLACRYLATE COPOLYMER | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ISOSTEAROYL GELATIN/KERATIN AMINO ACIDS/LYSINE HYDROXYPROPYLTRIMONIUM CHLORIDE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ISOSTEAROYL HYDROLYZED ELASTIN | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ISOSTEAROYL HYDROLYZED KERATIN | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ISOSTEAROYL HYDROLYZED SILK | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| AMP-ISOSTEAROYL WHEAT/CORN/SOY AMINO ACIDS | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ANATASE | 1317-70-0 | Per the U.S. FDA., titanium dioxide shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million. Antimony (as Sb), not more than 2 parts per million. Mercury (as Hg), not more than 1 part per million. Loss on ignition at 800 °C. (after drying for 3 hours at 105 °C.), not more than 0.5 percent. Water soluble substances, not more than 0.5 percent. TiO2, not less than 99.0 percent after drying for 3 hours at 105 °C. Lead, arsenic, and antimony shall be determined in the solution obtained by boiling 10 grams of the titanium dioxide for 15 minutes in 50 milliliters of 0.5N hydrochloric acid. |
| ANCIENT SEA CLAY | 0 | Products containing clays and minerals must meet international heavy metal limits of: Lead: 10 ppm, Arsenic: 3 ppm, Cadmium: 3 ppm, Mercury: 1 ppm, Antimony: 5 ppm, Chromium: 100 ppm, and Nickel: 200 ppm; in the finished product. |
| AO2 | 860-22-0 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 132) |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| APRICOT KERNEL OIL PEG-40 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| APRICOT KERNEL OIL PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| APRICOT KERNEL OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| APRICOTAMIDE DEA | 185123-36-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| APRICOTAMIDOPROPYL BETAINE | 133934-08-4 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| ARACHIS HYPOGAEA (PEANUT) EXTRACT | 0 | Europe restricts this chemical: Maximum concentration of peanut proteins: 0.5 ppm |
| ARACHIS HYPOGAEA (PEANUT) OIL | 2228777 | Europe restricts this chemical: Maximum concentration of peanut proteins: 0.5 ppm |
| ARGAN OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ASCOPHYLLUM NODOSUM (KNOTTED WRACK) EXTRACT | 84775-78-0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ASCOPHYLLUM NODOSUM POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ASCORBYL TOCOPHERYL MALEATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| ASPERGILLUS/RICE FERMENT FILTRATE | 0 | This substance may not contain detectable levels of aflatoxins, which are produced by some species of Aspergillus. |
| AVENA SATIVA (OAT) KERNEL FLOUR | 134134-86-4 | The Cosmetic Ingredient Review identified heavy metals as a possible contaminant therefore this substance must meet international heavy metal limits of: Lead: 10 ppm, Arsenic: 3 ppm, Cadmium: 3 ppm, Mercury: 1 ppm, Antimony: 5 ppm, Chromium: 100 ppm, and Nickel: 200 ppm; in the finished product. |
| AVOCADAMIDE DEA | 124046-21-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|-------------|--|
| AVOCADAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| AVOCADAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| AVOCADO OIL PEG-11 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| AVOCADO OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Aziridine, homopolymer, ethoxylated | 68130-99-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BABASSU OIL GLYCERETH-8 ESTERS | 31694-55-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BABASSUAMIDE DEA | 124046-24-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| BABASSUAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| BARIUM SILICOFLUORIDE | 17125-80-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| BARIUM SILICOFLUORIDE | 17125-80-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| BASIC VIOLET 11:1 | 73398-89-7 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| BASIC VIOLET 11:1 | 73398-89-7 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| BASIC VIOLET 16 | 6359-45-1 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| BASIC VIOLET 16 | 6359-45-1 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| BASIC YELLOW 40 | 29556-33-0 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| BASIC YELLOW 40 | 29556-33-0 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| BASIC YELLOW 57 | 68391-31-1 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| BASIC YELLOW 57 | 68391-31-1 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| BEETROOT RED | 89957-88-0 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E162) |
| BEHENAMIDE DEA | 70496-39-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| BEHENAMIDOPROPYL DIMETHYLAMINE | 60270-33-9 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| BEHENETH-30 | 26636-40-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BEHENTRIMONIUM DIMETHICONE PEG-8 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BERTHOLLETIA EXCELSA SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BETA TOCOPHEROLS | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| beta-PINENES | 127-91-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L |
| BETAINE | 107-43-7 | This substance may not contain detectable levels of heavy metals, dioxins, polycyclic aromatic hydrocarbons, or polychlorinated biphenyls. |
| BETULA ALBA (BIRCH) LEAF OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA ALBA (BIRCH) LEAF OIL EXTRACT | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA ALBA (BIRCH) OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA ALBA OIL | 8001-88-5 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA ALBA OIL | 8001-88-5 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| BETULA LENTA (BIRCH) BARK OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA LENTA (SWEET BIRCH) OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA LENTA (SWEET BIRCH) OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA LENTA (SWEET BIRCH) OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA LENTA (SWEET BIRCH) OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA NIGRA (BIRCH) OIL | 0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA PENDULA TWIG OIL | 85940-29-0 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BETULA PUBESCENS TWIG OIL | 91745-85-6 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BICARBOSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| BICARBOSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| BIRCH TAR OIL | 8001-88-5 | The International Fragrance Association prohibits use of the crude material and restricts the total benzopyrene and 1,2 benzanthracene content of the purified form of this ingredient to a maximum of 1ppb in the final product. |
| BIS-BUTYLOXYAMODIMETHICONE/PEG-60 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-HYDROXYETHYL TOCOPHERYLSUCCINOYLAMIDO HYDROXYPROPANE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| BIS-ISOBUTYL PEG-14/AMODIMETHICONE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-ISOBUTYL PEG-15/AMODIMETHICONE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-1 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| BIS-PEG-12 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-12 DIMETHICONE BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-12 DIMETHICONE CANDELILLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-15 DIMETHICONE/ IPDI COPOLYMER | 190793-18-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-15 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-18 METHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-18 METHYL ETHER DIMETHYL SILANE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-20 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-4 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG-8 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG/ PPG-14/ 14 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG/ PPG-16/ 16 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIS-PEG/ PPG-20/ 20 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| BIS-PEG/PPG-16/16 PEG/PPG-16/16 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BISAMINO PEG/ PPG-41/ 3 AMINOETHYL PG-PROPYL DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BISMUTH OXYCHLORIDE | 7787-59-9 | Per the U.S. FDA., the color additive bismuth oxychloride shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by good manufacturing practice: Volatile matter, not more than 0.5 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Bismuth oxychloride, not less than 98 percent; (2) Color additive mixtures of bismuth oxychloride may contain the following diluents: (i) For coloring cosmetics generally, only those diluents listed under § 73.1001(a)(1) & (ii) For coloring externally applied cosmetics, only those diluents listed in § 73.1001(b) and, in addition, nitrocellulose. |
| BISPOLYETHYLENE DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BITTER CHERRY SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BIXA ORELLANA (ANNATTO) SEED EXTRACT | 89957-43-7 | The European Commission restricts the arsenic, lead, mercury, cadmium, and total heavy metal contents of this ingredient to maximum concentrations of 3 ppm, 10 ppm, 1 ppm, 1 ppm, and 40 ppm, respectively. |
| BIXA ORELLANA (ANNATTO) SEED EXTRACT | 89957-43-7 | This ingredient must meet purity criteria as set out in European Commission Directive: Solvent residues Acetone, Methanol, or Hexane not more than 50 ppm singly or in combination; Dichloromethane not more than 10 ppm; Arsenic not more than 3 ppm, Lead |
| BIXA ORELLANA (ANNATTO) SEED EXTRACT | 89957-43-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 160b) |
| BORAGE SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Branched alcohol ethoxylates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BRASSICAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| BUTANE | 106-97-8 | The European Commission bans this ingredient from use in cosmetics if it contains over $0.1\%~\text{w/w}$ Butadiene |
| BUTANE | 106-97-8 | Health Canada bans this ingredient from use in cosmetics if it contains over 0.1% w/w Butadiene. |
| BUTETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| BUTYL BENZOIC ACID/PHTHALIC ANHYDRIDE/TRIMETHYLOLETHANE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| BUTYLENE/ ETHYLENE/ STYRENE COPOLYMER | 0 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| BUTYLOCTYL SALICYLATE | 190085-41-7 | Based on EWG scientists' risk assessment using reproductive toxicity data, butyloctyl salicylate (BOS) is limited to 0.02% in baby products. |
| C10 Alcohol Ethoxylate | 00000-00-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C10 Alcohol Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C10-12 Branched Alcohols Ethoxylated 5-7EO | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C10-16 Alcohols Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C10-16 Pareth-1 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C11-15 PARETH-7 CARBOXYLIC ACID | 68954-90-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-13 PARETH-7 | 66455-14-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-14 Alcohols Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-14 Alketh-12 | 68439-50-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-14 Pareth-11 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| C12-14 PARETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-14 PARETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-15 Alcohols Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-15 PARETH-2 | 68131-39-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-15 PARETH-3 | 68131-39-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-15 PARETH-7 | 68131-39-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-15 PARETH-9 | 68131-39-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-16 Alcohols Ethoxylated 7EO | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-16 ALKYL PEG-2 HYDROXYPROPYL HYDROXYETHYL ETHYLCELLULOSE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-20 ACID PEG-20 ESTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C12-20 ACID PEG-8 ESTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C14-15 PARETH-7 | 68951-67-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C24-28 ALKYLDIMETHYLSILOXY TRIMETHYLSILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| C24-28 ALKYLDIMETHYLSILOXY TRIMETHYLSILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| C6-12 Alcohols Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C6-20 Alcohols Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C8-10 Alcohols Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C8-10 ALKANE/CYCLOALKANE/AROMATIC HYDROCARBONS | 64742-82-1 | The European Commission bans this ingredient from use in cosmetics if its benzene content is over 0.1%. |
| C9-10 ALKANE/CYCLOALKANE | 64742-49-0 | The European Commission bans this ingredient from use in cosmetics if its benzene content is over 0.1%. |
| C9-11 Alcohols Ethoxylated 4-6EO | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C9-11 ALKANE/CYCLOALKANE C9-11 ALKANE/CYCLOALKANE | 64742-49-0 | The European Commission bans this ingredient from use in cosmetics if its benzene content is over 0.1%. |
| C9-11 PARETH-3 | 68439-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| C9-11 PARETH-8 | 68439-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CALCIUM ALUMINUM BOROSILICATE | 65997-17-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM ALUMINUM BOROSILICATE | 65997-17-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM BOROSILICATE | 59794-15-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM BOROSILICATE | 59794-15-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM CARBONATE | 1317-65-3 | The European Commission restricts the arsenic, lead, cadmium, fluoride, antimony, copper, zinc, and barium contents of this ingredient to maximum concentrations of 3 ppm, 10 ppm, 1 ppm, 50 ppm, 100 ppm, 100 ppm, and 100 ppm, respectively. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|------------|---|
| CALCIUM CARBONATE | 1317-65-3 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 170) |
| CALCIUM OXIDE SILICATE (CA3O(SIO4)) | 12168-85-3 | A 2019 CIR report lists the following heavy metal linits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM OXIDE SILICATE (CA3O(SIO4)) | 12168-85-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SILICATE | 10101-39-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SILICATE | 10101-39-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SILICOFLUORIDE | 16925-39-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SILICOFLUORIDE | 16925-39-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SODIUM BOROSILICATE | 65997-17-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SODIUM BOROSILICATE | 65997-17-3 | The Consumer Ingredient Review considers this ingredient safe as used at concentrations < 97% and report lists the following heavy metal limits: lead (<10 ppm), arsenic (< 2 ppm), mercury (<1 ppm). |
| CALCIUM SODIUM BOROSILICATE | 65997-17-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SODIUM PHOSPHOSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM SODIUM PHOSPHOSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CALCIUM TITANIUM BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| CALCIUM TITANIUM BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CANNABIS SATIVA (HEMP) | 0 | This ingredient is prohibited from use in European cosmetic products if it is prepared as an extract or tincture or resin of Cannabis from the flowering or fruiting tops of the cannabis plant. This ingredient may be used in cosmetics when obtained from cannabis, cannabis resin, cannabis extracts and cannabis tinctures originating from the seeds and leaves that are not accompanied with the fruiting tops of the cannabis plant and if the level of THC does not exceed 0.2%. |
| CANNABIS SATIVA (HEMP) ACID | 0 | Health Canada restricts the THC (delta9tetrahydrocannabinol) content of this ingredient to a maximum concentration of 10 microgram/g. |
| CANNABIS SATIVA (HEMP) EXTRACT | 89958-21-4 | Health Canada restricts the THC (delta9tetrahydrocannabinol) content of this ingredient to a maximum concentration of 10 microgram/g. |
| CANNABIS SATIVA (HEMP) SEED OIL | 89958-21-4 | Health Canada restricts the THC (delta9tetrahydrocannabinol) content of this ingredient to a maximum concentration of 10 microgram/g. |
| CANOLAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| CAPE ALOE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| CAPE ALOE | 0 | California Prop65 lists nondecolorized aloe as known to cause cancer. Companies must certify that the aloe has been decolorized. |
| CAPE ALOE EKISU | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| CAPRAMIDE DEA | 136-26-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| CAPRYL/ CAPRAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| Caprylic/Capric Triglyceride | 73398-61-5 | For the purposes of the Reviewed Ingredients program, this ingredient may only be used in combination with another restricted ingredient on the Ingredients Eligible for Reviewed List. |
| CAPRYLIC/CAPRIC TRIGLYCERIDE PEG-4 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CAPSANTHIN/CAPSORUBIN | 465-42-9 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E160c) |
| CARAMEL | 0 | The European Commission restricts the arsenic, lead, mercury, cadmium, and total heavy metal contents of this ingredient to maximum concentrations of 1 ppm, 2 ppm, 1 ppm, 1 ppm, and 25 ppm, respectively. |
| CARAMEL | 0 | Per the U.S. FDA., caramel shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 0.1 part per million. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|------------|---|
| CARAMEL COLOR | 8028-89-5 | Per the U.S. FDA., caramel shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 0.1 part per million. |
| CARAMEL COLOR | 8028-89-5 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E150a-d) |
| Caramel I | 8028-89-5 | Per the U.S. FDA., caramel shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 0.1 part per million. |
| Caramel III | 8028-89-5 | Per the U.S. FDA., caramel shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 0.1 part per million. |
| Caramel IV | 8028-89-5 | Per the U.S. FDA., caramel shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 0.1 part per million. |
| CARBOMER | 2615966 | These substances must not be polymerized in benzene, and, per, U.S. Pharmacopeia standards, the total residual monomers may not exceed 2500 ppm. Additionally, the total residual methacrylic acid and its salts may not exceed 100 ppm based on recommendations by the CIR panel that manufacturers minimize residual monomer content in in Acrylates Copolymers and concerns about the toxicity of methylacrylic acid and its salts. |
| CAROTENE | 0 | The European Commission restricts the arsenic, lead, mercury, cadmium, and total heavy metal contents of this ingredient to maximum concentrations of 3 ppm, 10 ppm, 1 ppm, 1 ppm, and 40 ppm, respectively. |
| CEDRUS ATLANTICA (ATLAS CEDAR) OIL | 8023-85-6 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA (ATLAS CEDAR) OIL | 8023-85-6 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA (ATLAS CEDAR) OIL | 8023-85-6 | The presence of the substance or substances shall be indicated as 'Cedrus Atlantica Oil and Extract' in the list of ingredients, when the concentration of the substance or substances exceeds: 0.001% in leave-on products and 0.01% in rinse-off products. The peroxide value for each substance shall be less than 10 mmoles/L |
| CEDRUS ATLANTICA BARK WATER | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA WOOD EXTRACT | 92201-55-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA WOOD EXTRACT | 92201-55-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA WOOD EXTRACT | 92201-55-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA WOOD EXTRACT | 92201-55-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CEDRUS ATLANTICA WOOD OIL | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CELLULOSE | 9004-34-6 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| CERIA/SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------|------------|--|
| CERIA/SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CERIA/SILICA TALC | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CERIA/SILICA TALC | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CETEARETH ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-10 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-100 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-11 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-13 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-14 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-15 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-16 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-16-18 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|---|
| CETEARETH-17 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-18 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-2 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-2 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-20 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-21 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-22 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-23 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-24 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-25 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-25 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-27 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-28 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------|------------|---|
| CETEARETH-29 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-3 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-30 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-33 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-34 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-4 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-40 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-5 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-5 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-50 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-55 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-6 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|-------------|---|
| CETEARETH-6 OLIVATE | 226708-41-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-60 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-60 MYRISTYL GLYCOL | 96081-39-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-7 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-7 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-8 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-80 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARETH-9 | 68439-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETEARYL ALCOHOL/ CETEARETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-1 | 2136-71-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-10 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-----------|---|
| CETETH-12 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-13 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-14 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-15 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-150 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-16 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-17 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-18 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-2 | 5274-61-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-20 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-20 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-23 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-24 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-----------|---|
| CETETH-25 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-3 | 4484-59-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-3 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-30 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-4 | 5274-63-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-4 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-40 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-45 | 9004-95-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-5 | 4478-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-5 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-56 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-6 | 5168-91-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|------------|---|
| CETETH-7 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-8 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETH-9 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETHYL MORPHOLINIUM ETHOSULFATE | 78-21-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETETHYLDIMONIUM BROMIDE | 0124-03-08 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-11 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-11 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-11 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-11 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-11 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-11 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-------------|---|
| CETOLETH-15 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-18 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-2 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-22 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-24 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-25 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-4 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-4 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-4 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-4 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETOLETH-5 | 68155-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| CETOLETH-6 | 8065-81-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETRIMONIUM CARBOXYDECYL PEG-8 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETRIMONIUM DIMETHICONE PEG-7 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETRIMONIUM LAURETH-12 SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL DIMETHICONE | 191044-49-2 | According to the Cosmetic Ingredient Review (CIR) this ingredient is safe as used at concentrations < 11.8%. The CIR also states that cyclic siloxanes, which are banned or restricted ingredients, can contaminate linear siloxanes, therefore the total concentration of D4 (octamethylcyclotetrasiloxane) and D5 (decamethylcyclopentasiloxane) must not exceed 0.01% or 100ppm in the final product. |
| CETYL PEG/ PPG-10/ 1 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL PEG/PPG-15/15 BUTYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL PEG/PPG-7/3 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL PG HYDROXYETHYL PALMITAMIDE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| CETYL PG HYDROXYETHYL PALMITAMIDE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| CETYL PPG-2 ISODECETH-7 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL TRIETHYLAMMONIUM DIMETHICONE PEG-8 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| CETYL TRIETHYLMONIUM DIMETHICONE PEG-8 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL TRIETHYLMONIUM DIMETHICONE PEG-8 SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CETYL-PG HYDROXYETHYL DECANAMIDE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| CEYLON CINNAMON OIL | 8015-91-6 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CHLORELLA VULGARIS (DERMOCHLORELLA ALGAE) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CHLORELLA VULGARIS (DERMOCHLORELLA ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CHLORODECETH-14 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLECALCIFEROL PEG-12 ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-10 | 27321-96-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-15 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-20 | 27321-96-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-24 | 27321-96-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-24 | 27321-96-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| CHOLETH-24 | 27321-96-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-24 | 27321-96-6 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 1.3%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane. |
| CHOLETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHOLETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CHONDRUS CRISPUS (SEAWEED) EXTRACT. | 244023-79-8 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CHROMIUM HYDROXIDE GREEN | 12001-99-9 | Based on findings from the Community rolling action plan in the EU, this substance must contain less than 0.1% chromium (VI) and the final product cannot have more than 0.01% Chromium (VI). Lastly, this substance cannot be in nanomaterial form (>50% particles in the size range of 1nm- 100nm). |
| CHROMIUM HYDROXIDE GREEN | 12001-99-9 | Per the U.S. FDA., chromium hydroxide green shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Water soluble matter, not more than 2.5%. Chromium in 2% NaOH extract, not more than 0.1% as Cr2O3 (based on sample weight). Boron (as B2O3), not more than 8 percent. Total volatile matter at 1000 °C, not more than 20%. Cr2O3 not less than 75%. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. |
| CI 14720 | 3567-69-9 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 122) |
| CI 15850 (D&C Red No. 6 or 7) | 5858-81-1 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) | 5858-81-1 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) | 5858-81-1 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 180) |
| CI 15850 (D&C Red No. 6 or 7) Barium Lake | 0 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Barium Lake | 0 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Calcium Lake | 0 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Calcium Lake | 0 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Lake | 1234986 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Lake | 1234986 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Strontium Lake | 5858-81-1 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Strontium Lake | 5858-81-1 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Zirconium Lake | 0 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 15850 (D&C Red No. 6 or 7) Zirconium Lake | 0 | This substance must contain <0.01% unsulfonated primary aromatic amines, <2 ppm lead and <1 ppm cadmium. |
| CI 16255 | 2611-82-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 124) |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| CI 18050 | 3734-67-6 | Per COSING, prohibited for use in products applied on mucous membranes. Purity criteria as set out in Commission Directive 95/45/EC (E 128). |
| CI 28440 | 2519-30-4 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 151) |
| CI 40825 | 1109-11-1 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 160f) |
| CI 40850 | 514-78-3 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 161g) |
| CI 42090 (FD&C Blue No. 1 or D&C Blue No. 4) | 3844-45-9 | This substance must contain less than: 100 ppm manganese, 2 ppm lead, 1 ppm mercury, 1 ppm cadmium, and 100 ppm unsulfonated primary aromatic amines. |
| CI 42090 (FD&C Blue No. 1 or D&C Blue No. 4) | 3844-45-9 | Per COSING, this ingredient shall conform to the purity criteria as sset out in Commission Directive 95/45/EC (E 133) |
| CI 42090 (FD&C Blue No. 1 or D&C Blue No. 4) Aluminum Lake | 53026-57-6 | This substance must contain less than: 100 ppm manganese, 2 ppm lead, 1 ppm mercury, 1 ppm cadmium, and 100 ppm unsulfonated primary aromatic amines. |
| CI 44090 | 3087-16-9 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 142) |
| CI 45405 | 6441-77-6 | Per COSING, prohobited for use in eye products. This ingredient must contain <1% 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid and <2% 2-(bromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid. |
| CI 61585 | 4474-24-2 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| CI 61585 | 4474-24-2 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| CI 73915 | 980-26-7 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| CI 73915 | 980-26-7 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| CI 75120 | 542-40-5 | This ingredient must meet purity criteria as set out in European Commission Directive: Solvent residues Acetone, Methanol, or Hexane not more than 50 ppm singly or in combination; Dichloromethane not more than 10 ppm; Arsenic not more than 3 ppm, Lead |
| CI 75120 | 542-40-5 | Per the U.S. FDA., annatto extract, including pigments precipitated therefrom, shall conform to the following specifications: (1) Arsenic (as As), not more than 3 parts per million; lead as Pb, not more than 10 parts per million. (2) When solvents listed under paragraph (a)(1)(ii) of this section are used, annatto extract shall contain no more solvent residue than is permitted of the corresponding solvents in spice oleoresins under applicable food additive regulations in parts 170 through 189 of this chapter. |
| CI 75125 | 502-65-8 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 160d) |
| CI 75130 | 7235-40-7 | The European Commission restricts the arsenic, lead, mercury, cadmium, and total heavy metal contents of this ingredient to maximum concentrations of 3 ppm, 10 ppm, 1 ppm, 1 ppm, and 40 ppm, respectively. |
| CI 75130 | 7235-40-7 | Per the U.S. FDA., β -carotene shall conform to the following specifications: Physical state, solid. 1 percent solution in chloroform, clear. Loss of weight on drying, not more than 0.2 percent. Residue on ignition, not more than 0.2 percent. Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Assay (spectrophotometric), 96-101 percent. |
| CI 75130 | 7235-40-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 160a) |
| CI 75130 | 7235-40-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 160a) |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|------------|---|
| CI 75130 | 7235-40-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 160a) |
| CI 75300 | 458-37-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 100) |
| CI 75470 | 1390-65-4 | The European Commission restricts the arsenic, lead, mercury, cadmium, and total heavy metal contents of this ingredient to maximum concentrations of 3 ppm, 10 ppm, 1 ppm, 1 ppm, and 40 ppm, respectively. |
| CI 75470 | 1390-65-4 | Per the U.S. FDA., carmine shall conform to the following specifications: Volatile matter (at 135 °C. for 3 hours), not more than 20.0 percent. Ash, not more than 12.0 percent. Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million. Carminic acid, not less than 50.0 percent. |
| CI 75470 | 1390-65-4 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 120) |
| CI 75810 | 11006-34-1 | The European Commission restricts the arsenic, lead, mercury, cadmium, and copper contents of this ingredient to maximum concentrations of 3 ppm, 10 ppm, 1 ppm, 1 ppm, and 200 ppm, respectively. |
| CI 75810 | 11006-34-1 | Per the U.S. FDA., potassium sodium copper chlorophyllin shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by good manufacturing practice: Moisture, not more than 5.0 percent. Nitrogen, not more than 5.0 percent. pH of 1 percent solution, 9 to 11. Total copper, not less than 4 percent and not more than 6 percent. Free copper, not more than 0.25 percent. Iron, not more than 0.5 percent. Lead (as Pb)), not more than 20 parts per million. Arsenic (as As), not more than 5 parts per million. Ratio, absorbance at 405 mµ to absorbance at 630 mµ, not less than 3.4 and not more than 3.9. Total color, not less than 75 percent. |
| CI 75810 | 11006-34-1 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 140, E 141) |
| CI 77015 | 1309-37-1 | Per the U.S. FDA., iron oxides shall conform to the following specifications, all on an "as is" basis: Arsenic (as As), not more than 3 parts per million. Lead (as Pb), not more than 10 parts per million. Mercury (as Hg), not more than 3 parts per million. |
| CI 77015 | 1309-37-1 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E172) |
| CI 77015 | 1309-37-1 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E172) |
| CI 77015 | 1309-37-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CI 77015 | 1309-37-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CI 77400 | 7440-50-8 | Per the U.S. FDA., copper powder shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Stearic or oleic acid, not more than 5 percent. Cadmium (as Cd), not more than 15 parts per million. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Copper (as Cu), not less than 95 percent. Maximum particle size 45µ (95 percent minimum). |
| CI 77499 | 1332-37-2 | Per the U.S. FDA., iron oxides shall conform to the following specifications, all on an "as is" basis: Arsenic (as As), not more than 3 parts per million. Lead (as Pb), not more than 10 parts per million. Mercury (as Hg), not more than 3 parts per million. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| CI 77499 | 1332-37-2 | Per the Commission Directive 95/45/EC (E 172), this ingredient shall conform to the following specifications: Arsenic (5 ppm) Barium (50 ppm) Cadmium (5 ppm) Chromium (100 ppm) Copper (50 ppm) Lead (20 ppm) Mercury (1 ppm) Nickel (200 ppm) Zinc (100 ppm) |
| CI 77499 | 1332-37-2 | The U.S. Food and Drug Administration and European Commission restricts the maximum concentration of the following heavy metals: lead (10 ppm), arsenic (3 ppm), mercury (1 ppm), cadmium (5 ppm), barium (50 ppm), zinc (100 ppm), chromium (100 ppm), copper (50 ppm), nickel (200 ppm) |
| CI 77510 | 0 | Per the U.S. FDA., ferric ammonium ferrocyanide shall conform to the following specifications and shall be free of impurities other than those named to the extent that the other impurities may be avoided by good manufacturing practice: Oxalic acid or its salts, not more than 0.1 percent. Water soluble matter, not more than 3 percent. Water soluble cyanide, not more than 10 parts per million. Volatile matter, not more than 4 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Nickel (as Ni), not more than 200 parts per million. Cobalt (as Co), not more than 200 parts per million. Mercury (as Hg), not more than 1 part per million. Total iron (as Fe corrected for volatile matter), not less than 33 percent and not more than 39 percent. |
| CICLOPIROX OLAMINE | 41621-49-2 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| CINNAMOMUM CAMPHORA (CAMPHOR) EXTRACT | 0 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CINNAMOMUM CAMPHORA (CAMPHOR) LEAF EXTRACT | 92201-50-8 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CINNAMOMUM CAMPHORA (CAMPHOR) OIL | 8008-51-3 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CINNAMOMUM CAMPHORA (CAMPHOR) OIL | 8008-51-3 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CINNAMOMUM CAMPHORA GUM EXTRACT | 0 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CINNAMOMUM ZEYLANICUM (CINNAMON) LEAF OIL | 8015-91-6 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CINNAMOMUM ZEYLANICUM (CINNAMON) LEAF OIL | 8015-91-6 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CITRINE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CITRINE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CITRINE CRYSTAL INFUSION | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| CITRINE CRYSTAL INFUSION | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CITRINE EXTRACT | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CITRINE EXTRACT | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CITRUS AMARA (NEROLI) FLOWER OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS ARANTIUM DULCIS FLOWER OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) FRUIT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) FRUIT EXTRACT | 90063-52-8 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) FRUIT OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) LEAF OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) PEEL | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) PEEL EXTRACT | 90063-52-8 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIFOLIA (LIME) PEEL OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM AMARA (BITTER ORANGE) FLOWER OIL | 68916-04-01 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM AMARA (BITTER ORANGE) FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| CITRUS AURANTIUM AMARA (BITTER ORANGE) LEAF/TWIG OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM AMARA (BITTER ORANGE) PEEL | 68916-04-01 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM AMARA (BITTER ORANGE) PEEL EXTRACT | 72968-50-4 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM AMARA (BITTER ORANGE) PEEL OIL | 68916-04-01 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM AMARA (BITTER ORANGE) PEEL POWDER | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM BERGAMIA (BERGAMOT) FRUIT EXTRACT | 89957-91-5 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM BERGAMIA (BERGAMOT) FRUIT OIL | 8007-75-8 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM BERGAMIA (BERGAMOT) FRUIT OIL | 8007-75-8 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM BERGAMIA (BERGAMOT) FRUIT WATER | 89957-91-5 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM BERGAMIA (BERGAMOT) LEAF OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM BERGAMIA (BERGAMOT) PEEL OIL | 92704-01-03 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) FLOWER OIL | 8016-38-4 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) FRUIT EXTRACT | 8028-48-6 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) FRUIT WATER | 8028-48-6 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| CITRUS AURANTIUM DULCIS (ORANGE) PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) PEEL OIL | 8028-48-6 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) PEEL POWDER | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) PEEL WAX | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS AURANTIUM DULCIS (ORANGE) WOOD OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| Citrus Australasica Fruit Extract | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS CLEMENTINA FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS CLEMENTINA JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS DEPRESSA FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GLAUCA FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) FRUIT EXTRACT | 90045-43-5 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) FRUIT WATER | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) PEEL | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) PEEL EXTRACT | 90045-43-5 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) PEEL OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS GRANDIS (GRAPEFRUIT) PEEL POWDER | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| CITRUS GRANDIS (GRAPEFRUIT) SEED EXTRACT | 90045-43-5 | This ingredient cannot contain triclosan, quaternary |
| CITRUS GRANDIS (GRAPEFRUIT) SEED OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS GRANDIS/PARADISI FRUIT WATER | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS HYSTRIX LEAF OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS HYSTRIX PEEL OIL | 91771-50-5 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS JABARA JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS JABARA PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS JAPONICA FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS JUNOS FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS JUNOS FRUIT POWDER | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| Citrus junos oil | 233683-84-6 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS JUNOS PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS JUNOS PEEL OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS JUNOS PEEL WATER | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS LIMON (LEMON) FRUIT EXTRACT | 84929-31-7 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS LIMON (LEMON) FRUIT OIL | 8008-56-8 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS LIMON (LEMON) FRUIT OIL | 8008-56-8 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS LIMON (LEMON) FRUIT WATER | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| CITRUS LIMON (LEMON) JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS LIMON (LEMON) JUICE EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| Citrus Limon (Lemon) Leaf Cell Extract | 92346-89-9 | The European Commission restricts this ingredient's furocoumarines content (e.g. trioxysalen (INN), 8- methoxypsoralen, 5-methoxypsoralen) to below 1 mg/kg in sun protection and bronzing products (except for normal content in natural essences used). |
| CITRUS LIMON (LEMON) LEAF EXTRACT | 84929-31-7 | The European Commission restricts this ingredient's furocoumarines content (e.g. trioxysalen (INN), 8- methoxypsoralen, 5-methoxypsoralen) to below 1 mg/kg in sun protection and bronzing products (except for normal content in natural essences used). |
| CITRUS LIMON (LEMON) LEAF OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS LIMON (LEMON) PEEL | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS LIMON (LEMON) PEEL EXTRACT | 92346-89-9 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS LIMON (LEMON) PEEL OIL | 8008-56-8 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS LIMON (LEMON) SEED OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS MADURENSIS FRUIT JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS MEDICA ACIDA PEEL OIL EXPRESSED | 93685-55-3 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS OIL EXTRACT | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS PARADISI (GRAPEFRUIT) FRUIT EXTRACT | 8016-20-4 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS PARADISI (GRAPEFRUIT) FRUIT OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS PARADISI (GRAPEFRUIT) JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| CITRUS PARADISI (GRAPEFRUIT) OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS PARADISI (GRAPEFRUIT) PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS PARADISI (GRAPEFRUIT) PEEL OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS PARADISI (GRAPEFRUIT) SEED OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS PARADISI,X C. RETICULATA PEEL OIL EXPRESSED | 93763-95-2 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS RETICULATA | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA FRUIT EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA FRUIT OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS RETICULATA FRUIT OIL | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA JUICE | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA LEAF OIL | 8014-17-3 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS RETICULATA OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| Citrus reticulata peel | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| CITRUS RETICULATA PEEL EXTRACT | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA PEEL OIL | 8008-31-9 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS RETICULATA PEEL POWDER | 0 | The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| CITRUS RETICULATA,X C. SINENSIS PEEL OIL EXPRESSED | 93686-22-7 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS SEED OIL | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS SPECIES LEAF OIL | 94266-47-4 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CITRUS SPECIES PEEL OIL EXPRESSED | 94266-47-4 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| CLADOSIPHON NOVAE-CALEDONIAE EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CLADOSIPHON OKAMURANUS EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CLOVER HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| CLOVER HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| COAL LIQUIDS, LIQ. SOLVENT EXTN. | 94114-48-4 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.005% w/w benzo[a]pyrene |
| COAL LIQUIDS, LIQ. SOLVENT EXTN. SOLN. | 94114-47-3 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.005% w/w benzo[a]pyrene |
| COCAMIDE DIPA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| COCAMIDOPROPYL BETAINE | 61789-40-0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| COCAMIDOPROPYL DIMETHYLAMINE | 68140-01-02 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| COCAMIDOPROPYL HYDROXYSULTAINE | 68139-30-0 | The CIR panel expressed concern about DMAPA impurities in this ingredient. The concentration of DMAPA in this ingredient must not exceed 0.01%. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| COCAMIDOPROPYL HYDROXYSULTAINE | 68139-30-0 | The Consumer Ingredient Review Expert Panel concluded that this ingredient is safe in cosmetics in the present practices of use and concentration < 11.5%. The CIR panel also noted Dimethylaminopropylamine (DMAPA) impurities in this ingredient. The concentration of DMAPA in this ingredient must not exceed 0.01%. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| COCAMIDOPROPYLAMINE OXIDE | 68155-09-09 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 4%. The concentration of DMAPA should not exceed 0.01%. |
| COCAMINE | 61788-46-3 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| COCETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| coco methyl ester ethoxylate | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| COCO/OLEAMIDOPROPYL BETAINE | 86438-79-1 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| COCO/SUNFLOWERAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| COCO/SUNFLOWERAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB) |
| COCODIMONIUM HYDROXYPROPYL HYDROLYZED RICE PROTEIN | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| COCONUT OIL ALCOHOL, ETHOXYLATED | 61791-13-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| COCONUT OIL PEG-10 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| COCONUT OIL PPG-2-PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CODIUM TOMENTOSUM (ALGAE) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CODIUM TOMENTOSUM (ALGAE) EXTRACT | 92128-82-0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| COENOCHLORIS SIGNIENSIS EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| COLOSTRUM | 0 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| CORN OIL PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CORN OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| CORN STARCH/ ACRYLAMIDE/ SODIUM ACRYLATE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| CORNAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| CORNAMIDE/COCAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| COTTONSEED GLYCERIDE | 8029-44-5 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: gossypol, heavy metals, and pesticides. |
| COUMARIN, 3-GLYOXYLOYL- | 91635-05-01 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| COUMARIN, 3-GLYOXYLOYL- | 91635-05-01 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| COUMARIN, 3-GLYOXYLOYL-8-METHOXY- | 92024-91-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| COUMARIN, 3-GLYOXYLOYL-8-METHOXY- | 92024-91-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| CUBEB OIL | 8007-87-2 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS (ITALIAN CYPRESS) CONE EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS (ITALIAN CYPRESS) CONE EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS (ITALIAN CYPRESS) CONE EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS (ITALIAN CYPRESS) CONE EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS (ITALIAN CYPRESS) CONE EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS (ITALIAN CYPRESS) OIL | 8013-86-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS BARK EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS FRUIT EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS LEAF WATER | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CUPRESSUS SEMPERVIRENS SEED EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| CUPUASSUAMIDOPROPYL BETAINE | 657350-94-2 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| Curry Red (Uncertified FD&C Red No. 40) | 25956-17-6 | This substance must contain <2ppm lead, <1ppm mercury, and <1ppm cadmium. |
| Curry Red (Uncertified FD&C Red No. 40) | 25956-17-6 | Due to their link to carcinogenicity, this substance must contain less than 100 ppm total unsulfonated primary aromatic amines, including aniline, 6methoxymtoluidine, and 1napthylamine. |
| CUTANEOUS LYSATE | 0 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| CYLINDROTHECA FUSIFORMIS EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CYPRESS EXTRACT | 84696-07-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| CYSTOSEIRA AMENTACEA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CYSTOSEIRA AMENTACEA/CAESPITOSA BRANCHYCARPA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CYSTOSEIRA TAMARISCIFOLIA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CYSTOSEIRA TAMARISIFOLIA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| CYTOCHROME C | 9007-43-6 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| d-allo-OCIMENOL | 126-91-0 | The International Fragrance Association restricts the total peroxide content (in the final product) to a maximum concentration of 20 millimoles peroxides per liter. |
| d-alpha-PINENE | 7785-70-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L |
| d-Limonene | 5989-27-5 | The European Commission restricts this ingredient's peroxide content to less than 20 mmoles/L. Required Warning: The European Commission requires that the presence of this substance be indicated in the list of ingredients when its concentration exceeds 0.001% in leaveon products and 0.01% in rinseoff products. |
| D&C GREEN NO. 5 (CI 61570) | 4403-90-1 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| D&C GREEN NO. 5 (CI 61570) | 4403-90-1 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| D&C Green No. 5 (Cl 61570) Lake | 4403-90-1 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| D&C Green No. 5 (CI 61570) Lake | 4403-90-1 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| D&C Green No. 6 (CI 61565) | 128-80-3 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| D&C Green No. 6 (Cl 61565) | 128-80-3 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| D&C Orange No. 4 (CI 15510) | 633-96-5 | This substance must contain <0.06% 2naphthol and <0.12% sodium sulfanilate. |
| D&C Orange No. 4 (CI 15510) Lake | 0 | This substance must contain <0.06% 2naphthol and <0.12% sodium sulfanilate. |
| D&C Red No. 17 (CI 26100) | 85-86-9 | This substance may not contain detectable levels of paraphenylenediamine (PPD; pphenylenediamine). |
| D&C Red No. 17 (CI 26100) | 85-86-9 | Per COSING, this ingredient shall conform to the purity criteria: anilin less than or equal to 0.2%, 2-naphthol less than or equal to 0.2%, 4-aminoazobenzene less than or equal to 0.1%, 1-(phenylazo)-2-naphthol less than or equal to 3%, 1-[2-(phenylazo)phenylazo]-2-naphthalenol less than or equal to 2%. Prohibited for use in products applied on mucous membranes. |
| D&C Red No. 17 (Cl 26100) Calcium Lake | 85-86-9 | This substance may not contain detectable levels of paraphenylenediamine (PPD; pphenylenediamine). |
| D&C Red No. 31 (CI 15800) | 6371-76-2 | This substance may not contain detectable levels of Sudan I (CI Solvent Yellow 14; 1phenylazo2naphthol). |
| D&C Red No. 31 (CI 15800) Lake | 0 | This substance may not contain detectable levels of Sudan I (CI Solvent Yellow 14: 1phenylazo2naphthol). |
| DEA PG-PROPYL PEG/PPG-18/21 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-CETEARETH-2 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-LAURETH SULFATE | 58855-36-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-OLETH-10 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-OLETH-10 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-OLETH-10 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| DEA-OLETH-10 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-OLETH-20 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-OLETH-3 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-OLETH-5 PHOSPHATE | 58855-63-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-PEG-4 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DEA-POLYPERFLUOROETHOXYMETHOXY PEG-2 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECANAMIDE, N,N-DIMETHYL- | 14433-76-2 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| Decanol alkoxylate | 166736-08-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-10 | 26183-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-4 | 5703-94-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-4 PHOSPHATE | 52019-36-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------|------------|---|
| DECETH-4 PHOSPHATE | 52019-36-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-5 | 26183-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-5 | 26183-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-5 | 26183-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-6 | 5168-89-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-6 PHOSPHATE | 52019-36-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-7 CARBOXYLIC ACID | 38815-93-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-7 CARBOXYLIC ACID | 38815-93-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-7 GLUCOSIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-8 | 26183-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-9 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DECETH-9 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| DECYL GLUCOSIDE | 54549-25-6 | This substance must contain <500 ppm magnesium oxide, <1 % free fatty alcohol, and <3 % sulfate ash |
| DECYLTETRADECETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DELTA TOCOPHEROLS | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| DI-PEG-2 SOYAMINE IPDI | 183681-06-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DI-PPG-3 CETETH-4 ADIPATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DI-TEA-COCAMIDE DIACETATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DI-TEA-OLEAMIDO PEG-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DI-TEA-OLEAMIDO PEG-2 SULFOSUCCINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DI-TEA-PALMITOYL ASPARTATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIAMMONIUM OLEAMIDO PEG-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIATOMACEOUS EARTH | 61790-53-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIATOMACEOUS EARTH | 61790-53-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIBEHENYL METHYLAMINE | 61372-91-6 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| DICAPRYLATE/ DICAPRATE PEG-7 GLYCERYL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DICETEARETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DICOCODIMETHYLAMINE DILINOLEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DICTYOPTERIS MEMBRANACEA (ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| DICTYOPTERIS POLYPODIOIDES EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| DIETHYL CAPRYLAMIDE | 996-97-4 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| DIETHYLAMINE LAURETH SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE | 302776-68-7 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE | 302776-68-7 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| DIETHYLAMINOETHYL PEG-4 COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIETHYLAMINOETHYL PEG-4 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIETHYLAMINOETHYL PEG-5 COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| DIETHYLAMINOETHYL PEG-5 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIETHYLENE GLYCOL PROPYL ETHER | 29911-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIETHYLENE GLYCOL/DMAP ACRYLAMIDE/PEG-180/HDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIHYDROCHOLETH 30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIHYDROCHOLETH-15 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIHYDROCHOLETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIHYDROGENATED TALLOW METHYLAMINE | 61788-63-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIHYDROXYETHYL TALLOW GLYCINATE | 61791-25-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIHYDROXYPROPYL PEG-10 STEARAMMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIHYDROXYPROPYL PEG-5 LINOLEAMMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIISOSTEAROYL TRIMETHYLOLPROPANE SILOXY SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIISOSTEAROYL TRIMETHYLOLPROPANE SILOXY SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1 ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| DILAURETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DILAURETH-4 DIMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DILAURETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DILAURETH-7 CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DILAUROYL TRIMETHYLOLPROPANE SILOXY SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DILAUROYL TRIMETHYLOLPROPANE SILOXY SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DILINOLEAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| DILINOLEAMIDOPROPYL DIMETHYLAMINE DIMETHICONE PEG- 7 PHOSPHATE | 138698-34-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE COPOLYOL PHOSPHATE | 132207-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE COPOLYOL PHOSPHATE | 132207-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG 10/ 15 CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-10 PHOSPHATE | 132207-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-15 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| DIMETHICONE PEG-7 AVOCADOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 LACTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 OCTYLDODECYL CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 OLIVATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 PHOSPHATE | 132207-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-7 UNDECYLENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 ADIPATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 AVOCADOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-------------|---|
| DIMETHICONE PEG-8 BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 BENZOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 BORAGEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 ISOSTEARATE | 133448-16-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 LANOLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 MEADOWFOAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 OLIVATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 POLYACRYLATE | 217958-64-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG-8 SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG/PPG-12/4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| DIMETHICONE PEG/PPG-20/23 BENZOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE PEG/PPG-7/4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE/PEG-10 CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIMETHICONE/PEG-15 CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Dimethicone/Silica Antifoam | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| Dimethicone/Silica Antifoam | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| Dimethicone/Silica/PEG Distearate Antifoam | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| Dimethicone/Silica/PEG Distearate Antifoam | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIMETHICONE/VINYLTRIMETHYLSILOXYSILICATE CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIMETHICONE/VINYLTRIMETHYLSILOXYSILICATE CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIMETHICONOL/METHYLSILANOL/SILICATE CROSSPOLYMER | 69856-02-06 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| DIMETHICONOL/METHYLSILANOL/SILICATE CROSSPOLYMER | 69856-02-06 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|------------|--|
| DIMETHYL BEHENAMINE | 21542-96-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL COCAMINE | 61788-93-0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL HYDROGENATED TALLOWAMINE | 61788-95-2 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL LAURAMINE | 112-18-5 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL LAURAMINE DIMER DILINOLEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL LAURAMINE ISOSTEARATE | 70729-87-2 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL LAURAMINE OLEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL MEA | 108-01-0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL MYRISTAMINE | 112-75-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| DIMETHYL PALMITAMINE | 112-69-6 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL SOYAMINE | 61788-91-8 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL STEARAMINE | 124-28-7 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DIMETHYL TALLOWAMINE | 68814-69-7 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DINONOXYNOL-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DINONOXYNOL-9 CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIOCTYLDODECETH-2 LAUROYL GLUTAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIOCTYLDODECETH-5 LAUROYL GLUTAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIOLETH-8 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DIOLEYL TOCOPHERYL METHYLSILANOL | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| DIOSCOREA VILLOSA | 90147-49-2 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 15% of max 2% plant solids. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides. |
| DIOSCOREA VILLOSA (WILD YAM) ROOT EXTRACT | 90147-49-2 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 15% of max 2% plant solids. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides. |
| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| DIOSCOREA VILLOSA (WILD YAM) ROOT EXTRACT | 90147-49-2 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 15% of max 2% plant solids. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides. |
| DIPOTASSIUM GLYCYRRHIZATE | 68797-35-3 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: pesticides/PCBs, toxic metals, and heavy metals. The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 1%. |
| DIPROPYLENE GLYCOL ISOCETETH-20 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Dipropylene Glycol Methyl Ether | 34590-94-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM COCAMIDO MIPA PEG-4 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM COCAMIDO PEG-3 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM DECETH-5 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM DECETH-6 SULFOSUCCINATE | 68311-03-05 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM ETHLENE DICOCAMIDE PEG 15 DISULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM GLYCYRRHIZATE | 71277-79-7 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: pesticides/PCBs, toxic metals, and heavy metals. |
| DISODIUM LAURAMIDO PEG-2 SULFOSUCCINATE | 56388-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURAMIDO PEG-5 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH SULFOSUCCINATE | 58450-52-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| DISODIUM LAURETH-12 SULFOSUCCINATE | 39354-45-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH-12 SULFOSUCCINATE | 39354-45-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH-12 SULFOSUCCINATE | 39354-45-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH-5 CARBOXYAMPHODIACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH-6 SULFOSUCCINATE | 39354-45-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH-7 CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURETH-9 SULFOSUCCINATE | 39354-45-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM LAURIMINODIPROPIONATE TOCOPHERYL PHOSPHATES | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| DISODIUM NONOXYNOL-10 SULFOSUCCINATE | 67999-57-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM OLEAMIDO PEG-2 SULFOSUCCINATE | 56388-43-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM OLETH-3 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PALMITAMIDO PEG-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PALMITOLEAMIDO PEG-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| DISODIUM PEG STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-12 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-12 DIMETHICONE SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-2 OLEAMIDO SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-4 COCAMIDO MIPA-SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-5 LANOLIN ETHER SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-5 LAURYLCITRATE SULFOSUCCINATE | 164458-73-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-8 GLYCERYL CAPRYLATE/CAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-8 PALM GLYCERIDES SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PEG-8 RICINOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM PPG-2-ISODECETH-7 CARBOXYAMPHODIACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISODIUM SUCCINOYL GLYCYRRHETINATE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: pesticides/PCBs, toxic metals, and heavy metals. |
| DISODIUM UNDECYLENAMIDO PEG-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| DISODIUM WHEAT GERMAMIDO PEG-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISTEARETH 100 IPDI | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISTEARETH-75 IPDI | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DISTEARYLDIMETHYLAMINE DILINOLEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| DISTILLATES (COAL-PETROLEUM), CONDENSED-RING AROM | 68188-48-7 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.005% w/w benzo[a]pyrene |
| DOBANOL 25-3 | 58391-12-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DODOXYNOL-12 | 9014-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| DURVILLAEA ANTARCTICA EXTRACT | 223749-87-9 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| DURVILLAEA ANTARTICA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| DURVILLAEA POTATORUM EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ECKLONIA CAVA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ECKLONIA KUROME EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|--|-----------|---|
| ECKLONIA RADIATA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| ESTER-C LIQUID SODIUM MAGNESIUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ESTER-C LIQUID SODIUM MAGNESIUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ETHANOL, 2,2'-(BUTYLIMINO)DI- | 102-79-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| ETHANOLAMINE DITHIODIGLYCOLATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ETHANOLAMINE GLYCEROPHOSPHATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ETHANOLAMINE HCL | 2002-24-6 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ETHANOLAMINE THIOGLYCOLATE | 126-97-6 | The European Commission restricts this ingredient to a maximum concentration of 8% (as thioglycolic acid) with a pH of 7 to 9.5 in general use hair products, 11% (as thioglycolic acid) with a pH of 7 to 9.5 in professional use hair products, 5% (as thioglycolic acid) with a pH of 7 to 12.7 in depilatories, and 2% (as thioglycolic acid) with a pH of 7 to 12.7 in depilatories, and 2% (as thioglycolic acid) with a pH of 7 to 9.5 in hair rinseoff products. Additionally, this substance cannot be used with nitrosating systems, it cannot have a secondary amine content over 0.5%, it must have a minimum purity of 99%, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. Required Warning: The European Commission requires the following conditions of use on the label/package of hair products, depilatories and hair rinseoff products: 'Avoid contact with eyes'; 'In the event of contact with eyes, rinse immediately with plenty of water and seek medical advice'. Additionally, the following conditions of use are required on hair products and hair rinseoff products: 'Wear suitable gloves'. The European Commission also requires the following warning text on the label/package of hair products and hair rinseoff products: 'Contains thioglycolate'; 'Follow the instructions'; 'Keep out of reach of children'. Additionally, the following warning text is required on hair products: 'For professionaly use only.' |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------|------------|---|
| ETHOXYDIGLYCOL | 111-90-0 | (*) The European Commission prohibits the use of this ingredient in eye and oral products, and restricts it to a maximum concentration of 7% in oxidative hair dye products, 5% in nonoxidative hair dye products, 10% in rinseoff products other than hair dye product, 2.6% in other nonspray cosmetic products, and 2.6% in the following spray products fine fragrances, hair sprays, antiperspirant and deodorant. Additionally, the level of ethylene glycol impurity in Ethoxydiglycol must be <= 0.1 %. |
| ETHOXYLATED ALKYL PHENOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ethoxylated amines | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------|------------|---|
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|------------|---|
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ethoxylated cocoalkylamines | 61791-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Ethoxylated Ethylhexanol | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED EVENING PRIMROSE OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHOXYLATED GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ethoxylated octadecylamine | 26635-92-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ethoxylated oleylamines | 13127-82-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| ETHOXYLATED PLANT STEROLS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ethoxylated soyaalkylamines | 73246-96-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ethoxylated tallowalkylamines | 61791-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Ethoxylated Undecyl Alcohol | 127036-24-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHYL DIMETHYLAMINOBENZOATE | 0 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| ETHYL DIMETHYLAMINOBENZOATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| Ethyl Ferulate | 4046-02-0 | For the purposes of the Reviewed Ingredients program, this ingredient may only be used in combination with another restricted ingredient on the Ingredients Eligible for Reviewed List. |
| Ethyl Hexanol Ethoxylated Propoxylated | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHYL PEG-15 COCAMINE SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ETHYLENE GLYCOL, ESTER WITH SILICIC ACID (4:1) | 17622-94-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ETHYLENE GLYCOL, ESTER WITH SILICIC ACID (4:1) | 17622-94-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| EVERNIA PRUNASTRI (OAKMOSS) EXTRACT | 90028-68-5 | According to the International Fragrance Association, this ingredient must not contain added tree moss. Additionally, dehydroabietic acid (DHA) must not exceed 0.1% in the extract, and the levels of atranol and chloroatranol should each be below 100ppm. |
| Ext. D&C Violet No. 2 (CI 60730) | 4430-18-6 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| Ext. D&C Violet No. 2 (CI 60730) | 4430-18-6 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| Ext. D&C Yellow No. 7 (CI 10316) | 846-70-8 | This substance must contain <10 ppm 1naphthol, <20 ppm 2,4dinitro1naphthol, and <10 ppm lead. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| Fatty acid methyl ester ethoxylates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Fatty acids, coco, esters with sorbitan, ethoxylated | 68154-33-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| FD&C Green No. 3 (CI 42053) | 2353-45-9 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| FD&C Green No. 3 (CI 42053) | 2353-45-9 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| FD&C Green No. 3 (CI 42053) Lake | 2353-45-9 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| FD&C Green No. 3 (CI 42053) Lake | 2353-45-9 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| FD&C Red No. 40 (CI 16035) | 25956-17-6 | This substance must contain <2ppm lead, <1ppm mercury, and <1ppm cadmium. |
| FD&C Red No. 40 (CI 16035) | 25956-17-6 | Due to their link to carcinogenicity, this substance must contain less than 100 ppm total unsulfonated primary aromatic amines, including aniline, 6methoxymtoluidine, and 1napthylamine. |
| FD&C Red No. 40 (CI 16035) | 25956-17-6 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 129) |
| FD&C Red No. 40 (CI 16035) Lake | 25956-17-6 | This substance must contain <2ppm lead, <1ppm mercury, and <1ppm cadmium. |
| FD&C Red No. 40 (CI 16035) Lake | 25956-17-6 | Due to their link to carcinogenicity, this substance must contain less than 100 ppm total unsulfonated primary aromatic amines, including aniline, 6methoxymtoluidine, and 1napthylamine. |
| FD&C Yellow No. 5 (Cl 19140) | 1934-21-0 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine, <5 ppb 2aminobiphenyl, and <5 ppb 1naphthylamine. |
| FD&C Yellow No. 5 (CI 19140) | 1934-21-0 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 102) |
| FD&C Yellow No. 5 (Cl 19140) Lake | 0 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine, <5 ppb 2aminobiphenyl, and <5 ppb 1naphthylamine. |
| FD&C Yellow No. 5 (Cl 19140) Zirconium Lake | 0 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine, <5 ppb 2aminobiphenyl, and <5 ppb 1naphthylamine. |
| FD&C Yellow No. 6 (Cl 15985) | 0 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine. |
| FD&C Yellow No. 6 (Cl 15985) Lake | 15790-07-05 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine. |
| FERRIC AMMONIUM FERROCYANIDE | 25869-00-5 | The European Commission requires that this ingredient be free of cyanide. |
| FERRIC AMMONIUM FERROCYANIDE | 25869-00-5 | Per the U.S. FDA., ferric ammonium ferrocyanide shall conform to the following specifications and shall be free of impurities other than those named to the extent that the other impurities may be avoided by good manufacturing practice: Oxalic acid or its salts, not more than 0.1 percent. Water soluble matter, not more than 3 percent. Water soluble cyanide, not more than 10 parts per million. Volatile matter, not more than 4 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Nickel (as Ni), not more than 20 parts per million. Cobalt (as Co), not more than 200 parts per million. Mercury (as Hg), not more than 1 part per million. Total iron (as Fe corrected for volatile matter), not less than 33 percent and not more than 39 percent. |
| | 20009-00-0 | rei cosing, this ingreatent must be free from cyanide ions. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| FERRIC FERROCYANIDE | 14038-43-8 | Per the U.S. FDA., ferric ferrocyanide shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Water soluble cyanide, not more than 10 parts per million. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Nickel (as Ni), not more than 200 parts per million. Cobalt (as Co), not more than 200 parts per million. Mercury (as Hg), not more than 1 part per million. Oxalic acid, not more than 0.1 percent. Water soluble matter, not more than 3 percent. Total iron (as Fe corrected for volatile matter), not less than 37 percent and not more than 45 percent. |
| FIBROIN/PEG-16/SODIUM ACRYLATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| FIBRONECTIN | 86088-83-7 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| FLAVYLIUM, 3,3'4',5,7-PENTAHYDROXY-, CHLORIDE | 528-58-5 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E163) |
| FLAVYLIUM, 3,4',5,7-TETRAHYDROXY-3',5'-DIMETHOXY-, ACID ANION | 10463-84-0 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E163) |
| FLAVYLIUM, 3,4',5,7-TETRAHYDROXY-3',5'-DIMETHOXY-, CHLORIDE | 643-84-5 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E163) |
| FLUORESCENT BRIGHTENER 230 | 27344-06-05 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| FLUORESCENT BRIGHTENER 230 | 27344-06-05 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| FLUOROSILICIC ACID | 16961-83-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| FLUOROSILICIC ACID | 16961-83-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| FUCOIDAN, FROM FUCUS VESICULOSUS | 9072-19-9 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| FUCUS SERRATUS | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| FUCUS SERRATUS EXTRACT | 94167-02-09 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| FUCUS VESICULOSIS (BLADDERWRACK) OIL | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| FUCUS VESICULOSUS | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| FUCUS VESICULOSUS EXTRACT | 84696-13-9 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| FUCUS VESICULOSUS POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| FURFURACEA (TREEMOSS) EXTRACT | 90028-67-4 | The International Fragrance Association restricts the dehydroabietic acid (DHA) concentration of this ingredient to a maximum of 0.8% in the extract, and the levels of atranol and chloroatranol should each be below 100ppm. |
| GAMMA TOCOPHEROLS | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| gamma-TERPINENE | 99-85-4 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| GASES (PETROLEUM, LIGHT STEAM-CRACKED, BUTADIENE CONC. | 68955-28-2 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.1% w/w Butadiene |
| GELATIN/LYSINE/POLYACRYLAMIDE HYDROXYPROPYLTRIMONIUM CHLORIDE | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| GELIDIUM CARTILAGINEUM (RED ALGAE) EXTRACT | 94945-01-04 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| GIGARTINA PAPILLATA (RED ALGAE) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| GLYCERETH-26 | 31694-55-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| GLYCERIN | 56-81-5 | Health Canada requires manufacturers of oral and leaveon products containing glycerin to ensure the raw material used is within the specifications of an accepted pharmacopoeia with respect to diethylene glycol (DEG) impurities. |
| GLYCERYL STEARATE/ PEG-100 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| GLYCOFUROL | 31692-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Glycols, 1,2-, C12-16, ethoxylated propoxylated | 154248-98-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| GLYCOPROTEINS | 66455-27-4 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| GLYCOSAMINOGLYCANS | 94945-04-07 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| GLYCOSPHINGOLIPIDS | 0 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |
| GLYCYRRHETINIC ACID | 471-53-4 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides/PCB, toxic metals, and heavy metals |
| GLYCYRRHETINYL STEARATE | 4827-59-2 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: pesticides/PCBs, toxic metals, and heavy metals. |
| GLYCYRRHIZINIC ACID | 1405-86-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.1%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides/PCB, toxic metals, and heavy metals |
| GOLD | 0 | The European Commission restricts the silver and copper contents of this ingredient to maximum concentrations of 7% and 4%, respectively. |
| GOLD (CI 77480) | 7440-57-5 | The European Commission restricts the silver and copper contents of this ingredient to maximum concentrations of 7% and 4%, respectively. |
| GOLD (CI 77480) | 7440-57-5 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E175) |
| GOSSYPIUM HERBACEUM (COTTON) SEED OIL | 8001-29-4 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: gossypol, heavy metals, and pesticides. |
| GOSSYPIUM HERBACEUM (COTTON) SEED OIL | 8001-29-4 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: gossypol, heavy metals, and pesticides. |
| GRAPE SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HAEMATOCOCCUS PLUVIALIS (ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HALIDRYS SILIQUOSA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HALOPTERIS SCOPARIA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) BARK EXTRACT | 0 | This substance may not be produced with, or contain detectable levels of, cyclopentasiloxane. |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) BARK EXTRACT | 0 | This substance must contain contain less than 20 ppm heavy metal, 10 ppm lead, 2 ppm arsenic, and 1 ppm cadmium |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) BARK EXTRACT | 0 | Products containing this substance must not contain detectable levels of phenol. |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) EXTRACT | 84696-19-5 | This substance may not be produced with, or contain detectable levels of, cyclopentasiloxane. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| HAMAMELIS VIRGINIANA (WITCH HAZEL) EXTRACT | 84696-19-5 | This substance must contain contain less than 20 ppm heavy metal, 10 ppm lead, 2 ppm arsenic, and 1 ppm cadmium |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) EXTRACT | 84696-19-5 | Products containing this substance must not contain detectable levels of phenol. |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) EXTRACT | 84696-19-5 | Products containing this substance must contain less than 0.01% safrole. |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) LEAF EXTRACT | 84696-19-5 | This substance may not be produced with, or contain detectable levels of, cyclopentasiloxane. |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) LEAF EXTRACT | 84696-19-5 | This substance must contain contain less than 20 ppm heavy metal, 10 ppm lead, 2 ppm arsenic, and 1 ppm cadmium |
| HAMAMELIS VIRGINIANA (WITCH HAZEL) LEAF EXTRACT | 84696-19-5 | Products containing this substance must not contain detectable levels of phenol. |
| HASLEA OSTREARIA (BLUE ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HAZEL SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HC BLUE 2 | 33229-34-4 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HC BLUE 2 | 33229-34-4 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HC BLUE NO. 11 | 23920-15-2 | The European Commission restricts this ingredient to a maximum concentration of 2.0% in nonoxidative hair dye products. Additionally, this substance cannot be used with nitrosating systems, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| HC BLUE NO. 11 | 23920-15-2 | The European Commission restricts this ingredient to a maximum concentration in non-oxidative hair dye products is 2.0%. Cannot be used with nitro sating agents and maximum nitrosamine content: 50 µg /kg. Keep in nitrite-free containers. |
| HC BLUE NO. 12 | 132885-85-9 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HC BLUE NO. 12 | 132885-85-9 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HC BLUE NO. 14 | 99788-75-7 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HC BLUE NO. 14 | 99788-75-7 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HC ORANGE NO. 2 | 85765-48-6 | The European Commission restricts this ingredient to a maximum concentration of 1.0% in nonoxidative hair dye products. Additionally, this substance cannot be used with nitrosating systems, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. Required Warning: The European Commission requires the following warning text on the product label/package: 'Hair colourants can cause severe allergic reactions'; 'Read and follow instructions' |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| HC RED NO. 11 | 95576-92-4 | The European Commission restricts this ingredient to a maximum concentration of 1.0% applied to hair after mixing under oxidative conditions in oxidative hair dye products, and 1.0% in nonoxidative hair dye products. Additionally, this substance cannot be used with nitrosating agents, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. Required Warning: The European Commission requires the following warning text on the product label/package: 'Hair colourants can cause severe allergic reactions'; 'Read and follow instructions' |
| HC RED NO. 7 | 24905-87-1 | The European Commission restricts this ingredient to a maximum concentration of 1.0% in nonoxidative hair dye products. Additionally, this substance cannot be used with nitrosating agents, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. Required Warning: The European Commission requires the following warning text on the product label/package: 'Hair colorants can cause severe allergic reactions.' |
| HC VIOLET NO. 2 | 104226-19-9 | The European Commission restricts this ingredient to a maximum concentration of 2.0% in non-oxidative hair dye products. Do not use with nitrosating agents and maximum nitrosamine content: 50 µg /kg. Keep in nitrite-free containers. Label should include "Can cause allergic reaction" |
| HC VIOLET NO. 2 | 104226-19-9 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HC VIOLET NO. 2 | 104226-19-9 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HC YELLOW 4 | 59820-43-8 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HC YELLOW 4 | 59820-43-8 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HC YELLOW NO. 9 | 86419-69-4 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HC YELLOW NO. 9 | 86419-69-4 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HEMATITE | 1317-60-8 | Per the U.S. FDA., iron oxides shall conform to the following specifications, all on an "as is" basis: Arsenic (as As), not more than 3 parts per million. Lead (as Pb), not more than 10 parts per million. Mercury (as Hg), not more than 3 parts per million. |
| HEXAMIDINE DIISETHIONATE | 659-40-5 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.1%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane. |
| HEXYLDECETH-2 | 52609-19-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HEXYLDECETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HIMANTHALIA ELONGATA (BROWN ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|-------------|--|
| HIMANTHALIA ELONGATA POWDER | 223751-70-0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HIZIKIA FUSIFORME EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HONEY | 8028-66-8 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| HONEY | 8028-66-8 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| HONEY COMB | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| HONEY COMB | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| HONEY EXTRACT | 91052-92-5 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| HONEY EXTRACT | 91052-92-5 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| HYDRATED SILICA | 112926-00-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYDRATED SILICA | 112926-00-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYDROGEN PEROXIDE | 7722-84-1 | According to Section 13 of Canada's Cosmetic Regulations the pH of oral products containing this ingredient must be greater than or equal to 4.0. Additionally, if an oral cosmetic contains more than 3% hydrogen peroxide (or equivalent), notifiers must submit a clinical study to demonstrate the salivary peroxide levels do not exceed 3% during the use of the product as per the directions of use. |
| HYDROGENATED CASTOR OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROGENATED COTTONSEED GLYCERIDE | 61789-07-09 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: gossypol, heavy metals, and pesticides. |
| HYDROGENATED HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| HYDROGENATED HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| HYDROGENATED LARD | 73138-67-7 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| HYDROGENATED LARD GLYCERIDE | 2242720 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| HYDROGENATED LARD GLYCERIDE | 2242720 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| HYDROGENATED LARD GLYCERIDES | 91744-48-8 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| HYDROGENATED MICROCRYSTALLINE WAX | 64742-60-5 | This ingredient is restricted due to its potential to bioaccumulate in human tissues. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, this ingredient must be highly refined including documentation of refining process and noncarcinogenic source material, with DMSO extractives below 3% and PAH levels must be below 10 ppb. Mineral waxes must have an average molecular weight of at least 500 Daltons and a viscosity value greater than or equal to 11 centistokes at 100oC or greater than or equal to 8 centistokes at 120oC. Additionally, no more than 5% of hydrocarbons with a chain length less than C25 may be present. |
| HYDROGENATED PALM/ PALM KERNEL OIL PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROGENATED TALLOWAMIDE DEA | 68440-32-4 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| HYDROGENATED TALLOWAMINE | 61788-45-2 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| HYDROLYZED ALGIN | 9005-38-3 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HYDROLYZED CITRUS AURANTIUM DULCIS (ORANGE) FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |
| HYDROLYZED FUCUS VESICULOSUS EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| HYDROLYZED FUCUS VESICULOSUS PROTEIN | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| HYDROLYZED HEMP SEED PROTEIN | 0 | Health Canada restricts the THC (delta9tetrahydrocannabinol) content of this ingredient to a maximum concentration of 10 microgram/g. |
| HYDROLYZED KERATIN | 69430-36-0 | Health Canada requires manufacturers using substances of human origin provide the following information to the Cosmetics Division of the Consumer Product Safety Bureau: source of the substance; a description of the method of production; quality control data, particularly those relating to microbial limits (including viruses) and the absence of estrogenic substances; product labelling. |
| HYDROLYZED PLUKENETIA VOLUBILIS SEED EXTRACT | 0 | Seedderived substances from P. volubilis can contain aflatoxins, depending on cultivation and processing. This substance must not contain detectable levels of aflatoxins. |
| HYDROLYZED RICE BRAN EXTRACT | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.0004%. Additionally, the ingredient cannot contain significant levels of pesticide residues or heavy metals. |
| HYDROLYZED RICE BRAN PROTEIN | 73049-73-7 | The Cosmetic Ingredient Review restricts this ingredient in that it cannot contain significant levels of pesticide residues or heavy metals. |
| HYDROLYZED RICE EXTRACT | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.3%. Additionally, the ingredient cannot contain significant levels of pesticide residues or heavy metals. |
| HYDROLYZED RICE PROTEIN | 94350-05-07 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, the ingredient cannot contain significant levels of pesticide residues or heavy metals. |
| HYDROLYZED SOY PROTEIN/DIMETHICONE PEG-7 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROLYZED WHEAT PROTEIN | 70084-87-6 | Europe restricts this chemical: Maximum molecular weight average of the peptides in hydrolysates: 3.5 kDa |
| HYDROLYZED WHEAT PROTEIN | 70084-87-6 | Europe restricts this chemical: Maximum molecular weight average of the peptides in hydrolysates: 3.5 kDa |
| HYDROLYZED WHEAT PROTEIN | 70084-87-6 | Europe restricts this chemical: Maximum molecular weight average of the peptides in hydrolysates: 3.5 kDa |
| HYDROLYZED WHEAT PROTEIN | 70084-87-6 | Europe restricts this chemical: Maximum molecular weight average of the peptides in hydrolysates: 3.5 kDa |
| HYDROLYZED WHEAT PROTEIN/DIMETHICONE PEG-7 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROLYZED WHEAT PROTEIN/DIMETHICONE PEG-7 PHOSPHATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROLYZED WHEAT PROTEIN/PEG-20 ACETATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROPHILIC SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| HYDROPHILIC SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYDROPHOBIC SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1 ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYDROPHOBIC SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYDROXYANTHRAQUINONEAMINOPROPYL METHYL MORPHOLINIUM METHOSULFATE | 38866-20-5 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| HYDROXYANTHRAQUINONEAMINOPROPYL METHYL MORPHOLINIUM METHOSULFATE | 38866-20-5 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| HYDROXYBENZOMORPHOLINE | 26021-57-8 | The European Commission restricts this ingredient to a maximum concentration of 1.0% applied to hair after mixing under oxidative conditions in oxidative hair dye products. Additionally, this substance cannot be used with nitrosating agents, it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. Required Warning: The European Commission requires the following on the product label/package of oxidative hair dyes: The mixing ratio; 'Hair colorants can cause severe allergic reactions.', 'Read and follow instructions.', 'This product is not intended for use on persons under the age of 16.', 'Temporary 'black henna' tattoos may increase your risk of allergy.', 'Do not colour your hair if: — you have a rash on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction after colouring your hair, — you have experienced a reaction to a temporary 'black henna' tattoo in the past.' |
| HYDROXYCETETH-60 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROXYCETYL HYDROXYETHYLSTEARAMIDE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| HYDROXYETHYL ISOSTEARYLOXY ISOPROPANOLAMINE | 158314-47-7 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| HYDROXYETHYLBUTYLAMINE LAURETH SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| HYDROXYPROPYL PANTHENYL PEG-7 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| HYDROXYPROPYLTRIMONIUM HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| HYDROXYPROPYLTRIMONIUM HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| HYDROXYPROPYLTRIMONIUM HYDROLYZED WHEAT PROTEIN/SILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYDROXYPROPYLTRIMONIUM HYDROLYZED WHEAT PROTEIN/SILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| HYPNEA MUSCIFORMIS (HYPNEACEAE) EXTRACT | 223751-71-1 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| INULIN | 9005-80-5 | The Cosmetic Ingredient Review panel states this substance should contain no more than the following: 1 mg/kg lead, 0.2% ash, and 15% (combined) of monosaccharides (as fructose and glucose) and disaccharides (as sucrose), calculated on the dried basis. |
| INULIN | 9005-80-5 | The Cosmetic Ingredient Review panel states this substance should contain no more than the following: 1 mg/kg lead, 0.2% ash, and 15% (combined) of monosaccharides (as fructose and glucose) and disaccharides (as sucrose), calculated on the dried basis. |
| IPDI/PEG-15 COCAMINE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| IPDI/PEG-15 COCAMINE COPOLYMER DIMER DILINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| IPDI/PEG-15 COCAMINE/GLYCERETH-7/POLYGLYCERYL-3 COPOLYMER | 373387-50-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| IPDI/PEG-15 SOY GLYCINATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| IPDI/PEG-15 SOYAMINE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| IPDI/PEG-15 SOYAMINE OXIDE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| IPDI/PEG-15 SOYETHONIUM ETHOSULFATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOAMYL ALLYLGLYCOLATE | 67634-00-8 | The European Commission restricts the level of free allyl alcohol in the ester to less than 0.1%. |
| ISOBUTANE | 75-28-5 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.1% w/w Butadiene |
| ISOBUTANE | 75-28-5 | Health Canada bans this ingredient from use in cosmetics if it contains over 0.1% w/w Butadiene. |
| ISOCETEARETH-8 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-10 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-15 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-20 | 69364-63-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-25 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-3 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOCETETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|---------|--|
| ISOCETETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISODECETH-2 COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISODECETH-4 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISODECETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISODECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOLAURETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOLAURETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOLAURETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOLAURETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOPROPANOLAMINE | 78-96-6 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ISOPROPANOLAMINE LANOLATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ISOPROPYL PPG-2 ISODECETH-7 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| ISOPROPYLAMINE | 75-31-0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ISOPROPYLAMINE DODECYLBENZENESULFONATE | 26264-05-01 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ISOPROPYLIDENEDIPHENOL BISHYDROXYPROPYL PEG-180 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOSTEARAMIDE DEA | 52794-79-3 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| ISOSTEARAMIDOPROPYL BETAINE | 63566-37-0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| ISOSTEARAMIDOPROPYL DIMETHYLAMINE | 67799-04-06 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| ISOSTEARETH-10 | 52292-17-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOSTEARETH-10 | 52292-17-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOSTEARETH-10 | 52292-17-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOSTEARETH-2 | 52292-17-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOSTEARETH-20 | 52292-17-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ISOSTEARYL CARBOXYDECYL PEG-8 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| ISOSTEARYL TRIMETHYLOLPROPANE SILOXY SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ISOSTEARYL TRIMETHYLOLPROPANE SILOXY SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| KELP SULFATED OLIGOSACCHARIDES | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| KIDACHI ALOE EKISU | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |
| KIWI FRUIT HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| KIWI FRUIT HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| I-allo-OCIMENOL | 126-90-9 | The International Fragrance Association restricts the total peroxide content (in the final product) to a maximum concentration of 20 millimoles peroxides per liter. |
| I-alpha-PINENE | 7785-26-4 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L |
| L-ASCORBIC ACID, 2-(3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2- (4,8,12-TRIMETHYLTRIDECYL)-2H-1- | 132746-07-7 | This ingredient should not contain detectable levels of hydroquinone. |
| I-beta-PINENE | 18172-67-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L |
| I-Limonene | 5989-54-8 | The European Commission restricts this ingredient's peroxide content to less than 20 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| LACTOBACILLUS/ALGAE EXTRACT FERMENT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LACTOBACILLUS/ALOE BARBADENSIS FERMENT FILTRATE | 0 | The Cosmetic Ingredient Review restricts the anthraquinone (or aloin) content of this ingredient to less than 50 ppm, 40 ppm PCB/pesticides, 10 ppm arsenic, 10 ppm heavy metals, and 10 ppm lead. |
| LACTOBACILLUS/KELP FERMENT FILTRATE | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LAMINARIA DIGITATA | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LAMINARIA DIGITATA EXTRACT | 90046-12-1 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|--|
| LAMINARIA DIGITATA POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LAMINARIA HYPERBOREA | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LAMINARIA HYPERBOREA EXTRACT | 90046-11-0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LAMINARIA SACCHARINA | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LAMINARIA SACCHARINA EXTRACT | 92128-82-0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LANETH-15 | 61791-20-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LANOLINAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| LARD | 61789-99-9 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| LARD GLYCERIDE | 61789-10-4 | The Cosmetic Ingredient Review restricts the lead, arsenic, mercury, and total PCB/pesticide contents of this ingredient to maximum concentrations of 0.1 ppm, 3 ppm, 1 ppm, and 40 ppm (with 10 ppm for any specific residue), respectively. |
| LAURAMIDE DEA | 120-40-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| LAURAMIDE/MYRISTAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| LAURAMIDE/MYRISTAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| LAURAMIDOPROPYL BETAINE | 873943 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| LAURAMIDOPROPYL DIMETHYLAMINE | 3179-80-4 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| LAURAMINE | 124-22-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| LAURDIMONIUM HYDROXYPROPYL HYDROLYZED WHEAT PROTEIN/SILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LAURDIMONIUM HYDROXYPROPYL HYDROLYZED WHEAT PROTEIN/SILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LAURETH SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-1 | 4536-30-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-1 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-10 | 6540-99-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-10 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-10 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-10 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-10 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|-------------|---|
| LAURETH-10 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-11 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-11 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-12 | 3056-00-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-12 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-12 SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-13 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-13 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-13 PG-HYDROXYETHYLCELLULOSE | 312601-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-14 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-14 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-15 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-16 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------|-------------|---|
| LAURETH-17 CARBOXYLIC ACID | 27306-90-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-2 | 3055-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-2 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-2 BENZOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-2 ETHYLHEXANOATE | 125804-14-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-2 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-20 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-21 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-25 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-3 | 3055-94-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-3 CARBOXYLIC ACID | 20858-24-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-3 PHOSPHATE | 25852-45-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-30 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------|------------|---|
| LAURETH-35 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-38 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-4 | 5274-68-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-4 CARBOXYLIC ACID | 20858-25-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-4 PHOSPHATE | 39464-66-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-4 PHOSPHATE | 39464-66-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-4 PHOSPHATE | 39464-66-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-40 | 9002-92-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-5 | 3055-95-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-5 BUTYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-5 CARBOXYLIC ACID | 21127-45-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-50 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-6 | 3055-96-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|-------------|--|
| LAURETH-6 CARBOXYLIC ACID | 20260-64-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-6 CITRATE | 161756-30-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-7 | 3055-97-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-7 CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-7 METHYL LACTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-7 PHOSPHATE | 39464-66-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-7 TARTRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-8 | 3055-98-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-8 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-8 PHOSPHATE | 39464-66-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURETH-9 | 3055-99-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAUROYL COLLAGEN AMINO ACIDS | 68920-59-2 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| LAUROYL COLLAGEN AMINO ACIDS | 68920-59-2 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| LAUROYL HYDROLYZED COLLAGEN | 68920-59-2 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| LAURYL DIMETHICONE PEG-15 CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURYL DIMETHYLAMINE CYCLOCARBOXYPROPYLOLEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| LAURYL PEG-10 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURYL PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURYL PEG/ PPG-18/ 18 METHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LAURYL POLYGLUCOSE | 110615-47-9 | |
| LAWSONE | 83-72-7 | Per the U.S. FDA., henna shall contorm to the following specifications: It shall not contain more than 10 percent of plant material from Lawsonia alba Lam. (Lawsonia inermis L.) other than the leaf and petiole, and shall be free from admixture with material from any other species of plant. Moisture, not more than 10 percent. Total ash, not more than 15 percent. Acid-insoluble ash, not more than 5 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. |
| LECITHINAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| LESSONIA NIGRESCENS (GREY WEED) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| LEUCONOSTOC/RADISH ROOT FERMENT FILTRATE | 0 | Use of this ingredient requires substantiation that (1) it contains < 0.01ppm of didecyldimethylammonium chloride and (2) meets current VERIFIED restrictions on salicylic acid, a component of this ingredient (maxiumum concentration of salicylic acid in final products = 0.2% according to Japanese Ministry of Health, Labour and Welfare; current as of October 2020). |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|------------|--|
| Lime oil terpeneless | 68916-84-7 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| LIMONENE | 138-86-3 | The European Commission restricts this ingredient's peroxide content to less than 20 mmoles/L. Required Warning: The European Commission requires that the presence of this substance be indicated in the list of ingredients when its concentration exceeds 0.001% in leaveon products and 0.01% in rinseoff products. |
| LIMONENE | 138-86-3 | The European Commission restricts this ingredient's peroxide content to less than 20 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| LIMONENE | 138-86-3 | The International Fragrance Association restricts the total peroxide content (in the final product) to a maximum concentration of 20 millimoles peroxides per liter. |
| LINALOOL | 78-70-6 | The International Fragrance Association restricts the total peroxide content (in the final product) to a maximum concentration of 20 millimoles peroxides per liter. |
| linear alcohol ethoxylates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LINOLEAMIDE DEA | 27883-12-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| LINOLEAMIDOPROPYL DIMETHYLAMINE | 81613-56-1 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| LINSEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LITHIUM ALUMINUM SILICATE | 1302-66-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LITHIUM ALUMINUM SILICATE | 1302-66-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LITHIUM MAGNESIUM SILICATE | 37220-90-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LITHIUM MAGNESIUM SILICATE | 37220-90-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LITHIUM MAGNESIUM SODIUM SILICATE | 53320-86-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| LITHIUM MAGNESIUM SODIUM SILICATE | 53320-86-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| LITHIUM OXIDIZED POLYETHYLENE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| LITSEA CUBEBA (MAY CHANG) OIL | 68855-99-2 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association . |
| LUBRICATING OILS | 74869-22-0 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| LYSOPHOSPHATIDYLETHANOLAMINE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MACADAMIA TERNIFOLIA SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MACROCYSTIS INTEGRIFOLIA (GIANT KELP) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| MACROCYSTIS PYRIFERA (KELP) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| MACROCYSTIS PYRIFERA (KELP) PROTEIN | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| MACROCYSTIS PYRIFERA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| MAGNESIUM ALUMINUM SILICATE | 1327-43-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM ALUMINUM SILICATE | 1327-43-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM FLUOROSILICATE | 16949-65-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|------------|---|
| MAGNESIUM FLUOROSILICATE | 16949-65-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM LAURETH SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH-11 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH-16 SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH-2 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH-3 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH-5 SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM LAURETH-8 SULFATE | 62755-21-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM OLETH SULFATE | 87569-97-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM OLETH-2 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-------------|--|
| MAGNESIUM PEG-3 COCAMIDE SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MAGNESIUM POTASSIUM FLUOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM POTASSIUM FLUOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM SILICATE | 13776-74-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM SILICATE | 13776-74-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM SILICATE HYDRATE | 1343-90-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM SILICATE HYDRATE | 1343-90-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM SODIUM FLUOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM SODIUM FLUOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM TRISILICATE | 14987-04-03 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM TRISILICATE | 14987-04-03 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MAGNESIUM/TEA-COCO-SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| MAGNETITE (FE3O4) | 1309-38-2 | Per the U.S. FDA., iron oxides shall conform to the following specifications, all on an "as is" basis: Arsenic (as As), not more than 3 parts per million. Lead (as Pb), not more than 10 parts per million. Mercury (as Hg), not more than 3 parts per million. |
| MAGNETITE (FE3O4) | 1309-38-2 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E172) |
| MANGANESE VIOLET | 10101-66-3 | The U.S. Food and Drug Administration restricts the lead, arsenic, and mercury content of this ingredient to maximum concentrations of 20 ppm, 3 ppm, and 1 ppm, respectively. |
| MANGANESE VIOLET | 10101-66-3 | Per the U.S. FDA., manganese violet shall conform to the following specifications and shall be free from impurities other than those named, to the extent that such other impurities may be avoided by good manufacturing practice: Ash (at 600 °C), not less than 81 percent. Volatile matter at 135 °C for 3 hours, not more than 1 percent. Water soluble substances, not more than 6 percent. PH of filtrate of 10 grams color additive (shaken occasionally for 2 hours with 100 milliliters of freshly boiled distilled water), not more than 4.7 and not less than 2.5. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 1 part per million. Total color, based on Mn content in "as is" sample, not less than 93 percent. |
| MANGO SEED OIL PEG-70 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MANUKA HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| MANUKA HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| MARINE ALGAE INFUSION | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| Mazzaella splendens (Splendid iridescent seaweed) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| MEA O-PHENYLPHENATE | 84145-04-0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA PPG-6 LAURETH-7 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MEA PPG-6 LAURETH-7 CARBOXYLATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|-------------|--|
| MEA-BIOTINATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-DICETEARYL PHOSPHATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-HYDROLYZED COLLAGEN | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-HYDROLYZED SILK | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-LAURETH SULFATE | 68184-04-03 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MEA-LAURETH SULFATE | 68184-04-03 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-LAURETH-6 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MEA-LAURETH-6 CARBOXYLATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-SALICYLATE | 59866-70-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEA-THIOLACTATE | 54266-38-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MEADOWFOAMAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| MELALEUCA ALTERNIFOLIA (TEA TREE) LEAF OIL | 68647-73-4 | Based on an SCCP (European Commission, Scientific Committee on Consumer Products) opinion, this substance must contain less than 8% pcymene to indicate lack of oxidative degradation. |
| MELALEUCA ALTERNIFOLIA FLOWER/LEAF/STEM OIL | 85085-48-9 | Based on an SCCP (European Commission, Scientific Committee on Consumer Products) opinion, this substance must contain less than 8% pcymene to indicate lack of oxidative degradation. |
| MENTHA PIPERITA (PEPPERMINT) OIL | 8006-90-4 | The presence of the Mentha piperita oil shall be indicated in the list of ingredients, when its concentration exceeds: 0.001% in leave-on products 0.01% in rinse-off products. |
| METHICONE | 9004-73-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| METHICONE | 9004-73-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| METHOXY PEG-10 | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-100 | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-100/POLYEPSILON CAPROLACTONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-114/POLYEPSILON CAPROLACTONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-12 RETINAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-16 | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-17/DODECYL GLYCOL COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-22 POLYDODECYL GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-22/ DODECYL GLYCOL COPOLYMER | 89678-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| METHOXY PEG-25 | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-40 | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-450 AMIDO HYDROXYSUCCINIMIDYL SUCCINAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-450 ETHYLMALEIMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-7 | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-7 ACORBIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG-7 ASCORBIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY PEG/ PPG-7/ 3 AMINOPROPYL DIMETHICONE | 298211-68-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXY-PEG-7 RUTINYL SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHOXYCINNAMOYLPROPYL SILSESQUIOXANE SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| METHOXYCINNAMOYLPROPYL SILSESQUIOXANE SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| METHYL DICOCAMINE | 61788-62-3 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| METHYL GLUCETH-10 | 68239-42-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHYL GLUCETH-20 | 68239-42-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHYL GLYCYRRHIZATE | 104191-95-9 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: pesticides/PCBs, toxic metals, and heavy metals. |
| METHYLEUGENYL PEG-8 DIMETHICONE | 200443-93-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHYLSILANOL PEG-7 GLYCERYL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHYLSILANOL TRI-PEG-8 GLYCERYL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| METHYLSILANOL/SILICATE CROSSPOLYMER | 68584-81-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| METHYLSILANOL/SILICATE CROSSPOLYMER | 68584-81-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MICA | 12001-26-2 | Per the U.S. FDA., mica shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by good manufacturing practice: Fineness, 100 percent shall pass through a 100-mesh sieve. Loss on ignition at 600-650 °C, not more than 2 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. |
| MICA | 12001-26-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MICA | 12001-26-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| MICROCITRUS AUSTRALIS FRUIT EXTRACT | 0 | (*) The Cosmetic Ingredient Review restricts the 5methoxypsoralen concentration of this ingredient to a maximum concentration of 0.0015% in the final product for leaveon products. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| MICROCRYSTALLINE WAX (CERA MICROCRISTALLINA) | 63231-60-7 | This ingredient is restricted due to its potential to bioaccumulate in human tissues. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, this ingredient must be highly refined including documentation of refining process and noncarcinogenic source material, with DMSO extractives below 3% and PAH levels must be below 10 ppb. Mineral waxes must have an average molecular weight of at least 500 Daltons and a viscosity value greater than or equal to 11 centistokes at 100oC or greater than or equal to 8 centistokes at 120oC. Additionally, no more than 5% of hydrocarbons with a chain length less than C25 may be present. |
| MILKAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| MINERAL OIL | 8012-95-1 | This ingredient can bioaccumulate in human tissues and is prohibited in lip and oral products. It is restricted in other product categories based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment. The ingredient must be highly refined including documentation of refining process and noncarcinogenic source material, with DMSO extractives below 0.2% and less than 250 ppm MOAH after refining. High viscosity mineral oils must have a carbon chain length of at least C28 atoms (at 5% boiling point), a molecular mass of at least 500 Daltons and a viscosity value of 11 centistokes. Lowmedium viscosity mineral oils must have a carbon chain length of at least C25 atoms (at 5% boiling point), a molecular mass of 480500 Daltons and a viscosity value of 8.511 centistokes. |
| MINERAL OIL | 8012-95-1 | This ingredient is restricted due to its potential to bioaccumulate in human tissues. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, this ingredient must be highly refined including documentation of refining process and noncarcinogenic source material with DMSO extractives below 3% and PAH levels must be below 10 ppb. High viscosity mineral oils must have an average molecular mass of at least 500 Daltons, a viscosity value greater than 11 centistokes and no more than 5% of hydrocarbons with a chain length less than C28 may be present. Lowmedium viscosity mineral oils must have an average molecular mass of 480500 Daltons, a viscosity value of 8.511 centistokes, and no more than 5% of hydrocarbons with a carbon chain length less than C25 atoms may be present |
| MINERAL OIL, PETROLEUM DISTILLATES CATALYTIC DEWAXED HEAVY NAPHTENIC (MILD OR NOSOLVENT- | 64742-68-3 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES CATALYTIC DEWAXED HEAVY PARAFFINIC (MILD OR NOSOLVENT- | 64742-70-7 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES CATALYTIC DEWAXED LIGHT NAPHTHENIC (MILD OR NOSOLVENT- | 64742-69-4 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES CATALYTIC DEWAXED LIGHT PARAFFINIC (MILD OR NOSOLVENT- | 64742-71-8 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, HYDROTREATED (MILD) HEAVY NAPHTHENIC | 64742-52-5 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, HYDROTREATED (MILD) HEAVY PARAFFINIC | 64742-54-7 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, HYDROTREATED (MILD) LIGHT NAPHTHENIC | 64742-53-6 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, HYDROTREATED (MILD) LIGHT PARAFFINIC | 64742-55-8 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, SOLVENT-DEWAXED HEAVY NAPHTHENIC (MILD OR NOSOLVENT- | 64742-63-8 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, SOLVENT-DEWAXED HEAVY PARAFFINIC (MILD OR NOSOLVENT- | 64742-65-0 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINERAL OIL, PETROLEUM DISTILLATES, SOLVENT-DEWAXED LIGHT NAPHTHENIC (MILD OR NOSOLVENT- | 64742-64-9 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| MINERAL OIL, PETROLEUM DISTILLATES, SOLVENT-DEWAXED | 64742-56-9 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| MINK OIL PEG-13 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MINKAMIDE DEA | 124046-27-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MIPA C12-15 PARETH SULFATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MIPA-DODECYLBENZENESULFONATE | 42504-46-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MIPA-LAURETH SULFATE | 83016-76-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MIPA-LAURETH SULFATE | 83016-76-6 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MIPA-LAURYL SULFATE MIPA-LAURYL SULFATE | 21142-28-9 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MIPA-MYRISTATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MIXED CITRUS OILS | 0 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| MIXED LINEAR AND BRANCHED C14-15 ALCOHOLS ETHOXYLATED, REACTION PRODUCT WITH EPICHLOROHYDRIN | 158570-99-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Modified Polyethoxylated Alcohol | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MONOSACCHARIDE COMPLEX | 0 | The Cosmetic Ingredient Review restricts the anthraquinone content of this ingredient to less than 50 ppm. Additionally, the CIR has identified the following potential contaminants/impurities in this ingredient: PCB/pesticides, arsenic, heavy metals, and lead |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| MYRETH-10 | 27306-79-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MYRETH-3 | 26826-30-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| MYRISTAMIDE DEA | 7545-23-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MYRISTAMIDE DEA | 7545-23-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MYRISTAMIDE DEA MYRISTAMIDE DEA | 7545-23-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MYRISTAMIDE DEA MYRISTAMIDE DEA | 7545-23-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| MYRISTAMIDOPROPYL BETAINE | 59272-84-3 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| MYRISTAMIDOPROPYL DIMETHYLAMINE | 45267-19-4 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| MYRISTICA FRAGRANS (NUTMEG) KERNEL OIL | 2230874 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| MYRISTICA FRAGRANS (NUTMEG) SEED HULL | 0 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| MYRISTICA FRAGRANS KERNEL EXTRACT | 0 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| MYRISTYLAMIDOPROPYL DIMETHYLAMINE DIMETHICONE PEG-7 PHOSPHATE | 137145-36-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| N-(3-HEXADECYLOXY-2-HYDROXYPROP-1-YL)-N-(2- HYDROXYETHYL)PALMITAMIDE | 110483-07-3 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| N-(3-HEXADECYLOXY-2-HYDROXYPROP-1-YL)-N-(2- HYDROXYETHYL)PALMITAMIDE | 110483-07-3 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| N-LAURYL DIETHANOLAMINE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| n-octyl-polyoxyethylene | 27252-75-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NEREOCYCSTIS LEUTKEANA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| NONOXYNOL | 26027-38-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL | 26027-38-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-1 | 27986-36-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-10 | 37205-87-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-10 CARBOXYLIC ACID | 28212-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-10 PHOSPHATE | 51609-41-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-11 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-120 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------|------------|---|
| NONOXYNOL-13 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-14 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-15 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-18 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-2 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-20 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-23 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-25 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-3 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-3 PHOSPHATE | 51811-79-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-30 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-35 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-4 | 7311-27-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|------------|--|
| NONOXYNOL-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-40 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-44 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-5 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-5 CARBOXYLIC ACID | 28212-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-50 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-6 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-6 PHOSPHATE | 29994-44-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-7 | 9016-45-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-8 CARBOXYLIC ACID | 28212-44-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-9 | 26571-11-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONOXYNOL-9 PHOSPHATE | 51609-41-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL 7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|---|
| NONYL NONOXYNOL-10 | 9014-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-100 | 9014-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-11 PHOSPHATE | 39464-64-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-15 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-150 | 9014-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-24 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-30 | 9014-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-49 | 9014-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-5 | 9014-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-7 PHOSPHATE | 66172-78-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-8 PHOSPHATE | 39464-64-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| NONYL NONOXYNOL-9 PHOSPHATE | 66172-82-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|-------------|---|
| NOOTKATONE | 4674-50-4 | The International Fragrance Association requires that the raw ingredient be at least 98% pure with a melting point of at least 32°C. |
| OAKMOSS CONCRETE | 68917-10-2 | According to the International Fragrance Association, this ingredient must not contain added tree moss. Additionally, dehydroabietic acid (DHA) must not exceed 0.1% in the extract, and the levels of atranol and chloroatranol should each be below 100ppm. |
| OATAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| OATAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| OATMEAL HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| OATMEAL HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| OCOTEA CYMBARUM OIL | 68917-09-09 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| OCTOXYNOL 12 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTOXYNOL 12 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTOXYNOL-1 | 2315-67-5 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-10 | 2315-66-4 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 25% in hair bleaches. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-12 | 9002-93-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-16 | 9002-93-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-20 | 9002-93-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-20 CARBOXYLIC ACID | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-25 | 9002-93-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-3 | 2315-62-0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|------------|---|
| OCTOXYNOL-30 | 9002-93-1 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-33 | 9002-93-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-40 | 9002-93-1 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.02%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-5 | 2315-64-2 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-6 | 9002-93-1 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-7 | 9002-93-1 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-70 | 9002-93-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-8 | 2638-43-9 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTOXYNOL-9 CARBOXYLIC ACID | 25338-58-3 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| OCTYLDODECETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTYLDODECETH-16 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTYLDODECETH-2 | 32128-65-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTYLDODECETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTYLDODECETH-25 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OCTYLDODECETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|--|
| OCTYLDODECETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Octylphenol ethoxylate | 9036-19-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oils, treemoss, resinoid | 68917-40-8 | The International Fragrance Association restricts the dehydroabietic acid (DHA) concentration of this ingredient to a maximum of 0.8% in the extract, and the levels of atranol and chloroatranol should each be below 100ppm. |
| OLEAMIDE DEA | 93-83-4 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| OLEAMIDOPROPYL BETAINE | 25054-76-6 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| OLEAMIDOPROPYL DIMETHYLAMINE | 109-28-4 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| OLEAMINE | 112-90-3 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-----------|---|
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------|------------|---|
| OLETH-10 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 CARBOXYLIC ACID | 57635-48-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 CARBOXYLIC ACID | 57635-48-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 CARBOXYLIC ACID | 57635-48-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-10 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-106 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-11 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-12 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------|------------|---|
| OLETH-15 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-16 | 25190-05-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-2 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-2 BENZOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-2 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-2 POLYSORBATE 20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-20 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-20 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-23 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-24 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-25 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-3 CARBOXYLIC ACID | 57635-48-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------|------------|---|
| OLETH-3 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-30 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-35 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-4 | 5353-26-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-4 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-40 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-44 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-5 PHOSPHATE | 39464-69-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-50 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-6 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-6 CARBOXYLIC ACID | 57635-48-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-7 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|-------------|--|
| OLETH-8 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-82 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLETH-9 | 9004-98-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVAMIDE DEA | 124046-30-6 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| OLIVAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| OLIVE OIL GLYCERETH-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4- dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG-10 ESTERS | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG-10 ESTERS | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG-10 ESTERS | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG-10 ESTERS | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG-6 ESTERS | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG-7 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| OLIVE OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OLIVE OIL PEG/PPG-3/1 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ORBIGNYA OLEIFERA SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ORYZA SATIVA (BROWN RICE) | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) BRAN | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| ORYZA SATIVA (RICE) BRAN EXTRACT | 90106-37-9 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| ORYZA SATIVA (RICE) BRAN OIL | 68553-81-1 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) BRAN WATER | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) BRAN WAX | 8016-60-2 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| ORYZA SATIVA (RICE) BRAN WAX | 8016-60-2 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| ORYZA SATIVA (RICE) EXTRACT | 68553-81-1 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) EXTRACT | 68553-81-1 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| ORYZA SATIVA (RICE) FLOUR | 68553-81-1 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) GERM OIL | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 3%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| ORYZA SATIVA (RICE) HULL POWDER | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) HULLS | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| Oryza Sativa (Rice) Lipids | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| Oryza Sativa (Rice) Lipids | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| ORYZA SATIVA (RICE) OIL | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) POWDER | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) PROTEIN | 0 | Upon review of these ingredients, the Panel expressed concern regarding gossypol (for cotton-derived ingredients), pesticide residues, and heavy metals that may be present in botanical ingredients. |
| ORYZA SATIVA (RICE) STARCH | 9005-25-8 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: heavy metals and pesticides. |
| OXIDIZED POLYETHYLENE | 68441-17-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|---------|---|
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Oxirane, 2-methyl-, polymer with oxirane | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| OZOKERITE | 12198-93-5 | This ingredient is restricted due to its potential to bioaccumulate in human tissues. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, this ingredient must be highly refined including documentation of refining process and noncarcinogenic source material, with DMSO extractives below 3% and PAH levels must be below 10 ppb. Mineral waxes must have an average molecular weight of at least 500 Daltons and a viscosity value greater than or equal to 11 centistokes at 100oC or greater than or equal to 8 centistokes at 120oC. Additionally, no more than 5% of hydrocarbons with a chain length less than C25 may be present. |
| P-METHYLAMINOPHENOL SULFATE | 1936-57-8 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| P-METHYLAMINOPHENOL SULFATE | 1936-57-8 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| PADIMATE O | 21245-02-03 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| PADIMATE O | 21245-02-03 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| PALM KERNELAMIDE DEA | 73807-15-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| PALM KERNELAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| PALM OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PALMAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|------------|--|
| PALMAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| PALMITAMIDE DEA | 7545-24-6 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| PALMITAMIDOPROPYL BETAINE | 32954-43-1 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| PALMITAMIDOPROPYL DIMETHYLAMINE | 39669-97-1 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| PALMITAMINE | 143-27-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| PARAFFIN | 64742-51-4 | This ingredient is restricted due to its potential to bioaccumulate in human tissues. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, this ingredient must be highly refined including documentation of refining process and noncarcinogenic source material, with DMSO extractives below 3% and PAH levels must be below 10 ppb. Mineral waxes must have an average molecular weight of at least 500 Daltons and a viscosity value greater than or equal to 11 centistokes at 100oC or greater than or equal to 8 centistokes at 120oC. Additionally, no more than 5% of hydrocarbons with a chain length less than C25 may be present. |
| PEANUT GLYCERIDES | 91744-77-3 | Europe restricts this chemical: Maximum concentration of peanut proteins: 0.5 ppm |
| PEANUT OIL PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG RICINOLEATE/DIMETHICONE COPOLYL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG SOYA STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-----------|---|
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-----------|---|
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|------------|---|
| PEG-## HYDROGENATED CASTOR OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-1 GLYCERYL SORBITAN OLEOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-1 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 | 5579-66-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 C12-18 ALKYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 COCO-BENZONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 COCONUT OIL ESTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 DIMALEATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 DIMETHICONE CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-10 DIMETHICONE/ VINYL DIMETHICONE CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-10 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 ISOLAURYL THIOETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 NONAFLUOROHEXYL DIMETHICONE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|------------|---|
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|-----------|---|
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLIVE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLIVE OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 OLIVE OIL GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|------------|---|
| PEG-10 PHYTOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 POLYGLYCERYL-2 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 PROPYLENE GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 RAPESEED STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 SOYA STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|-------------|---|
| PEG-10 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 STEARYL BENZONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 SUNFLOWER GLYCERIDES | 180254-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 SUNFLOWER GLYCERIDES | 180254-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-10 TALLOW AMINOPROPYLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10 TSUBAKIATE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-10/LAURYL DIMETHICONE CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 ISOPROPYL MYRISTAT | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 SOYA STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-100 STEARATE | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 25%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-100/IPDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-105 BEHENYL PROPYLENEDIAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-11 AVOCADO GLYCERIDES | 103819-44-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 AVOCADO GLYCERIDES | 103819-44-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 BABASSU GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 COCOA BUTTER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 LAURAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-11 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-114 METHYLETHER POLYEPSILON CAPRALACTONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-115M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-1182 METHYL ESTER SERICIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|---------|---|
| PEG-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 CARNAUBA | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DIMETHICONE COPOLYOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DIMETHICONE CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|-------------|--|
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DITALLATE | 61791-01-03 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 DITALLATE | 61791-01-03 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 GLYCERYL DIMYRISTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 GLYCERYL DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 GLYCERYL DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-12 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 METHYL ETHER LAUROXY PEG-5 AMIDOPROPYL DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 METHYL GLUCOSE DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 PALM KERNEL GLYCERIDES | 124046-52-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 PALMITAMINE | 68155-33-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-12 STEARATE | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 1%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|------------|---|
| PEG-12 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 METHYL GLUCOSE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 METHYL GLUCOSE DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 METHYL GLUCOSE EXTRACT | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 METHYL GLUCOSE TRIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 PROPYLENE GLYCOL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-120 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-125 COCOPOLYAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-13 DIPHENYLOL PROPANE | 9014-86-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-13 ETHYLHEXANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|-------------|---|
| PEG-13 HYDROGENATED TALLOW AMIDE | 68783-22-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-13 MINK GLYCERIDES | 103819-45-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-13 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-13 SUNFLOWER GLYCERIDES | 70377-91-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-130 GLYCERYL TALLOWATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-135 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-136 Polyvinyl Alcohol | 25820-49-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14 AVOCADO GLYCERIDES | 103819-44-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|---|
| PEG-14 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-140 GLYCERYL TRISTEARATE | 41080-66-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-140 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-14M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 BUTANEDIOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|------------|---|
| PEG-15 COCAMINE OLEATE/PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCOMONIUM METHOSULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 COCOPOLYAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 DEDM HYDANTOIN | 68130-12-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 DEDM HYDANTOIN STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL ISOSTEARATE | 68958-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL ISOSTEARATE | 68958-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL ISOSTEARATE | 68958-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL LAURATE | 57107-95-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL RICINOLEATE | 51142-51-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-15 GLYCERYL RICINOLEATE | 51142-51-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL TRIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 HYDROGENATED LANOLIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 HYDROGENATED TALLOWMONIUM CHLORIDE | 68187-69-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 HYDROXYSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 JOJOBA ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 JOJOBA ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-15 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 OCTADECYL AMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 OLEAMMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 PENTAERYTHRITYL TETRA(LAURETH-6 CARBOXYLATE) | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 PHYTOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 SOYAMIDE/ IPDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-15 STEARMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 STEARYL ETHER | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 TALLOW AMINOPROPYLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15 TALLOW POLYAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-15/ LAURYL DIMETHICONE CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------------|------------|--|
| PEG-150 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 BEHENTRIMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 DIBEHENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 PENTAERYTHRITYL TETRASODIUM | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 PENTAERYTHRITYL TETRASTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 SMDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-150/ DECYL ALCOHOL/ SMDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-150/ STEARYL ALCOHOL/ SMDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-1500 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 CETYL/OLEYL/STEARYL/LANILIN ALCOHOL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 HYDROGENATED COTTENSEED OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 MACADAMIA GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 SOY STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-16 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|-------------|---|
| PEG-160 SORBITAN TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-160M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-17 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-175 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-175 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 CASTOR OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 CASTOR OIL DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 GLYCERYL OLEATE/ COCOATE | 999999-19-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 PALM GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 PALMITATE | 9004-94-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 PALMITATE | 9004-94-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 PALMITATE | 9004-94-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-18 SORBITAN TRIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-18 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-180 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-180 BISPOLYLACTIDE | 131151-09-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-180 STEARAMIDOPROPYL DIMETHYLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-180/LAURETH-50/TMMG COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-180/OCTOXYNOL-40/TMMG COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-190 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-192 APRICOT KERNEL GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 BENZYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 COCAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-2 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 COCO-BENZONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 COCOMONIUM CHLORIDE | 70750-47-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIETHYLHEXANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIISONONANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DILAURATE | 1600224 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIMEADOWFOAMAMDOETHYLMONIUM METHOSULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIMEADOWFOAMAMIDOETHYLMONIUM METHOSULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DIROSINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 DISTEARATE | 109-30-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|-------------|---|
| PEG-2 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 LAURAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 LAURAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 LAURATE | 141-20-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 LAURATE SE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 MILK SOLIDS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 MYRISTYL ETHER PROPIONATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 OLEAMINE | 25307-17-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 OLEAMINE HYDROFLUORIDE | 207916-33-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 OLEAMMONIUM CHLORIDE | 18448-65-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 OLEAMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 OLEATE | 0106-12-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|-------------|---|
| PEG-2 OLEATE SE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 OLIVE GLYCERIDES | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 PALMITAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 RAPESEEDAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 RICINOLEATE | 5401-17-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 SORBITAN ISOSTEARATE | 66794-58-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 SORBITAN ISOSTEARATE | 66794-58-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 SORBITAN TRIOLEATE | 9005-70-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 STEARAMIDE CARBOXYLIC ACID | 90453-59-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 STEARAMIDE CARBOXYLIC ACID | 90453-59-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 STEARATE | 0106-11-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------|-------------|---|
| PEG-2 STEARATE | 0106-11-6 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-2 STEARATE SE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 STEARMONIUM CHLORIDE | 60687-87-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 SUNFLOWER GLYCERIDES | 180254-52-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 TALLOW AMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2 TALLOWAMIDE DEA | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 ALMOND GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 CARAUBA WAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 CARBOMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 CETEARYL ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-------------|---|
| PEG-20 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 COCAMIDE MEA | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 CORN GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 DIRICINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 EVENING PRIMROSE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERIDES | 999999-82-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL ISOSTEARATE | 68958-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-20 GLYCERYL MONOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL RICINOLEATE | 51142-51-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HEXADECENYLSUCCINATE | 178254-04-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED CASTOR OIL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED CASTOR OIL PCA ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-20 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED PALM GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 MANNITAN LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 METHYL GLUCETH-20 SESQUISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-20 METHYL GLUCOSE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 METHYL GLUCOSE DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 METHYL GLUCOSE DISTEARATE | 119831-19-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 METHYL GLUCOSE SESQUICAPRYLATE/SESQUICAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 METHYL GLUCOSE SESQUILAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 METHYL GLUCOSE SESQUISTEARATE | 68389-70-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 MYRISTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 PALMITATE | 9004-94-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 PHYTOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SORBITAN BEESWAX | 8051-73-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SORBITAN COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|------------|---|
| PEG-20 SORBITAN ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SORBITAN LANOLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SORBITAN OLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SORBITAN TETRAOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SORBITAN TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 SOY STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 STEARATE | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 4%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-20 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 TALLOW AMMONIUM ETHOSULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 TALLOWATE | 68153-64-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-20 TSUBAKIATE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-20-PPG-10 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 GLYCERYL TALLOWATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 HYDROGENATED GLYCERYL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 HYDROGENATED GLYCERYL PALMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 HYDROGENATED GLYCERYL PALMITATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 METHYLGLUCOSE DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 TALLOWATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-200 TRIHYDROXYSTEARIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG-20M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-22 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-22/DODECYL GLYCOL COPOLYMER | 78336-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-220 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 GLYCERYL DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 HEXADECYLEICOSANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 OCTYLDODECANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 OLIVATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-23M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-24 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-24 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-24 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-240 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-240/HDI COPOLYMER BIS-DECYLTETRADECETH-20 ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 DIETHYLMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 GLYCERYL TRIOLEATE | 68958-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 LANOLIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 METHYL GLUCOSE ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|-------------|---|
| PEG-25 MORINGA GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 PABA | 113010-52-9 | As reported by the International Agency for Research on Cancer (IARC), primary aromatic amines generally form harmful metabolites with the potential to cause cancer. Therefore, non-primary aromatic amine ingredients should provide testing demonstrating no aniline is present. |
| PEG-25 PABA | 113010-52-9 | The European Commission restricts the usage and purity of this ingredient: the maximum nitrosamine content cannot exceed 50 microgram/kg. |
| PEG-25 PHYTOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 PROPYLENE GLYCOL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 SOY STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25 TALLOW ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-250 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-250 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-25M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|------------|---|
| PEG-26 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-26 JOJOBA ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-26 JOJOBA ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-26-PPG-30 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-27 LANOLIN | 8051-81-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-27 LANOLIN ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-28 GLYCERYL TALLOWATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-29 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-2M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 BUTYLENE GLYCOL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 COCAMIDE DEA | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| PEG-3 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DICAPRYLATE/CAPRATE | C | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIETHYLENETRIAMINE DIPALMAMIDE | c | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIISOSTEARATE | C | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIMETHICONE | c | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIOLEATE | C | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIOLEOYLAMIDOETHYLMONIUM METHOSULFATE | C | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIPALMITATE | 32628-06-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DIROSINATE | 8050-25-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DISOYOYLAMIDOETHYLMONIUM METHOSULFATE | 68605-27-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 DISTEAROYLAMIDOETHYLMONIUM METHOSULFATE | C | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 GLYCERYL COCOATE | C | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG-3 GLYCERYL DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 LAURAMIDE | 26635-75-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 LAURAMINE OXIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 METHYL ETHER | 112-35-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 OLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 PPG-20 SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 RAPESEED AMINOPROPYLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-3 SORBITAN OLEATE | 9005-65-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 SORBITAN STEARATE | 9005-67-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 SORBITAN TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 TALLOW AMINOPROPYLAMINE | 90367-27-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 TALLOW PROPYLENEDIMONIUM DIMETHOSULFATE | 93572-63-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 TRIMETHYLOLPROPANE TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3 TRIMETHYLOLPROPANE TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3-BUTETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3/PPG-2 GLYCERYL/SORBITOL HYDROXYSTEARATE/ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 DIPOLYHYDROXYSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-30 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 GLYCERYL ISOSTEARATE | 689-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 GLYCERYL LAURATE | 51248-32-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 GLYCERYL OLEATE | 68889-49-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 GLYCERYL SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 HYDROGENATED CASTOR OIL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 HYDROGENATED CASTOR OIL PCA ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|------------|---|
| PEG-30 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 JOJOBA OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 PHYTOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 POLYHYDROXYSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 SORBITAN BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 SORBITAN TETRAOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 SOY STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-30 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-300 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG-32 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 PVP | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 SODIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-32 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-33 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-33 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-3350 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|-------------|---|
| PEG-35 ALMOND GLYCERIDES | 124046-50-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-35 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-35 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-35 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-35 SOY GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-35 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-350 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-36 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-36 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-36 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 CAPRYLIC/CAPRIC GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|------------|---|
| PEG-4 COCAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DIHEPTANOATE | 70729-68-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DIMETHACRYLATE | 109-17-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DISTEARATE | 142-20-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DISTEARYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DISTEARYLETHONIUM ETHOSULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 DITALLOW ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 ETHYLHEXANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 GLYCERYL DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG-4 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 METHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 MONTANATE | 68476-04-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 OLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 OLIVATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 POLYGLYCERYL-2 DISTEARATE | 72828-11-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 POLYGLYCERYL-2 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 PROLINE LINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 PROLINE LINOLENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 RAPESEEDAMIDE | 85536-23-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Substance/Ingredient | CAS | Restrictions |
|---------------------------------------|------------|---|
| PEG-4 SORBITAN LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 SORBITAN STEARATE | 9005-67-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 SORBITAN TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 STEARAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 STEARATE | 106-07-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 TRIETHANOLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4 TRIMETHYLOLPROPANE DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-4-PPG-7 C13/C15 ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 ALMOND GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 BUTYLOCTANOL WHEAT GERM ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-40 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED CASTOR EXTRACT | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED CASTOR OIL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED CASTOR OIL PCA ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED LANOLIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------|------------|---|
| PEG-40 JOJOBA ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 JOJOBA ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|------------|---|
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 OLIVE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 RICINOLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN LANOLATE | 8036-77-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN OLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN PERISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN PEROLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN STEARATE | 9005-67-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 SORBITAN TETRAOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG-40 SOY STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-40 STEARATE | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 7%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-40/DODECYL GLYCOL COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|------------|---|
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------|------------|---|
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-400 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-42 BABASSU GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-42 MUSHROOM GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-44 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|-------------|---|
| PEG-44 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 PALM KERNEL GLYCERIDES | 124046-52-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 PALM KERNEL GLYCERIDES | 124046-52-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 SAFFLOWER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45 STEARATE PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45/ DODECYL GLYCOL COPOLYMER | 78336-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45/ DODECYL GLYCOL COPOLYMER | 78336-31-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-450 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-45M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|-------------|---|
| PEG-5 CETETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCAMINE | 61791-14-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 COCOMONIUM METHOSULFATE | 68989-03-07 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 DEDM HYDANTOIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 DEDM HYDANTOIN OLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 DITRIDECYLMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-5 ETHYLHEXANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 GLYCERYL OLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 GLYCERYL SESQUIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 GLYCERYL STEARATE | 51158-08-08 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 GLYCERYL TRIISOSTEARATE | 86846-21-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 HYDROGENATED CORN GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|---|
| PEG-5 ISODECYLOXYPROPYLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 LANOLINAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|------------|---|
| PEG-5 LAURAMIDE | 26635-75-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 OLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 OLEAMIDE DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 OLEAMMONIUM METHOSULFATE | 64611-81-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 PENTAERYTHRITYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 PHYTOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 RAPESEED STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SORBITAN ISOSTEARATE | 66794-58-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SORBITAN OLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SOYA STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SOYA STEROL | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|-------------|---|
| PEG-5 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 STEARYL AMMONIUM CHLORIDE | 80238-02-04 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 STEARYL AMMONIUM LACTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 STEARYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TALL OIL STEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TALLOW AMIDE | 8051-61-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------------|------------|---|
| PEG-5 TALLOW BENZONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TRICAPRYL CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TRICETYL CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TRILAURYL CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TRIMETHYLOLPROPANE TRIMYRISTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TRIMYRISTYL CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TRISTEARYL CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 TSUBAKIATE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5 UNDECYLENATE P-HYDROXYBENZOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-5-CETETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 DISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-50 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED CASTOR OIL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED CASTOR OIL SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED PALMAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 HYDROGENATED TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 SHEA BUTTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 STEARAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 STEARAMINE | 9003-93-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-50 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-50 STEARATE | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 9%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-50 TALLOW AMIDE | 68155-24-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-500 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-54 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-54 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 PROPYLENE GLYCOL DIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 PROPYLENE GLYCOL OLEATE | 86481-08-05 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-55 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-58 HYDROGENATED CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|------------|---|
| PEG-5M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 | 2615-15-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ALMOND GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 BUTYLENE GLYCOL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 CAPRYLATE/CAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 CAPRYLIC GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 CAPRYLIC/ CAPRIC GLYCERIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 CAPRYLIC/CAPRIC GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 COCAMIDE PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-6 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 GLYCERYL CAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 GLYCERYL TRISTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 HYDROGENATED PALM OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 HYDROGENATED PALM/PALM KERNEL GLYCERIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 HYDROGENATED PALMAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ISOLAURYL THIOETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ISOPALMITATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------|------------|---|
| PEG-6 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 LAURAMIDE | 26635-75-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 LAURAMIDE | 26635-75-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 LAURAMIDE | 26635-75-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 LAURATE | 2370-64-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 LAURATE/TARTRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHICONE ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER | 9004-74-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 OLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 OLEAMINE | 26635-93-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 OLIVE GLYCERIDES | 103819-46-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 PALMITATE | 9004-94-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 PROPYLENE GLYCOL CAPRYLATE/CAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------|------------|---|
| PEG-6 SORBITAN OLEATE | 9005-65-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 SORBITAN STEARATE | 9005-67-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 SORBITOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 STEARYLGUANIDINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6 UNDECYLENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6-32 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6-32 GLYCERETH-26 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6-32 PROPYLENE GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6-32 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-6-32 STEARATE SE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 ALMOND GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG-60 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 CASTOR OIL ISOSGTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 CASTOR OIL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 CORN GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 EVENING PRIMROSE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 GLYCERYL ISOSTEARATE | 68958-58-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 GLYCERYL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 GLYCERYL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 HYDROGENATED CASTOR OIL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 HYDROGENATED CASTOR OIL PCA ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 HYDROGENATED CASTOR OIL TRIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-60 PASSIFLORA EDULIS SEED GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 PASSIFLORA INCARNATA SEED GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 SHEA BUTTER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 SORBITAN STEARATE | 9005-67-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 SORBITAN TETRAOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 SORBITAN TETRASTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60 TSUBAKIATE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-600 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-60M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-65 HYDROGENATED CASTOR OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-65 LANOLIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-65M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-66 TRIHYDROXYSTEARIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|-------------|---|
| PEG-6M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 AMODIMETHICONE | 133779-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 AVOCADOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 BETA-NAPHTHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 CAPRYLIC/CAPRIC GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 COCAMIDE | 61791-08-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 DIMETHICONE C8-C18 ESTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 DIMETHICONE ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 GLYCERIN COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 GLYCERYL COCOATE | 66105-29-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 GLYCERYL SOYATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|------------|---|
| PEG-7 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 METHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 OLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 OLIVATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 OLIVE GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 PANTHENYL PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 RICINOLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 RICINOLEATE | 9004-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 RICINOLEATE | 9004-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 RICINOLEATE | 9004-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|------------|---|
| PEG-7 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 SUNFLOWER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-70 HYDROGENATED LANOLIN | 68648-27-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-70 LANOLIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-70 MANGO GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7000 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 BETA-SITOSTEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 COCOA BUTTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 COCOA BUTTER GLYCERIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 COCOA BUTTER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|------------|---|
| PEG-75 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 DISTEARATE | 2595268 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 LANOLIN | 2242474 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 LANOLIN OIL | 68648-38-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 LANOLIN WAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 MEADOWFOAM OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 PROPYLENE GLYCOL STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 SHEA BUTTER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 SHOREA BUTTER GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 SORBITAN LANOLATE | 8051-13-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------|------------|---|
| PEG-75 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 SOY GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-75 STEARYL ETHER DIMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-76 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-78 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-7M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 AVOCADOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 BEESWAX | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 BEHENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 C12-18 ESTER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 CAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|------------|---|
| PEG-8 CAPRYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 CAPRYLATE/ CAPRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 CAPRYLIC/ CAPRIC GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 CETYL DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 CRANBERRIATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DI/TRIRICINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DICOCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------|------------|---|
| PEG-8 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DILAURATE | 2595081 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIMETHICONE | 68937-54-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIMETHICONE | 68937-54-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIMETHICONE COPOLYOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| PEG-8 DIMETHICONE MEADOWFOAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIMETHICONE/DIMER DILINOLEIC ACID COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DIOLEATE | 2595236 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DISTEARATE | 52668-97-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 DITALLATE | 61791-01-03 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|------------|---|
| PEG-8 DODECENYLSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 GLYCERYL LAURATE | 59070-56-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 HYDROGENATED CASTOR OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 HYDROGENATED FISH GLYCERIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 HYDROGENATED FISH GLYCERIDES | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 ISOLAURYL THIOETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 ISOSTEARATE | 56002-14-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LANOLATE | 68459-50-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-----------|---|
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LAURATE | 9004-81-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 LINOLENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 MEADOWFOAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 METHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 METHYL ETHER TRIETHOXYSILANE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 MYRISTATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG-8 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 PALMITOYL METHYL DIETHONIUM METHOSULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 PALMITOYL OLIGOPEPTIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 PG-COCO-GLUCOSIDE DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 POLYSORBATE 60 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 PPG-3 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 PROPYLENE GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 PROPYLENE GLYCOL COCOATE | 126645-98-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 RASPBERRIATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 RICINOLEATE | 9004-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 SESQUILAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 SESQUIOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 SOYAMINE | 61791-24-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|------------|---|
| PEG-8 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 STEARATE | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 3%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-8 TALLATE | 61791-00-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TALLOW AMINE | 61791-26-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TOCOPHEROL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 TOCOPHEROL | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG-8 TRIFLUOROPROPYL DIMETHICONE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8 UNDECYLENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8-CETETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-8/ SMDI COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|------------|---|
| PEG-8/PPG-2 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 GLYCERYL COCOATE | 68201-46-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 GLYCERYL TALLOWATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 HYDROGENATED CASTOR OIL | 61788-85-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 HYDROGENATED GLYCERYL PALMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 JOJOBA ALCOHOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 METHYL GLUCOSE LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|------------|--|
| PEG-80 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4- dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4-dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN LAURATE | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN LAURATE SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-80 SORBITAN PALMITATE | 9005-66-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-800 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-800/POLYVINYL ALCOHOL COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-82 GLYCERYL TALLOWATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-85 LANOLIN | 61790-81-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 | 3386-18-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 AVOCADOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|------------|---|
| PEG-9 BORAGEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 BUTYLENE GLYCOL LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 BUTYLOCTANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 CASTOR OIL | 61791-12-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 COCAMIDE MEA | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 COCOATE | 61791-29-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 COCOGLYCERIDES | 67762-35-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 DIETHYLMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 DIMETHACRYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 DIMETHICONE | 68937-54-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 DISTEARATE | 109-34-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 GRAPESEEDATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG-9 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 LAURATE | 0106-08-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 METHYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 OCTYLDODECANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 OLEAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 OLEATE | 9004-96-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 OLIVEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 RICINOLEATE | 9004-97-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 SOYATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 STEARAMIDE CARBOXYLIC ACID | 90453-59-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9 STEARATE | 5349-52-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-90 | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG-90 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-90 GLYCERYL ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-90 STEARATE | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-90/POLYEPSILON CAPROLACTONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-90M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-9M | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-LYCEROL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-STEARATES | 9004-99-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG-STEARATES | 9004-99-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| PEG-XX | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PEG-20/ 20 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------|---------|---|
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 116/ 66 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 20/ 22 BUTYL ETHER DIMETHICONE | 67762-87-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 20/ 22 BUTYL ETHER DIMETHICONE | 67762-87-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|---------|---|
| PEG/ PPG 38/ 8 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 4/ 12 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG 8/ 3 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-10/ 2 RICINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-14/ 4 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-15/ 15 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-17/ 18 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-17/ 6 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-18/ 18 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-18/ 8 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-20/ 15 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-20/ 23 BENZOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-20/ 6 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|---------|---|
| PEG/ PPG-22/ 24 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-240/ 60 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-25/ 25 DIMETHICONE/ ACRYLATES COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/ PPG-8/ 3 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-1/2 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-1/25 DIETHYLMONIUM CHLORIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/2 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/2 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/2 DIRICINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/3 OLEYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/30 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/65 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-10/70 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PEG/PPG-100/70 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-100/70 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-12/16 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-12/18 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-12/35 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-125/30 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-14/7 DIMETHYL ETHER | 61419-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-14/7 DIMETHYL ETHER | 61419-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-14/7 DIMETHYL ETHER | 61419-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-150/30 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-150/35 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-16/17 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-16/2 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|---------|---|
| PEG/PPG-16/8 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-160/30 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-160/31 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-17/4 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-18/18 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-18/18 LAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-18/4 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-19/19 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-19/21 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-190/60 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-2/5 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-2/5 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-20/20 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| PEG/PPG-20/20 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-20/22 METHYL ETHER DIMETHICONE | 125857-75-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-20/23 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-20/29 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-20/60 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-20/65 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-20/9 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-200/40 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-200/70 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-22/22 BUTYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-22/23 BUTYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-22/23 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-22/25 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PEG/PPG-22/40 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-23/17 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-23/23 BUTYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-23/50 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-23/6 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-24/18 BUTYL ETHER DIMETHICONE | 67762-87-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-24/24 METHYL ETHER GLYCIDOXY DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-25/25 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-25/30 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-26/31 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-27/14 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-27/27 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-27/9 BUTYL ETHER DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|------------|---|
| PEG/PPG-28/21 ACETATE DIMETHICONE | 68037-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-28/30 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-3/1 OLIVE OIL ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-3/10 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-3/17 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-3/6 DIMETHYL ETHER | 61419-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-30/10 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-30/10 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-30/10 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-30/160 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-30/33 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-30/35 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-30/55 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|---------|--|
| PEG/PPG-300/55 COPLOYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-300/55 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-32/3 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-32/3 DIRICINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-32/3 RICINOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-35/40 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-35/40 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-35/9 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-36/41 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-4/2 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-5/10 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-5/10 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-5/20 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-5/20 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|---------|---|
| PEG/PPG-5/3 TRISILOXANE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-5/30 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-5/30 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-5/30 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-5/35 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-50/20 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-50/20 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-50/40 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-50/40 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-55/28 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-6/11 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-6/2 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-7/12 DIMETHYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-7/50 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| PEG/PPG-70/30 TOCOPHERYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-70/30 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PEG/PPG-8/13 DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-8/14 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-8/17 COPOLYMER | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-8/26 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-8/55 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG-9/2 DIMETHYL ETHER | 61419-46-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG/BUTYLENE/DIMETHICONE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEG/PPG/POLYBUTYLENE GLYCOL-8/5/3 GLYCERIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEGLICOL 5 OLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PEGOXOL 7 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PELVETIA CANALICULATA (CHANNELLED WRACK) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| PENTADOXYNOL-200 | 40160-92-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PERFLUORONONYLETHYL CARBOXYDECYL PEG-10 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PETROLEUM DISTILLATES | 8052-41-3 | The European Commission bans this ingredient from use in cosmetics if its benzene content is over 0.1%. |
| PETROLEUM DISTILLATES, CLAY-TREATED HEAVY NAPHTHENIC | 64742-44-5 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| PETROLEUM DISTILLATES, CLAY-TREATED LIGHT NAPHTHENIC | 64742-45-6 | The European Commission bans this ingredient from use in cosmetics if it contains over 3% w/w DMSO extract |
| PETROLEUM GASES, LIQUEFIED, SWEETENED, C4 FRACTION | 92045-80-2 | The European Commission bans this ingredient from use in cosmetics if it contains over 0.1% w/w Butadiene |
| PHAEOPHYCEA SEAWEED EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| PHENYLPROPYLDIMETHYLSILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| PHENYLPROPYLDIMETHYLSILOXYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| PHTHALIC ANHYDRIDE/ADIPIC ACID/CASTOR OIL/NEOPENTYL GLYCOL/PEG-3/TRIMETHYLOLPROPANE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PHYLLACANTHA FIBROSA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| PHYTANTRIOL | 74563-64-7 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 3%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: sulphated ash, heavy metals, and diastereomer of phytantriol (3,7,11,15 tetramethyl1,2,3,4tetrahydroxyhexadecane) |
| PHYTOL PPG-5-CETETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PICEA MARIANA LEAF EXTRACT | 91722-19-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PICEA MARIANA LEAF EXTRACT | 91722-19-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PICEA MARIANA LEAF OIL | 91722-19-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PICEA MARIANA LEAF OIL | 91722-19-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| PINUS BANKSIANA (JACK PINE) BARK EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS CEMBRA TWIG LEAF EXTRACT | 92202-04-05 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS CEMBRA TWIG LEAF EXTRACT | 92202-04-05 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS CEMBRA TWIG LEAF EXTRACT ACETYLATED | 94334-26-6 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS CEMBRA TWIG LEAF OIL | 92202-04-05 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO LEAF OIL | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO LEAF OIL | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO LEAF OIL | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO PUMILIO TWIG LEAF EXTRACT | 90082-73-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO PUMILIO TWIG LEAF EXTRACT | 90082-73-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO PUMILIO TWIG LEAF OIL | 90082-73-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO TWIG LEAF EXTRACT | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO TWIG LEAF EXTRACT | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO TWIG LEAF EXTRACT | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS MUGO TWIG OIL | 90082-72-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS NIGRA TWIG LEAF EXTRACT | 90082-74-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS NIGRA TWIG LEAF EXTRACT | 90082-74-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS NIGRA TWIG LEAF OIL | 90082-74-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS (LONGLEAF PINE) OIL | 2228957 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS (LONGLEAF PINE) OIL | 2228957 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS (PITCH PINE) | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS LEAF EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS LEAF EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS LEAF EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS TWIG LEAF EXTRACT | 97435-14-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| PINUS PALUSTRIS TWIG LEAF EXTRACT | 97435-14-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS TWIG LEAF EXTRACT | 97435-14-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PALUSTRIS TWIG LEAF OIL | 97435-14-8 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PINASTER TWIG LEAF EXTRACT | 90082-75-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PINASTER TWIG LEAF EXTRACT | 90082-75-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PINASTER TWIG LEAF OIL | 90082-75-0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PUMILA TWIG LEAF EXTRACT | 97676-05-06 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PUMILA TWIG LEAF EXTRACT | 97676-05-06 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS PUMILA TWIG LEAF OIL | 97676-05-06 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS STROBUS (WHITE PINE) BARK EXTRACT | 90082-77-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS STROBUS (WHITE PINE) CONE EXTRACT | 94266-48-5 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) BARK EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) BUD EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) CONE EXTRACT | 94266-48-5 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) LEAF EXTRACT | 84012-35-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) LEAF EXTRACT | 84012-35-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) LEAF EXTRACT | 84012-35-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) LEAF EXTRACT | 84012-35-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS (SCOT'S PINE) LEAF OIL | 8023-99-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PINUS SYLVESTRIS LEAF WATER | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| PIROCTONE OLAMINE | 68890-66-4 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| POLIANTHES TUBEROSA CALLUS EXTRACT | 94334-35-7 | P. tuberosa extract contains methyl eugenol (CAS: 93152), which the EU restricts in cosmetics and is an EWG unacceptable ingredient due to cancer hazard. Products containing P. tuberosa must not contain detectable levels of methyl eugenol. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|------------|---|
| POLIANTHES TUBEROSA EXTRACT | 94334-35-7 | P. tuberosa extract contains methyl eugenol (CAS: 93152), which the EU restricts in cosmetics and is an EWG unacceptable ingredient due to cancer hazard. Products containing P. tuberosa must not contain detectable levels of methyl eugenol. |
| POLIANTHES TUBEROSA FLOWER WAX | 0 | P. tuberosa extract contains methyl eugenol (CAS: 93152), which the EU restricts in cosmetics and is an EWG unacceptable ingredient due to cancer hazard. Products containing P. tuberosa must not contain detectable levels of methyl eugenol. |
| POLIANTHES TUBEROSA POLYSACCHARIDE | 0 | P. tuberosa extract contains methyl eugenol (CAS: 93152), which the EU restricts in cosmetics and is an EWG unacceptable ingredient due to cancer hazard. Products containing P. tuberosa must not contain detectable levels of methyl eugenol. |
| POLOXAMER 101 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 105 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 3%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 105 BENZOATE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 108 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 122 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 123 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 124 | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLOXAMER 124 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 181 | 2594628 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLOXAMER 181 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 6%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 182 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 6%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 182 DIBENZOATE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 183 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|---------|--|
| POLOXAMER 184 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 10%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 185 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 9%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 188 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 212 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 215 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 217 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 231 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 234 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 10%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 235 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 237 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 238 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 282 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 284 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 288 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 331 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 333 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 1%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| POLOXAMER 334 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.3%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 335 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 338 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 401 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 402 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 403 | 2594628 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| POLOXAMER 407 | 2594628 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 20%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: aldehydes, formic acid, acetic acid, 1,4dioxane, residual ethylene oxide, and residual propylene oxide |
| Poly(oxy-1,2-ethanediyl), .alpha;(4-nonylphenyl)omega;hydroxy-, branched | 127087-87-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLY(OXY-1,2-ETHANEDIYL), .ALPHA;(NONYLPHENYL) OMEGA;HYDROXY-, BRANCHED | 68412-54-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLY(OXY-1,2-ETHANEDIYL), .ALPHA;(OCTYLPHENYL) OMEGA;HYDROXY-, BRANCHED | 68987-90-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLY(OXY-1,2-ETHANEDIYL), ALPHA-ISODECYL-OMEGA- HYDROXY- | 61827-42-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLY(OXY-1,2-ETHANEDIYL), ALPHA,ALPHA'- ((OCTADECYLIMINO)DI-2,1-ETHANEDIYL)BIS(OMEGA- HYDROXY- | 26635-92-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLY(OXY-1,2-ETHANEDIYL), ALPHA,ALPHA',ALPHA'', ALPHA'''-(1,2-ETHANEDIYLBIS(NITRILODI-2,1- | 27014-42-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYACRLYAMIDE C 13-14 ISOPARAFFIN LAURETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| POLYACRYAMIDE/ ISOPARRAFIN/ LAURETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYACRYLAMIDE | 2594446 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYACRYLAMIDE | 2594446 | The Cosmetic Ingredient Review restricts the acrylamide monomer conent of this ingredient to a maximum concentration of 5 ppm. |
| POLYACRYLATE-10 | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYACRYLATE-11 | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYACRYLATE-2 | 31759-42-9 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYACRYLATE-7 | 243140-33-2 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYAMIDE | 0 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| POLYDIMETHYLSILOXY PEG/PPG-24/19 BUTYL ETHER SILSESQUIOXANE | 68554-65-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYESTER FIBER | 0 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| POLYESTER/EPOXY/CALCIUM SODIUM BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| POLYESTER/EPOXY/CALCIUM SODIUM BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| POLYETHYLENE | 9002-88-4 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| POLYETHYLENE BEADS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYETHYLENE GLYCOL | 25322-68-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYETHYLENE GLYCOL MONOSTEARATE 1000 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| Polyethylene glycol octylphenol ether; | 9002-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Polyethylene glycol octylphenol ether; | 9002-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYETHYLENE HDI/ TRIMETHYLOL HEXYLLACTONE CROSSPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYETHYLENE HYDROXYETHYLCELLULOSE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYETHYLENE POLYGLYCERYL-4 ISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYETHYLENE TEREPHTHALATE | 25038-59-9 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| POLYETHYLENE/ISOPROPYL MALEATE/MA COPOLYOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Polyethyleneglycol isotridecyl Ether | 9043-30-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Polyethyleneimine ethoxylates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Polyethyleneimine Propoxyethoxylate | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYGLYCERYL-2-PEG-4 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYGLYCERYL-4-PEG-2 COCAMIDE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Polyhydroxystearic Acid | 27924-99-8 | For the purposes of the Reviewed Ingredients program, this ingredient may only be used in combination with another restricted ingredient on the Ingredients Eligible for Reviewed List. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| POLYOX PEG 7M | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYOXYETHYLENE CETYL STEARYL DIETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYOXYETHYLENE GLYCOL DIMERCAPTOACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYOXYETHYLENE POLYOXYPROPYLENE GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYPERFLUOROETHOXYMETHOXY DIFLUOROETHYL PEG DIISOSTEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYPERFLUOROETHOXYMETHOXY PEG-2 PHOSPHATE | 162567-74-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYPROPYLENE | 9003-07-0 | When this ingredient is used as a wipe substrate, testing must be provided to confirm purity. Total PAHs are limited to less than 0.2 ppm, and dioxin, furans, and pesticide residues must not be detectable. |
| POLYQUATERNIUM-15 | 35429-19-7 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-32 | 35429-19-7 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-33 | 69418-26-4 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-39 | 25136-75-8 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-43 | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-5 | 26006-22-4 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-53 | 84647-38-1 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-63 | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYQUATERNIUM-7 | 26590-05-06 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POLYSORBATE-20 | 9005-64-5 | The U.S. Food & Drug Administration has identified 1,4- dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4-dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| POLYSORBATE-40 | 9005-66-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYSORBATE-40 | 9005-66-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYSORBATE-60 | 9005-67-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYSORBATE-80 | 9005-65-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYSORBATE-85 | 9005-70-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POLYURETHANE-17 | 347175-78-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| POLYURETHANE-21 | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| PORPHYRA UMBILICALIS (RED ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| PORPHYRA YEZOENSIS (ALGAE) LEAF | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| POTASSIUM ACRYLATES/ACRYLAMIDE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| POTASSIUM ASCORBYL TOCOPHERYL PHOSPHATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| POTASSIUM DECETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM DIMETHICONE PEG-7 PANTHENYL PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| POTASSIUM DIMETHICONE PEG-7 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM FLUOROSILICATE | 16871-90-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| POTASSIUM FLUOROSILICATE | 16871-90-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| POTASSIUM GLYCYRRHETINATE | 85985-61-1 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 1%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides/PCB, toxic metals, and heavy metals. |
| POTASSIUM LAURETH PHOSPHATE | 68954-87-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM LAURETH-10 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM LAURETH-3 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM LAURETH-4 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM LAURETH-5 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM LAURETH-6 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM OCTOXYNOL-12 PHOSPHATE | 68891-73-6 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 0.05%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: 1,4dioxane and ethylene oxide. |
| POTASSIUM PEG-50 HYDROGENATED CASTOR OIL SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM SILICATE | 1312-76-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-----------|---|
| POTASSIUM SILICATE | 1312-76-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| POTASSIUM TRIDECETH-15 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM TRIDECETH-19 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM TRIDECETH-3 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM TRIDECETH-4 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM TRIDECETH-6 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM TRIDECETH-7 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| POTASSIUM TRIDECETH-7 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1 CETETH-3 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1 TRIDECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-CETETH-1 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-CETETH-10 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|---|
| PPG-1-CETETH-5 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-DECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-ISOCETETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-PEG-9 LAURYL GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-1-PEG-9 LAURYL GLYCOL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-10 TOCOPHERETH-30 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PPG-10-CETEARETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-10-Laureth-7 | 68439-51-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-12 BUTETH-16 | 9038-95-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-12-PEG-50 LANOLIN | 68458-88-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-12-PEG-65 LANOLIN OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-13-DECYLTETRADECETH-24 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-14 DECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| PPG-14 LAURETH-60 ALKYL DICARBAMATE | 226994-82-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-14 LAURETH-60 HEXYL DICARBAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-14 LAURETH-60 ISOPHORYL DICARBAMATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-15-PEG-11 HYDROGENATED LAURYL ALCOHOL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2 ISOCETETH-20 ACETATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2 TOCOPHERETH-5 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PPG-2-CETEARETH-9 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-CETETH-1 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-CETETH-10 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-CETETH-5 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------|-------------|---|
| PPG-2-DECETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-15 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-40 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-50 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-60 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-DECETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-ISODECETH-12 | 155683-77-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-ISODECETH-4 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-ISODECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-ISODECETH-9 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| PPG-2-LAURETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-LAURETH-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-PEG-11 HYDROGENATED LAURYL ALCOHOL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-2-PEG-6 COCONUT OIL ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-20 TOCOPHERETH-50 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PPG-20-DECYLTETRADECETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-20-PEG-20 HYDROGENATED LANOLIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-23-PEG-4 TRIMETHYLOLPROPANE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-23-STEARETH-34 | 9038-43-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-24-PEG-21 TALLOWAMINOPROPYLAMINE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-25-LAURETH-25 | 37311-00-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-25-PEG-25 TRIMETHYLOLPROPANE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3 METHYL ETHER | 25498-49-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|-----|---|
| PPG-3-DECETH-2 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3-ISODECETH-1 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3-LAURETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3-LAURETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3-LAURETH-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3-LAURETH-9 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-3-PEG-6 OLEYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-30 TOCOPHERETH-70 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PPG-4 DECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4 LAURETH-2 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4 LAURETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4 LAURETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4 Laureth-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|-----------|---|
| PPG-4 OLETH-10 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4 TRIDECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-CETEARETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-CETETH-1 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-CETETH-10 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-CETETH-5 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-DECETH-4 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-ISODECETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-4-LAURETH-15 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-40-PEG-60 LANOLIN OIL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5 CETEARETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5 TOCOPHERETH-2 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PPG-5 TOCOPHERYL ETHER | 0 | This ingredient should not contain detectable levels of hydroquinone. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------|-----------|---|
| PPG-5-CETEARETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Substance/Ingredient | CAS | Restrictions |
|---------------------------|-------------|---|
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-5-LAURETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6 C12-15 PARETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6 C9-11 PARETH-5 | 154518-36-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6 DECYLTETRADECETH-30 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6 TRIDECETH-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6-DECETH-4 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-----------|---|
| PPG-6-DECETH-9 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6-DECYLTETRADECETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6-DECYLTETRADECETH-20 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-6-LAURETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-65-PEG-5 PENTAERYTHRITYL ETHER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-68-PEG-10 TRIMETHYLOLPROPANE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-70 TOCOPHERETH-100 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| PPG-75-PEG-300 HEXYLENE GLYCOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-8 DECETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-8-CETETH-1 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-8-CETETH-10 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-8-CETETH-2 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG-8-CETETH-20 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|-------------|--|
| PPG-8-CETETH-5 | 9087-53-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG/ PEG-18 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG/PEG-10/2 GLYCERYL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PPG/PEG-2/10 GLYCERYL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPHYRIDIUM CRUENTUM EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| PROPYLENE GLYCOL CETETH-3 ACETATE | 93385-03-06 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPYLENE GLYCOL CETETH-3 PROPIONATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPYLENE GLYCOL ISOCETETH-3 ACETATE | 178900-23-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPYLENE GLYCOL ISODECETH-12 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPYLENE GLYCOL ISODECETH-4 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPYLENE GLYCOL LAURETH-6 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| PROPYLENE GLYCOL OLETH-5 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|----------------------------------|------------|--|
| PUMPKIN SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| QUATERNIUM-18 MAGNESIUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| QUATERNIUM-18 MAGNESIUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| QUATERNIUM-53 | 68410-69-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| RAPESEED OIL PEG-20 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| RAPESEED OIL PEG-3 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| RASPBERRY SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| RED ALGAE CAREGEENAN | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| RIBOFLAVIN | 83-88-5 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E101) |
| RICE BRAN ACID | 93165-33-4 | The Cosmetic Ingredient Review restricts this ingredient in that it cannot contain significant levels of pesticide residues or heavy metals. |
| RICEBRANAMIDE DEA | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| RICHINOLETH-18 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| RICINOLEAMIDE DEA | 40716-42-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| RICINOLEAMIDOPROPYL BETAINE | 71850-81-2 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| RICINOLEAMIDOPROPYL DIMETHYLAMINE | 20457-75-4 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| RICINOLETH-40 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| ROSA HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| ROSA HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| ROSA RUBIGINOSA SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| RUTILE | 1317-80-2 | Per the U.S. FDA., titanium dioxide shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million. Antimony (as Sb), not more than 2 parts per million. Mercury (as Hg), not more than 1 part per million. Loss on ignition at 800 °C. (after drying for 3 hours at 105 °C.), not more than 0.5 percent. Water soluble substances, not more than 0.5 percent. TiO2, not less than 99.0 percent after drying for 3 hours at 105 °C. Lead, arsenic, and antimony shall be determined in the solution obtained by boiling 10 grams of the titanium dioxide for 15 minutes in 50 milliliters of 0.5N hydrochloric acid. |
| S-TRIAZINE, 4,6-DIAMINO-2-NONOXY- | 19619-57-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Saccharina japonica | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| Saccharina japonica extract | 92128-82-0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SACCHAROMYCES/LAMINARIA SACCHARINA FERMENT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| Saccharomyces/Sugarcane Juice Extract Ferment Extract | 0 | The 2022 CIR Safety Assessment of Saccharum officinarum (Sugarcane)-Derived Ingredients as Used in Cosmetics states that sugarcane-derived ingredients, specifically sugar cane juice extract, are likely to be contaminated with PAHs, heavy metals (iron, zinc, manganese, copper, lead, cadmium, nickel, and cobalt), and pesticide residues. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| SACCHARUM OFFICINARUM (SUGAR CANE) | 0 | Per the Cosmetic Ingredient Review (CIR) February 2022 Safety Assessment of Saccharum officinarum (Sugarcane)- Derived Ingredients as Used in Cosmetics, sugarcane- derived ingredients may be contaminated with polycyclic aromatic hydrocarbons (PAHs) due to the burning that occurs during the harvest. |
| SACCHARUM OFFICINARUM (SUGAR CANE) EXTRACT | 91722-22-4 | Per the Cosmetic Ingredient Review (CIR) February 2022 Safety Assessment of Saccharum officinarum (Sugarcane)- Derived Ingredients as Used in Cosmetics, sugarcane- derived ingredients may be contaminated with polycyclic aromatic hydrocarbons (PAHs) due to the burning that occurs during the harvest. |
| SACCHARUM OFFICINARUM (SUGAR CANE) JUICE | 0 | Per the Cosmetic Ingredient Review (CIR) February 2022 Safety Assessment of Saccharum officinarum (Sugarcane)- Derived Ingredients as Used in Cosmetics, sugarcane- derived ingredients may be contaminated with polycyclic aromatic hydrocarbons (PAHs) due to the burning that occurs during the harvest. |
| SACCHARUM OFFICINARUM FERMENT EXTRACT | 91770-72-8 | Per the Cosmetic Ingredient Review (CIR) February 2022 Safety Assessment of Saccharum officinarum (Sugarcane)- Derived Ingredients as Used in Cosmetics, sugarcane- derived ingredients may be contaminated with polycyclic aromatic hydrocarbons (PAHs) due to the burning that occurs during the harvest. |
| SACHARINA ANGUSTATA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SAFFLOWER SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SARGASSEM FILIPENDULA (SEAWEED) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM FILIPENDULA (SARGASSUM WEED) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM FUSIFORME EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM FUSIFORME POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM MUTICUM EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| SARGASSUM PALLIDUM (SARGASSUM WEED) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM PALLIDUM (SARGASSUM WEED) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM PALLIDUM POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM SEA MINERALS | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SARGASSUM VULGARE EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SASSAFRAS OFFICINALE ROOT OIL | 8006-80-2 | Products containing this substance must contain less than 0.01% safrole as indicated by the International Fragrance Association |
| Secondary alcohol ethoxylates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SESAMIDE DEA | 124046-35-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| SESAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| SESAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| SHEA BUTTER PEG-32 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SHEA BUTTER PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| SHEA BUTTERAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| SILANE | 7803-62-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE | 7803-62-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, CHLOROTRIMETHYL- | 75-77-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, CHLOROTRIMETHYL- | 75-77-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| Silane, dichlorodimethyl-, reaction products with silica | 68611-44-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| Silane, dichlorodimethyl-, reaction products with silica | 68611-44-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, ETHYLTRICHLORO- | 115-21-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, ETHYLTRICHLORO- | 115-21-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, TRICHLOROETHENYL- | 75-94-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, TRICHLOROETHENYL- | 75-94-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILANE, TRIETHOXYVINYL- | 78-08-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|------------|--|
| SILANE, TRIETHOXYVINYL- | 78-08-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA ACRYLATES COPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA ACRYLATES COPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA AEROGEL | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA AEROGEL | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA ALUMINA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA ALUMINA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA DIMETHICONE SILYLATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA DIMETHICONE SILYLATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA DIMETHYL SILYLATE | 68611-44-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA DIMETHYL SILYLATE | 68611-44-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA EXTRACT | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA EXTRACT | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------|------------|---|
| SILICA GEL | 63231-67-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA GEL | 63231-67-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA GEL LIQUID | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA GEL LIQUID | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1 ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA OIL | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA OIL | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA POLYGLYCERYL-3 | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA POLYGLYCERYL-3 | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA SILCYLATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA SILCYLATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA SILYATE ALUMINA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA SILYATE ALUMINA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA SILYLATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------|-------------|--|
| SILICA SILYLATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA, AMORPHOUS | 7631-86-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA, AMORPHOUS | 7631-86-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA, AMORPHOUS-FUME | 69012-64-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA, AMORPHOUS-FUME | 69012-64-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA, FUMED | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICA, FUMED | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE | 12627-13-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE | 12627-13-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE, PORTLAND CEMENT | 65997-15-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE, PORTLAND CEMENT | 65997-15-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO- | 17084-08-01 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO- | 17084-08-01 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| SILICATE(2-), HEXAFLUORO- DINITRYL | 19184-38-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO- DINITRYL | 19184-38-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO-, ALUMINUM (3:2) | 17099-70-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO-, ALUMINUM (3:2) | 17099-70-6 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO-, STRONTIUM | 18943-30-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO-, STRONTIUM | 18943-30-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO-, ZINC | 16871-71-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICATE(2-), HEXAFLUORO-, ZINC | 16871-71-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID (H2SIO3), DISODIUM SALT, PENTAHYDRATE | 10213-79-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID (H2SIO3), DISODIUM SALT, PENTAHYDRATE | 10213-79-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID (H2SIO4), TETRAKIS(1-METHYLPROPYL) ESTER | 5089-76-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID (H2SIO4), TETRAKIS(1-METHYLPROPYL) ESTER | 5089-76-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID (ORTHO) | 10193-36-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| SILICIC ACID (ORTHO) | 10193-36-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, CALCIUM SALT | 1344-95-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, CALCIUM SALT | 1344-95-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRA(2-ETHYLBUTYL) ESTER | 78-13-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRA(2-ETHYLBUTYL) ESTER | 78-13-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRAKIS(1,1-DIMETHYLPENTYL) ESTER | 63449-47-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRAKIS(1,1-DIMETHYLPENTYL) ESTER | 63449-47-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRAKIS(2-CHLOROETHYL) ESTER | 18290-84-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRAKIS(2-CHLOROETHYL) ESTER | 18290-84-1 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRAMETHYL ESTER | 681-84-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILICIC ACID, TETRAMETHYL ESTER | 681-84-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILOXANES AND SILICONES, DI-ME, REACTION PRODUCTS WITH SILICA | 67762-90-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILOXANES AND SILICONES, DI-ME, REACTION PRODUCTS WITH SILICA | 67762-90-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| SILVER BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILVER BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SILVER, COLLOIDAL | 7440-22-4 | Per the U.S. FDA., silver shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by good manufacturing practice: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 5 parts per million. Mercury (as Hg), not more than 1 part per million. Silver (as Ag), not less than 99.9 percent. |
| SIMMONDSIA CHINENSIS (JOJOBA) OIL PEG-150 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SIMMONDSIA CHINENSIS (JOJOBA) OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SIMMONDSIA CHINENSIS (JOJOBA) WAX PEG-120 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SIMMONDSIA CHINENSIS (JOJOBA) WAX PEG-80 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE/ACRYLAMIDE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| SODIUM ACRYLOYLDIMETHYL TAURATE/ACRYLAMIDE/VP COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| SODIUM BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM BOROSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM C11-15 PARETH-7 CARBOXYLATE | 68603-23-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Sodium C12-14 Amines-tert-Alkylated Ethoxylated Sulfates | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|---|
| SODIUM C12-14 OLEFIN SULFONATE | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2% in leaveon products. Additionally, CIR restricts the gamma sultone contents of this ingredient to the following concentrations: 10ppm for unsubstituted alkane sultones, 1ppm for chlorosultones, and 0.1ppm for unsaturated sultones. |
| SODIUM C12-15 PARETH-6 CARBOXYLATE | 70632-06-03 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM C14-16 OLEFIN SULFONATE | 68439-57-6 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2% in leaveon products. Additionally, CIR restricts the gamma sultone contents of this ingredient to the following concentrations: 10ppm for unsubstituted alkane sultones, 1ppm for chlorosultones, and 0.1ppm for unsaturated sultones. |
| SODIUM C14-18 OLEFIN SULFONATE | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2% in leaveon products. Additionally, CIR restricts the gamma sultone contents of this ingredient to the following concentrations: 10ppm for unsubstituted alkane sultones, 1ppm for chlorosultones, and 0.1ppm for unsaturated sultones. |
| SODIUM C16-18 OLEFIN SULFONATE | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 2% in leaveon products. Additionally, CIR restricts the gamma sultone contents of this ingredient to the following concentrations: 10ppm for unsubstituted alkane sultones, 1ppm for chlorosultones, and 0.1ppm for unsaturated sultones. |
| SODIUM CARBOXYDECYL PEG-8 DIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM CETEARETH-13 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM CETETH-13 CARBOXYLATE | 33939-65-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM CETETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM COCETH SULFATE/ PEG-40 GLYCERYL COCOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM COCETH-30 SULFATE | 68891-38-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DECETH SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| SODIUM DECETH-2 CARBOXYLATE | 38815-93-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DECETH-3 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DICETEARETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DICOCOYLETHYLENEDIAMINE PEG-15 STEARATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DICOCOYLETHYLENEDIAMINE PEG-15 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DILAURETH-10 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DILAURETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DILAURETH-7 CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DIMETHICONE PEG-7 ACETYL METHYLTAURATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM DIOLETH-8 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Sodium Disilicate | 13870-28-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| Sodium Disilicate | 13870-28-5 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM FLUOROSILICATE | 16893-85-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|------------|---|
| SODIUM FLUOROSILICATE | 16893-85-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM HEXAMETAPHOSPHATE | 10124-56-8 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: lead. |
| SODIUM LANETH SULFATE | 68919-23-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-1 SULFATE | 15826-16-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-11 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-12 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|------------|---|
| SODIUM LAURETH-12 SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-13 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-14 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-16 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------|------------|---|
| SODIUM LAURETH-17 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-2 PHOSPHATE | 42612-52-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-2 PHOSPHATE | 42612-52-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-2 SULFATE | 3088-31-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-3 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-3 SULFATE | 13150-00-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-4 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-4 PHOSPHATE | 42612-52-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-40 SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-5 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-5 SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-6 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-7 SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|-------------|--|
| SODIUM LAURETH-7 TARTRATE | 141250-42-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-8 CARBOXYLATE | 33939-64-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-8 SUFLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAURETH-8 SULFATE | 9004-82-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM LAUROAMPHOACETATE | 66161-62-4 | This substance must not contain any residual aminoethylethanolamine (AEE). |
| SODIUM MAGNESIUM FLUOROSILICATE | 85085-18-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM MAGNESIUM FLUOROSILICATE | 85085-18-3 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM MAGNESIUM SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM MAGNESIUM SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM MAGNESIUM SILICATE | 101659-01-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM MAGNESIUM SILICATE | 101659-01-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM METAPHOSPHATE | 10361-03-02 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: lead. |
| SODIUM METASILICATE | 6834-92-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM METASILICATE | 6834-92-0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|------------|---|
| SODIUM NONOXYNOL-1 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-10 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-25 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-3 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-4 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-6 PHOSPHATE | 12068-19-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-6 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-8 SULFATE | 9014-90-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM NONOXYNOL-9 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM OCTOXYNOL-2 ETHANE SULFONATE | 2917-94-4 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| SODIUM OCTOXYNOL-2 SULFATE | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| SODIUM OCTOXYNOL-6 SULFATE | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 5% in leaveon products. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| SODIUM OCTOXYNOL-9 SULFATE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: ethylene oxide and 1,4dioxane. |
| SODIUM OLETH SULFATE | 27233-34-7 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|---|
| SODIUM OLETH-2 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM OLETH-7 PHOSPHATE | 57486-09-06 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM OLETH-7 PHOSPHATE | 57486-09-06 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM OLETH-8 PHOSPHATE | 57486-09-06 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-3 LAURAMIDE CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-4 COCAMIDE SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-4 LAURAMIDE CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-4 LAURAMIDE SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-4 TRIDECYL ETHER SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-50 HYDROGENATED CASTOR OIL SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-6 COCAMIDE CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-7 OLIVE OIL CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM PEG-8 COCAMIDE CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| SODIUM PEG-8 PALM GLYCERIDES CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM POLYACRYLATE | 2594415 | These substances must not be polymerized in benzene and the summed concentration of residual monomers (acrylic acid, methacrylic acid and their simple esters) are restricted to 100 ppm in this substance based on recommendations by the CIR panel that manufacturers minimize residual monomer content in in Acrylates Copolymers. Additionally, the CIR panel concluded these substances are safe as used at concentrations up to 29.7% when formulated to be non- irritating. |
| SODIUM POTASSIUM ALUMINOSILICATE | 12736-96-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM POTASSIUM ALUMINOSILICATE | 12736-96-8 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM PROPOXYHYDROXYPROPYL THIOSULFATE SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM PROPOXYHYDROXYPROPYL THIOSULFATE SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICATE | 15859-24-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICATE | 15859-24-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICATE | 15859-24-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICATE | 15859-24-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|---|
| SODIUM SILICOALUMINATE | 1344-00-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILICOALUMINATE | 1344-00-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILVER ALUMINUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM SILVER ALUMINUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SODIUM STYRENE/ PEG-10 MALEATE/ NONOXYNOL-10 MALEATE/ ACRYLATES COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM STYRENE/ACRYLATES/PEG-10 DIMALEATE COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM STYRENE/PEG-10 MALEATE/NONOXYNOL-10 MALEATE/ACRYLATE COPOL | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TOCOPHERYL PHOSPHATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| SODIUM TRIDECETH SULFATE | 25446-78-0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-12 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-15 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-19 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-3 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------|------------|---|
| SODIUM TRIDECETH-3 SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-4 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-6 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-7 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIDECETH-8 CARBOXYLATE | 61757-59-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM TRIMETAPHOSPHATE | 7785-84-4 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: lead. |

| Substance/Ingredient | CAS | Restrictions |
|---|-----|--|
| SODIUM UNDECETH-5 CARBOXYLATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM/ TEA LAUROYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/ TEA LAUROYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/ TEA LAUROYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/MEA LAURETH-2 SULFOSUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM/MEA LAURETH-2 SULFOSUCCINATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| SODIUM/MEA-PEG-3 COCAMIDE SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SODIUM/MEA-PEG-3 COCAMIDE SULFATE | 0 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| SODIUM/TEA C12-13 PARETH-3 SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-LAUROYL COLLAGEN AMINO ACIDS | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|--|-----|--|
| SODIUM/TEA-LAUROYL HYDROLYZED KERATIN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-LAUROYL KERATIN AMINO ACIDS | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL ALGINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL CARRAGEENAN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL COLLAGEN AMINO ACIDS | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL HYDROLYZED CORN PROTEIN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL HYDROLYZED SOY PROTEIN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SODIUM/TEA-UNDECYLENOYL HYDROLYZED WHEAT PROTEIN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SOLUBLE PROTEOGLYCAN | 0 | FDA has flagged this ingredient for possible bovine spongiform encephalopathy (BSE) contamination. To use this ingredient, a company must document that the ingredient is not of bovine origin. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------|------------|--|
| SORBETH-230 TETRAOLEATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SORBETH-6 BEESWAX | 8051-15-8 | The Cosmetic Ingredient Review restricts this ingredient's use in products if the ingredient is formulated with PEG6, PEG20 or PEG75. |
| SORBETH-6 HEXASTEARATE | 66828-20-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SORBETH-8 BEESWAX | 0 | The Cosmetic Ingredient Review restricts this ingredient's use in products if the ingredient is formulated with PEG6, PEG20 or PEG75. |
| SOYAMIDE DEA | 68425-47-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| SOYAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| SOYAMIDOPROPYL DIMETHYLAMINE | 68188-30-7 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| SOYAMINE | 61790-18-9 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| SOYBEAN OIL PEG-36 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SOYBEAN OIL, ETHOXYLATED | 61791-23-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SPHACELARIA SCOPARIA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SPHINGOLIPIDS | 85116-74-1 | The European Commission does not allow sphingolipids isolated from the brain and central nervous system of animals (known as Cerebrosides) per Annex II, Directive 419. |
| SPIRULINA (ALGAE) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| SPIRULINA MAXIMA (ALGAE) | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SPIRULINA MAXIMA (ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SQUALANE | 0111-01-03 | This substance can be derived from either plant or animal sources. Only plantderived squalane (i.e., phytosqualane) is acceptable in Verified products. |
| STARCH/ ACRYLATES/ ACRYLAMIDE COPOLYMER | 0 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| STEARALKONIUM DIMETHICONE PEG-8 PHTHALATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARAMIDE DEA | 93-82-3 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| STEARAMIDOPROPYL BETAINE | 6179-44-8 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| STEARAMIDOPROPYL DIMETHYLAMINE | 2100549 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| STEARAMIDOPROPYL DIMETHYLAMINE | 2100549 | The CIR Panel concluded that Stearamidopropyl dimethylamine is safe in cosmetics when they are formulated to be nonsensitizing and at concentrations < 5%. The Panel also noted that, for stearamidopropyl dimethylamine, products may result in DMAPA concentrations that exceed the limit for this impurity recommended by the Panel. DMAPA should not exceed concentration of 0.01%. |
| STEARAMINE | 124-30-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| STEARDIMONIUM HYDROXYPROPYL PANTHENYL PEG-7 DIMETHICONE PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARDIMONIUM HYDROXYPROPYL PANTHENYL PEG-7 DIMETHICONE PHOSPHATE CHLORIDE | 220714-77-2 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARDIMONIUM HYDROXYPROPYL PEG-7 DIMETHICONE PHOSPHATE CHLORIDE | 220714-63-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|-------------|--|
| STEARETH-10 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-100 | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-100/PEG-136/HDI COPOLYMER | 103777-69-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-16 | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-2 | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-20 | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-21 | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETH-4 | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARETHS-(2-100) | 9005-00-9 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| STEARYL GLYCYRRHETINATE | 13832-70-7 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used up to a concentration of 1%. Additionally, CIR has identified the following potential contaminants/impurities in this ingredient: pesticides/PCB, toxic metals, and heavy metals. |
| STEARYL HDI/PEG-50 COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Styrene/Acrylamide Copolymer | 24981-13-3 | The European Commission restricts this ingredient's residual acrylamide content to a maximum of 0.1 mg/kg for body leaveon products and 0.5 mg/kg for all other products. |
| SULFATED PEANUT OIL | 73138-79-1 | Europe restricts this chemical: Maximum concentration of peanut proteins: 0.5 ppm |
| SULFUR-CONTAINED ALUMINUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| SULFUR-CONTAINED ALUMINUM SILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| SULFURIZED TEA-RICINOLEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| SUNFLOWER SEED OIL PEG-32 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SUNFLOWER SEED OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SUNFLOWERSEEDAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| Sunset Yellow (Uncertified FD&C Yellow No. 6) | 2783-94-0 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine. |
| Sunset Yellow (Uncertified FD&C Yellow No. 6) | 2783-94-0 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/EC (E 110) |
| Sunset Yellow (Uncertified FD&C Yellow No. 6) Lake | 2783-94-0 | This substance must contain <2ppm lead, <1ppm cadmium, <1 ppb combined (free+bound) benzidine. |
| SWEET ALMOND OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SYNECHOCOCCUS ELONGATUS/ALGAE FERMENT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| SYNTANOL DS 6 | 85422-93-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| SYNTHETIC BEESWAX | 71243-51-1 | Synthetic beeswax may include hydrocarbons sourced from petroleum. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, petroleum-derived ingredients must be highly refined including documentation of refining process and noncarcinogenic source material, with DMSO extractives below 3% and PAH levels below 10 ppb. |
| TALLAMIDE DEA TALLAMIDE DEA | 68155-20-4 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| TALLAMIDOPROPYL DIMETHYLAMINE | 68650-79-3 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|-------------|--|
| TALLOW AMINE | 61790-33-8 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| TALLOWAMIDE DEA | 68140-08-09 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| TALLOWAMIDOPROPYL DIMETHYLAMINE | 68425-50-3 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| TALLOWETH-18 | 61791-28-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| Tangerine oil terpenes | 68608-38-8 | The International Fragrance Association restricts the total bergapten (5methoxypsoralen) concentration of this ingredient (in combination with other citrus oils) to a maximum concentration of 15 ppm in the final product for leaveon products. |
| TEA CARBOMER | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA COCOATE | 61790-64-5 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA COCOYL GLUTAMATE | 68187-29-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA COCOYL HYDROLYZED COLLAGEN | 68952-16-9 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA DODECYLBENZENESULFONATE | 27323-41-7 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA ISOSTEARATE | 88120-12-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|---------------------------------|------------|--|
| TEA ISOSTEARATE | 88120-12-1 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. |
| TEA LAUROYL GLUTAMATE | 53576-49-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA LAUROYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA MYRISTATE | 41669-40-3 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA OLEATE | 2717-15-9 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA PALM KERNEL SARCOSINATE | 73049-98-6 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA PALMITATE | 49719-60-0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA PALMITATE | 49719-60-0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. |
| TEA PEG 3 COCAMIDE SULFATE | 73246-94-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TEA PEG 3 COCAMIDE SULFATE | 73246-94-3 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA PEG 3 COCAMIDE SULFATE | 73246-94-3 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. Additionally, this ingredient may not be used in products in which Nnitroso compounds may form (do not contain nitrosating agents). |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| TEA STEARATE | 4568-28-9 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-ABIETOYL HYDROLYZED COLLAGEN | 68918-77-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-ACRYLATES/ACRYLONITROGENS COPOLYMER | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-ACRYLATES/ETHYLHEXYL ACRYLATE COPOLYMER | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-ALGINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C10-15 ALKYL SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C11-15 ALKYL SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C11-15 PARETH SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C12-13 ALKYL PHOSPHATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|-----|--|
| TEA-C12-13 ALKYL SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C12-13 PARETH-3 SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C12-14 ALKYL PHOSPHATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C12-14 ALKYL SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-C12-15 ALKYL SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-CANOLATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-COCAMIDE DIACETATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-COCO-SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-COCOYL ALANINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| TEA-COCOYL GLUTAMINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-COCOYL GLYCINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-COCOYL HYDROLYZED SOY PROTEIN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-COCOYL SARCOSINATE | 68411-96-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-DEXTRIN OCTENYLSUCCINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-DIETHANOLAMINOETHYL POLYISOBUTENYLSUCCINATE | 67762-80-5 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-DIMETHICONE PEG-7 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TEA-DIMETHICONE PEG-7 PHOSPHATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-EDTA | 60544-70-9 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-GLYCERYL DIMALEATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|------------|--|
| TEA-HYDROCHLORIDE | 637-39-8 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-HYDROGENATED COCOATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-HYDROGENATED TALLOWOYL GLUTAMATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-HYDROIODIDE | 7601-53-8 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-ISOSTEAROYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LACTATE | 20475-12-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LANETH-5 SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAURAMINOPROPIONATE | 14171-00-7 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAURATE | 2224-49-9 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAURATE | 2224-49-9 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------------|------------|--|
| TEA-LAURATE/MYRISTATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAURETH SULFATE | 27028-82-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TEA-LAURETH SULFATE | 27028-82-6 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAURETH SULFATE | 27028-82-6 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. |
| TEA-LAURETH-4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TEA-LAURETH-4 PHOSPHATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAUROYL COLLAGEN AMINO ACIDS | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAUROYL KERATIN AMINO ACIDS | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAUROYL LACTYLATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAUROYL METHYLAMINOPROPIONATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| TEA-LAUROYL SARCOSINATE | 16693-53-1 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAUROYL/MYRISTOYL ASPARTATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-LAURYL PHOSPHATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-MYRISTAMINOPROPIONATE | 61791-98-8 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-MYRISTOYL HYDROLYZED COLLAGEN | 69430-23-5 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-OLEOYL HYDROLYZED COLLAGEN | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-OLEOYL SARCOSINATE | 17736-08-02 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-OLEYL SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-PCA | 55901-20-7 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-PEG-50 HYDROGENATED CASTOR OIL SUCCINATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| TEA-PEG-50 HYDROGENATED CASTOR OIL SUCCINATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-PHENYLBENZIMIDAZOLE SULFONATE | 10020-01-06 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-ROSINATE | 68002-57-3 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-SALICYLATE | 2174-16-5 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-SORBATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-SORBATE | 0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. |
| TEA-SULFATE | 7376-31-0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-SULFATE | 7376-31-0 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. |
| TEA-TALLATE | 8043-27-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-TALLATE | 8043-27-4 | The Cosmetic Ingredient Review has determined that this ingredient is safe as used when the levels of free diethanolamine do not exceed the present practices of use and concentration of diethanolamine itself. Additionally, this ingredient may not be used in products in which Nnitroso compounds may form (do not contain nitrosating agents). |
| TEA-TRIDECYLBENZENESULFONATE | 59599-58-5 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|-------------|--|
| TEA-UNDECYLENATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TEA-UNDECYLENOYL HYDROLYZED COLLAGEN | 68951-91-7 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TERGITOL MIN-FOAM 1X | 103331-86-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TERPENE ALCOHOLS ACETATES | 69103-01-01 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| TERPENE HYDROCARBONS | 68956-56-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| TERPENES AND TERPENOIDS | 65996-98-7 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| TERPENES AND TERPENOIDS SINPINE | 68917-63-5 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L |
| TERPINOLENE | 586-62-9 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| TETRADECYLHEPTAETHOXYLATE | 40036-79-1 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TETRAETHYL SILICATE | 78-10-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TETRAETHYL SILICATE | 78-10-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TETRASELMIS CHUI EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| TETRASODIUM GLUTAMATE DIACETATE | 51981-21-6 | This substance must not contain any residual nitrilotriacetic acid (NTA). |
| THIOSULFATE SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| THIOSULFATE SILICA | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|------------|--|
| THUJA OCCIDENTALIS (ARBORVITAE) LEAF OIL | 8007-20-3 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS BARK EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS LEAF | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS LEAF EXTRACT | 0 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS ROOT EXTRACT | 90131-58-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS ROOT EXTRACT | 90131-58-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS ROOT EXTRACT | 90131-58-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| THUJA OCCIDENTALIS ROOT EXTRACT | 90131-58-1 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| TIPA-ACRYLATES/ETHYLHEXYL ACRYLATE COPOLYMER | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TIPA-LAURETH SULFATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TIPA-LAURETH SULFATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TIPA-LAURYL SULFATE | 66161-60-2 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TIPA-MYRISTATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TIPA-STEARATE | 10042-67-8 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TITANIUM DIOXIDE | 13463-67-7 | Titanium dioxide is not allowed in powdered or spray products as it poses a cancer risk per IARC's assessment. Further, the European Commission restricts the maximum concentrations of arsenic to 3ppm, lead to 10ppm, mercury to 1ppm, cadmium to 1ppm, antimony to 50ppm and zinc to 50ppm. |

| Substance/Ingredient | CAS | Restrictions |
|------------------------------------|------------|---|
| TITANIUM DIOXIDE | 13463-67-7 | Per the U.S. FDA., titanium dioxide shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million. Antimony (as Sb), not more than 2 parts per million. Mercury (as Hg), not more than 1 part per million. Loss on ignition at 800 °C. (after drying for 3 hours at 105 °C.), not more than 0.5 percent. Water soluble substances, not more than 0.5 percent. Acid soluble substances, not more than 0.5 percent. Acid soluble substances, not more than 0.5 percent. Tol2, not less than 99.0 percent after drying for 3 hours at 105 °C. Lead, arsenic, and antimony shall be determined in the solution obtained by boiling 10 grams of the titanium dioxide for 15 minutes in 50 milliliters of 0.5N hydrochloric acid. |
| TITANIUM DIOXIDE | 13463-67-7 | Per COSING, this ingredient shall conform to the purity criteria as set out in Commission Directive 95/45/E (E 171), Titanium dioxide in powder form containing 1 % or more of particles with aerodynamic diameter less than or equal to 10 micrometers, to be used in compliance with Annex III, No 321 (For use as a UV filter, see Annex VI, No 27) |
| TITANIUM DIOXIDE (sunscreen grade) | 13463-67-7 | Titanium dioxide is not allowed in powdered or spray products as it poses a cancer risk per IARC's assessment. Further, the European Commission restricts the maximum concentrations of arsenic to 3ppm, lead to 10ppm, mercury to 1ppm, cadmium to 1ppm, antimony to 50ppm and zinc to 50ppm. |
| TITANIUM DIOXIDE (sunscreen grade) | 13463-67-7 | Per the U.S. FDA., titanium dioxide shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million. Antimony (as Sb), not more than 2 parts per million. Mercury (as Hg), not more than 1 part per million. Loss on ignition at 800 °C. (after drying for 3 hours at 105 °C.), not more than 0.5 percent. Water soluble substances, not more than 0.5 percent. TiO2, not less than 99.0 percent after drying for 3 hours at 105 °C. Lead, arsenic, and antimony shall be determined in the solution obtained by boiling 10 grams of the titanium dioxide for 15 minutes in 50 milliliters of 0.5N hydrochloric acid. |
| TITANIUM DIOXIDE (sunscreen grade) | 13463-67-7 | Per COSING, the maximum concentration in RTU preparation is 25% - In case of combined use of Titanium Dioxide and Titanium Dioxide (nano), the sum shall not exceed the limit of 25%. Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation Only nanomaterials having the following characteristics are allowed: — purity \geq 99%, — rutile form, or rutile with up to 5 % anatase, with crystalline structure and physical appearance as clusters of spherical, needle, or lanceolate shapes, — median particle size based on number size distribution \geq 30 nm, — aspect ratio from 1 to 4.5. and volume specific surface area \leq 460 m2/cm3, — coated with Silica, Hydrated Silica, Alumina, Aluminium Hydroxide, Aluminium Stearate, Stearic Acid, Trimethoxycaprylylsilane, Glycerin, Dimethicone, Hydrogen Dimethicone, Simethicone; or coated with one of the following combinations: —Silica at a maximum concentration of 16% and Cetyl Phosphate at a Per COSING, the maximum concentration of 6%, —Alumina at a maximum con centration of 7% and Manganese Dioxide at a Per COSING, the maximum concentration of 0,7% (not to be used in lip products), —Alumina at a maximum con centration of 3% and Triethoxycaprylylsilane at a Per COSING, the maximum concentration of 9%, — photocatalytic activity \leq 10% compared to corresponding non-coated or non-doped reference, — nanoparticles are photostable in the final formulation. Wording of conditions of use and warnings: For face products containing Titanium Dioxide (nano) coated with the combination Alumina and Manganese Dioxide: Not to be used on the lips. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| TITANIUM/TITANIUM DIOXIDE | 0 | Per the U.S. FDA., titanium dioxide shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million. Antimony (as Sb), not more than 2 parts per million. Mercury (as Hg), not more than 1 part per million. Loss on ignition at 800 °C. (after drying for 3 hours at 105 °C.), not more than 0.5 percent. Water soluble substances, not more than 0.5 percent. Acid soluble substances, not more than 0.5 percent. TiO2, not less than 99.0 percent after drying for 3 hours at 105 °C. Lead, arsenic, and antimony shall be determined in the solution obtained by boiling 10 grams of the titanium dioxide for 15 minutes in 50 milliliters of 0.5N hydrochloric acid. |
| TOCOPHERETH-10 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERETH-12 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERETH-18 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERETH-5 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERETH-50 | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHEROL | 10191-41-0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHEROL NICOTINATE | 51898-34-1 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHEROL, D-ALPHA- | 59-02-9 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHEROL, DL-ALPHA | 10191-41-0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERSOLAN | 30999-06-05 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL ACETATE | 58-95-7 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL DIMETHYLGLYCINATE HCI | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL ETHYL SUCCINATE ETHYLDIMONIUM ETHOSULFATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL FERULATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL GLUCOSIDE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL LINOLEATE | 36148-84-2 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL LINOLEATE/ OLEATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL NICOTINATE | 16676-75-8 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL OLEATE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL PHOSPHATE | 425429-22-7 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL POLYPEPTIDE | 0 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOPHERYL RETINOATE | 40516-49-2 | This ingredient should not contain detectable levels of hydroquinone. |
| TOCOQUINONE | 2067006 | This ingredient should not contain detectable levels of hydroquinone. |
| TREEMOSS CONCRETE | 68648-41-9 | The International Fragrance Association restricts the dehydroabietic acid (DHA) concentration of this ingredient to a maximum of 0.8% in the extract, and the levels of atranol and chloroatranol should each be below 100ppm. |
| TRIBEHENIN PEG-20 ESTERS | 220207-10-3 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|---|
| TRICETEARETH 4 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRICETETH-5 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-10 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-10 PHOSPHATE | 2610033 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-10 PHOSPHATE | 2610033 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-10 PHOSPHATE | 2610033 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-11 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-12 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-15 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-15 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-15 TRIDECYL ETHER CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-18 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-19 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|-------------|---|
| TRIDECETH-2 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-2 CARBOXAMIDE MEA | | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-20 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-21 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-3 | 91454 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-3 CARBOXYLIC ACID | | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-3 PHOSPHATE | 261003 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-4 | 69011-36-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-4 CARBOXYLIC ACID | 127174-97-4 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-5 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-50 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-6 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-6 PHOSPHATE | 261003 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|-----------------------------|------------|---|
| TRIDECETH-7 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-7 CARBOXYLIC ACID | 56388-96-6 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-8 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-8 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|---|------------|--|
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 | 24938-91-8 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9 PG-AMODIMETHICONE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECETH-9/ PEG-5 OCTANOATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIDECYLHEXAETHOXYLATE | 0930-09-06 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIETHANOLAMINE LAURYL SULFATE | 139-96-8 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TRIETHANOLAMINE POLYOXYETHYLENE ALKYLPHENYLETHER PHOSPHATE | 0 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| Triethoxycaprylylsilane | 73398-61-5 | For the purposes of the Reviewed Ingredients program, this ingredient may only be used in combination with another restricted ingredient on the Ingredients Eligible for Reviewed List. |
| TRIISOPROPANOLAMINE | 122-20-3 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| TRIISOSTEARIN PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRILAURETH-4 PHOSPHATE | 31800-90-5 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRILAURETH-9 CITRATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRILAURYLAMINE | 102-87-4 | The European Commission restricts this ingredient to a maximum concentration of 2.5% in leaveon products. Additionally, this substance cannot be used with nitrosating systems, the minimum purity of the ingredient should be 99%, it cannot have a secondary amine content of more than 0.5% (applies to raw materials), it cannot have a nitrosamine content of more than 50 microgram/kg, and it should be kept in nitritefree containers. |
| TRIMETHYLATED SILICA | 68988-56-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLATED SILICA | 68988-56-7 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLATED SILICA/ DIMETHICONE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLATED SILICA/ DIMETHICONE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLOLETHANE-BENZOIC ACID-PHTHALIC ANHYDRIDE RESIN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIMETHYLSILOXYPOLYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYPOLYSILICATE | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE | 56275-01-05 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|---|-------------|--|
| TRIMETHYLSILOXYSILICATE | 56275-01-05 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE ACRYLATES/ CARBAMATE COPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE ACRYLATES/ CARBAMATE COPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE/DIMETHICONE CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE/DIMETHICONE CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE/DIMETHICONOL CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIMETHYLSILOXYSILICATE/DIMETHICONOL CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TRIOLEIN PEG-6 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRIOLETH-8 PHOSPHATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| TRISODIUM GLYCYRRHIZATE | 0 | The Cosmetic Ingredient Review has identified the following potential contaminants/impurities in this ingredient: pesticides/PCBs, toxic metals, and heavy metals. |
| TROMETHAMINE | 77-86-1 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| TROMETHAMINE MAGNESIUM ALUMINUM SILICATE | 66456-45-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| TROMETHAMINE MAGNESIUM ALUMINUM SILICATE | 66456-45-9 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| TURPENTINE OIL | 8006-64-2 | The European Commission restricts this ingredient's peroxide content to less than 10 mmoles/L (this limit applies to the substance and not the finished cosmetic product). |
| ULTRAMARINES | 1317-97-1 | The U.S. Food and Drug Administration restricts the lead, arsenic, and mercury content of this ingredient to maximum concentrations of 20 ppm, 3 ppm, and 1 ppm, respectively. |
| ULTRAMARINES | 1317-97-1 | Per the U.S. FDA., the ultramarines shall conform to the following specifications and shall be free from impurities other than those named, to the extent that such other impurities may be avoided by good manufacturing practice. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. |
| UNDARIA PINNATIFIDA CELL CULTURE EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae-derived ingredients, EWG does not allow this substance to contain detectable levels of cadmium, lead, mercury, copper, zinc, arsenic, nickel, silver, or iodine. |
| UNDARIA PINNATIFIDA EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| UNDARIA PINNATIFIDA POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| UNDARIA PINNATIFIDA ROOT POWDER | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| UNDECETH-11 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECETH-3 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECETH-5 | 34398-01-01 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECETH-5 CARBOXYLIC ACID | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECETH-7 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECETH-8 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |

| Substance/Ingredient | CAS | Restrictions |
|--|-------------|--|
| UNDECETH-9 | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECYLENAMIDE DEA | 25377-64-4 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |
| UNDECYLENAMIDOPROPYL BETAINE | 0 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| UNDECYLENAMIDOPROPYL PEG-2 DIMONIUM UNDECYLENATE | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| UNDECYLENOYL PEG 5 PARABEN | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| VA/CROTONIC ACID/PEG-20M COPOLYMER | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| VEGETABLE GLYCERIN | 56-81-5 | Health Canada requires manufacturers of oral and leaveon products containing glycerin to ensure the raw material used is within the specifications of an accepted pharmacopoeia with respect to diethylene glycol (DEG) impurities. |
| VINYL DIMETHYL/TRIMETHYLSILOXYSILICATE STEARYL DIMETHICONE CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| VINYL DIMETHYL/TRIMETHYLSILOXYSILICATE STEARYL DIMETHICONE CROSSPOLYMER | 0 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| VITAMIN E SUCCINATE | 893081 | This ingredient should not contain detectable levels of hydroquinone. |
| WHEAT GERM OIL PEG-40 BUTYLOCTANOL ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| WHEAT GERM OIL PEG-8 ESTERS | 0 | The U.S. Food & Drug Administration has identified 1,4 dioxane as a potential impurity in this ingredient and recommends that manufacturers utilize vacuum stripping at the end of the polymerization process. Based on this finding, the concentration of 1,4 dioxane cannot exceed 1 ppm in the final product. |
| WHEAT GERMAMIDE DEA | 124046-39-5 | The European Commission restricts the usage and purity of this ingredient: the maximum secondary amine content cannot exceed 0.5% (applies to raw materials); the ingredient cannot be used with nitrosating systems; the minimum purity should be at least 99%; the maximum nitrosamine content cannot exceed 50 microgram/kg; and the product must be kept in nitritefree containers |

| Substance/Ingredient | CAS | Restrictions |
|-------------------------------------|-------------|--|
| WHEAT GERMAMIDOPROPYL BETAINE | 133934-09-5 | The concentrations of DMAPA and amidoamine in this ingredient must not exceed 0.01% and 0.5% respectively. Additionally, this ingredient must be formulated to be nonsensitizing, as determined by a quantitative risk assessment (QRA) as outlined in the Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl betaine (CAPB). |
| WHEAT GERMAMIDOPROPYL DIMETHYLAMINE | 0 | This ingredient cannot be used in leaveon products and must not exceed 0.5% in rinseoff products. Additionally, this ingredient should not contain DMAPA at concentrations greater than 0.01%. |
| WHITE PETROLATUM | 2231335 | This ingredient is restricted due to its potential to bioaccumulate in human tissues. Based on European cosmetics legislation, European Pharmacopeia and recommendations from Cosmetics Europe and German Federal Institute for Risk Assessment, this ingredient must be highly refined including documentation of refining process and noncarcinogenic source material with DMSO extractives below 3% and PAH levels must be below 10 ppb. High viscosity mineral oils must have an average molecular mass of at least 500 Daltons, a viscosity value greater than 11 centistokes and no more than 5% of hydrocarbons with a chain length less than C28 may be present. Lowmedium viscosity mineral oils must have an average molecular mass of 480500 Daltons, a viscosity value of 8.511 centistokes, and no more than 5% of hydrocarbons with a carbon chain length less than C25 atoms may be present |
| WILD FLOWER HONEY | 0 | This substance must contain less than 40 mg/kg of 5hydroxymethylfurfural (HMF), in accordance with EU COUNCIL DIRECTIVE 2001/110/EC of 20 December 2001 relating to honey. |
| WILD FLOWER HONEY | 0 | The CIR panel notes this substance may be contaminated with harmful impurites. EWG requires that this substance contains undetectable levels of the following: pesticides, heavy metals, polychlorinated biphenyls/persistent organic pollutants, and antibiotics. |
| ZEOLITE | 1318-02-01 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZEOLITE | 1318-02-01 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZINC BOROSILICATE | 37341-47-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZINC BOROSILICATE | 37341-47-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZINC OXIDE | 1314-13-2 | Per the U.S. FDA., zinc oxide shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Zinc oxide (as ZnO), not less than 99 percent. Loss on ignition at 800 °C, not more than 1 percent. Cadmium (as Cd), not more than 15 parts per million. Mercury (as Hg), not more than 1 part per million. Arsenic (as As), not more than 3 parts per million. |

| Substance/Ingredient | CAS | Restrictions |
|--------------------------------------|------------|---|
| Zinc Oxide(Sunscreen Grade) | 1314-13-2 | The European Commission restricts this ingredient to a maximum concentration of 25% as a UV filter. In the case of combined use with Zinc Oxide (nano), the sum shall not exceed the limit of 25%. Additionally, this ingredient may not be used in applications that may lead to exposure of the enduser's lungs by inhalation. Only nanomaterials having the following characteristics are allowed: — purity \ge 96%, with wurtzite crystalline structure and physical appearance as clusters that are rodlike, starlike and/or isometric shapes, with impurities consisting only of carbon dioxide and water, whilst any other impurities are less than 1% in total. — median diameter of the particle number size distribution D50 (50% of the number below this diameter) > 30 nm and D1 (1% below this size) > 20 nm, — water solubility < 50 mg/L, —uncoated, or coated with triethoxycaprylylsilane cross polymer, or octyl triethoxy silane. |
| Zinc Oxide(Sunscreen Grade) | 1314-13-2 | Per the U.S. FDA., zinc oxide shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Zinc oxide (as ZnO), not less than 99 percent. Loss on ignition at 800 °C, not more than 1 percent. Cadmium (as Cd), not more than 15 parts per million. Arsenic (as As), not more than 30 parts per million. Lead (as Pb), not more than 20 parts per million. |
| ZINC SILICATE | 13597-65-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZINC SILICATE | 13597-65-4 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZINC SULFIDE | 1314-98-3 | The U.S. Food and Drug Administration restricts the copper, lead, arsenic, mercury, and cadmium content of this ingredient to maximum concentrations of 5 ppm, 20 ppm, 3 ppm, 1 ppm and 15 ppm, respectively. |
| ZIRCONIUM(IV) SILICATE (1:1) | 14940-68-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZIRCONIUM(IV) SILICATE (1:1) | 14940-68-2 | A 2019 CIR report lists the following heavy metal limits for silica: antimony (< 5 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), and cadmium (< 1ppm). Older CIR reports for varied silicate, borosilicate, and methicone substances suggest that similar restrictions should apply to these substances as well. |
| ZONARIA TOURNEFORTII (ALGAE) EXTRACT | 0 | Based on a Cosmetic Ingredient Review safety assessment of brown algae derived ingredients, EWG restricts the amount of iodine in the final product to 1 ppm. Additionally, products formulated with this substance must meet international standards for heavy metal concentrations including, cadmium; 3 ppm, lead; 10 ppm, mercury; 1ppm, and arsenic; 3 ppm. |
| | | |